Biochemical analysis of MBD1 by Lyst, Matthew James
 i
 












Thesis presented for the degree of Doctor of Philosophy 
Wellcome Trust Centre for Cell Biology 

















I declare that this thesis was composed by myself, and that the research presented is my 
own except where otherwise stated. This work has not been submitted for any other 













First of all I thank my supervisor, Irina, for taking me on as a PhD student, and for her 
guidance over the last three and a half years. I also thank all members of her laboratory 
for making my time there so enjoyable. In particular Kevin Myant for helping me with 
the language, Jose de las Heras for the regular Friday morning pantomime, Katrina 
Gordon for telling us off when we needed to be, Cara Merusi for the tea and Thomas 
Clouaire for his boundless cynicism. I also thank everyone in the laboratory of Adrian 
Bird for the banter, help and advice, and many stimulating discussions.  
 
I am also grateful to the following for gifts of reagents: Bill Earnshaw’s laboratory for 
plasmids encoding various affinity tags, Aimee Deaton for pCMV10 3xFLAG Mbd2, 
and Klaus Hansen and Patrick Varga-Weisz for antibodies. I thank Juri Rappsilber and 
Flavia Alves as well as Axel Imhof and people in his laboratory for carrying out mass 
spectrometry. I also gratefully acknowledge the contribution of Alex Tuck to the work 
on the potential self association of MBD1. 
 
Finally I am thankful for the friends I have shared my time in Scotland with, in 
particular my flatmates Oyinlola Oyebode and Ruth Corrigan, as well as everyone at 
Sporting ICAPB, the most tremendously brilliantly mediocre football team in the whole 
of Edinburgh. 
 
The work in Dr Irina Stancheva’s laboratory is funded by Cancer Research UK and the 
Wellcome Trust. I am grateful to the BBSRC for the studentship I received. 
 
 1
Table of Contents 
 
Table of Contents……………………………………………………………………... 1 
Figure List ……………………………………………………………………………..4 
Abstract ……………………………………………………………………………….. 5 
Abbreviations ………………………………………………………………………… 6 
 
1.    Chapter One – Introduction ……………............................................................. 8 
 
1.1 The distribution of DNA methylation….…………………………………………... 8 
   1.1.1 DNA molecules as an information repository………………………….……… 8 
   1.1.2 Bacterial DNA methylation and restriction-modification systems…………….. 9 
   1.1.3 The distribution of 5-methylcytosine across the eukaryotes……………………9 
   1.1.4 Symmetrical methylation of CpG dinucleotides……………………………….. 11 
   1.1.5 Methylated and unmethylated compartments of the genome…………………...12 
   1.1.6 5-methylcytosine as a mutagen………………………………………………… 13 
1.2 DNA methylation machinery………………………………………………………. 14 
   1.2.1 Identification of DNA methyltransferases……………………………………... 14 
   1.2.2 Catalytic mechanism…………………………………………………………… 15 
   1.2.3 Maintenance methylation and epigenetics……………………………………... 17 
   1.2.4 De novo methylation…………………………………………………………… 18 
   1.2.5 Factors required for targeting methylation…………………………………….. 20 
   1.2.6 Aberrant DNA methylation……………………………………………………..24 
1.3 Functions of DNA methylation………………………………..…………………… 25 
   1.3.1 DNA methylation is essential for proper development in mammals…………... 25 
   1.3.2 Genome stability………………………………………………………………...26 
   1.3.3 Transcriptional repression……………………………………………………… 27 
   1.3.4 X-inactivation…………………………………………………………………...29 
   1.3.5 Imprinting……………………………………………………………………… 31 
1.4 Mediators of the methylation signal………………………………………………...33 
   1.4.1 Identification of methyl-CpG binding proteins…………………………………33 
   1.4.2 Structure of the MBD…………………………………………………………...34 
   1.4.3 MBD1…………………………………………………………………………...35 
   1.4.4 MeCP2…………………………………………………………………………..35 
   1.4.5 MBD2…………………………………………………………………………...37 
   1.4.6 MBD4…………………………………………………………………………...38 
   1.4.7 Kaiso and Kaiso-like proteins………………………………………………….. 39 
1.5 The methyl-CpG binding domain protein MBD1………………………………….. 41 
   1.5.1 Identification of MBD1…………………………………………………………41 
   1.5.2 DNA binding and transcriptional repression by MBD1………………………...41 
   1.5.3 Regulation of MBD1 by SUMO modification…………………………………. 44 
   1.5.4 Aims of thesis…………………………………………………………………...45 
 
 2
2.    Chapter Two - Materials and Methods ………………………………………… 47 
 
2.1 Bacterial methods………………………………………………………….………..47 
   2.1.1 Bacterial culture conditions…………………………………………….……….47 
   2.1.2 Preparation of competent cells and transformation……………………….…….47 
   2.1.3 Plasmid preparation………………………………………………………….… 48 
   2.1.4 Protein expression and cell lysis……………………………………………….. 48 
2.2 Molecular cloning………………………………………………………………….. 48 
   2.2.1 Preparation of cDNA…………………………………………………………... 48 
   2.2.2 Polymerase chain reaction….………………………………………………….. 49 
   2.2.3 Restriction digests……………………………………………………………… 49 
   2.2.4 Purification of restriction fragments and PCR products……………………….. 50 
   2.2.5 Determination of DNA concentration and quality……………………………... 50 
   2.2.6 Dephosphorylation and ligation of DNA……..………………………………... 50 
   2.2.7 DNA sequencing……………………………………………………………….. 50 
2.3 Mammalian cell culture…………………………………………………….……….51 
   2.3.1 Culture conditions…………………………………………………….……..…. 51 
   2.3.2 Cryogenic storage……………………………………………………….………51 
   2.3.3 Transfection and transduction………………………………………………….. 51 
   2.3.4 Preparation of nuclear extracts…………………………………………………. 52 
   2.3.5 Cell fixation and microscopy………..…………………………………………. 52 
2.4 Protein purification……………………………………..…………………………...53 
   2.4.1 Purification of proteins containing a 3xFLAG tag……………………………...53 
   2.4.2 Immobilized metal affinity chromatography (IMAC)…………………………..53 
   2.4.3 Purification of proteins containing a GST-tag…………………………………..53 
   2.4.4 Cation exchange chromatography……………………………………………… 54 
2.5 Protein analysis……………………………………………………………………...54 
   2.5.1 Determination of protein concentration …………………………………..…….54   
   2.5.2 SDS-PAGE ……………………………………………………………………..54 
   2.5.3 Coomassie staining ……………………………………………………………..55 
   2.5.4 Western blotting ……………………………………………………………….. 55 
   2.5.5 Immunoprecipitation…………………………………………………………… 56 
   2.5.6 SUMO protease assay………………………………………………………….. 56 
   2.5.7 Gel filtration……………………………………………………………………. 57 
   2.5.8 Sucrose gradient sedimentation…………………………………………………57 
   2.5.9 Mass spectrometry………………………………………………………………57 
 
3.    Chapter Three – Evidence for self association of MBD1……………………… 58 
 
3.1 Endogenous MBD1 does not behave as a monomer………………………………. 58 
3.2 Bacterially expressed MBD1 behaves as a monomer……………………………… 60 
3.3 SETDB1 association does not explain the apparent size of MBD1………………... 61 
3.4 Nucleic acid does not contribute to the apparent size of MBD1…………………... 62 
3.5 Affinity tagging of MBD1…………………………………………………………. 63 
 
 3
3.6 Absence of stable and stoichiometric MBD1 binding partners……………………. 66 
3.7 Co-immunoprecipitation of MBD1 over-expressed in HeLa cells………………… 70 
 
4.    Chapter Four – Proteomics of MBD protein partners………………………… 72 
 
4.1 Nuclease allows extraction of MBD1 at mild ionic strength………………………. 72 
4.2 Purification of 3xFLAG-tagged chromatin-associated proteins…………………… 74 
4.3 Identification of co-purifying proteins by mass spectrometry……………………... 77 
4.4 Validation of mass spectrometry data by Western blotting………………………... 81 
4.5 Histone modifications associated with MBD proteins……………………………... 83 
 
5.    Chapter Five – Regulation of SUMO modification of MBD1…………………. 86 
 
5.1 Ubiquitin-like modifiers………………………………..…………………………...86 
5.2 Recombinant MBD1-SUMO is efficiently cleaved in vitro……………………….. 89 
5.3 Native MBD1-SUMO is refractory to SUMO proteases in vivo…………………... 92 
5.4 Native MBD1-SUMO is refractory to SUMO proteases in vitro………………….. 94 
5.5 SUMO modification destabilizes native MBD1 in vitro………….……………….. 96 
5.6 MBD1-SUMO is not degraded by the proteasome in vivo………………………… 99 
5.7 PCM1 is not the major isoform of MBD1 in HeLa cells………………………….101     
  
 
6.    Chapter Six – Discussion……….……………………………………………….1 04 
 
6.1 MBD1 potentially forms dimers…………………………………………………...104 
6.2 Binding partners of MBD proteins………………………………………………...106 
6.3 Regulation of SUMO modification of MBD1…………………………………….   107 
6.4 Conclusions and future perspectives………………………………………………1 08 
 
7.    Appendix I…………………………………………………………………...…...110 
8.    Appendix II…………………………………...………………………………….   112 





FIGURE 1.1 – Methylated bases found in DNA………………………………………. 8 
FIGURE 1.2 – Catalytic mechanism of cytosine methylation reaction………………... 16 
FIGURE 1.3 – Domain structure of methyl-CpG binding proteins…………………..... 40 
FIGURE 3.1 - Native MBD1 in HeLa nuclear extracts is not monomeric…………….. 59 
FIGURE 3.2 - Recombinant MBD1 expressed in E.coli behaves as a monomer……… 60 
FIGURE 3.3 – Separation of MBD1 and SETDB1 by gel filtration……………………62 
FIGURE 3.4 – Nucleic acid does not contribute to the large apparent size of MBD1… 63 
FIGURE 3.5 – Generation of affinity tagged MBD1…………………………………...65 
FIGURE 3.6 – Affinity tagging of MBD1 does not alter its Stoke’s radius or S value...67 
FIGURE 3.7 – Absence of proteins strongly co-purifying with FS-MBD1…………….69 
FIGURE 3.8 – Purified FS-MBD1 maintains its S value…………………………….....70 
FIGURE 3.9 – Self association of MBD1 by co-immunoprecipitation………………... 71 
FIGURE 4.1 – Extraction of MBD1 from nuclei treated with benzonase…................... 73 
FIGURE 4.2 – Purification of 3xFLAG-tagged DNA binding proteins from nuclease   
                        solubilized chromatin using the M2 monoclonal antibody…....……….. 76 
FIGURE 4.3 – Western blots for factors co-purifying with LSH and MBD proteins…. 82 
FIGURE 4.4 – Mass spectra showing peptides corresponding to different modification   
                        states of amino acids 27-40 of histone H3……………………………... 85 
FIGURE 5.1 – The SUMO cycle………………………………………………………. 87 
FIGURE 5.2 – Cleavage of recombinant SUMO modified MBD1 in vitro…………… 91 
FIGURE 5.3 – Over-expression of SENP1 or SENP2 does not reduce levels of MBD1    
                        SUMO modification in vivo……………………………………………. 93 
FIGURE 5.4 – Native SUMO modified MBD1 resists SUMO proteases in vitro…….. 95 
FIGURE 5.5 – Destabilization of native SUMO modified MBD1 in vitro……………. 98 
FIGURE 5.6 – SUMO modified MBD1 is not targeted by the proteasome in vivo…...100 
FIGURE 5.7 – An uncharacterized isoform accounts for most of the MBD1 protein in 





Methylation of cytosines within CpG dinucleotides is a feature of vertebrate DNA. The 
precise role of DNA methylation is unknown to date, although it has been implicated in 
several processes relating to transcriptional regulation. One approach to study DNA 
methylation is the characterization of proteins that bind specifically to methylated DNA. 
One such family of proteins is the methyl-CpG binding domain (MBD) containing 
family and MBD1 is a member of this family. MBD1 is implicated in transcriptional 
repression and various mechanisms by which it might bring about gene silencing have 
been proposed. These are mainly based on studies reporting interactions between MBD1 
and various proteins that regulate chromatin structure. Also MBD1 function can be 
modified by PIAS proteins, which stimulate its conjugation to SUMO (small ubiquitin-
like modifier).The original aim of this work was to address two questions about MBD1:  
 
(1) Does MBD1 form part of a stable complex with other factors, and if so, what are the 
identities of the other components? Purification of MBD1 revealed the presence of no 
stably bound interacting proteins. However, some evidence indicates MBD1 may 
interact with itself and form dimers, a finding which impacts on many aspects of the 
function of MBD1. Also a proteomics screen for transient interaction partners identified 
candidate binding partners for MBD1 and the related protein MeCP2, which may throw 
light on the function of these proteins. 
 
(2) Are there any activities which regulate MBD1 function by the removal of SUMO 
from this protein? No activities capable of removing SUMO from native MBD1 were 
found but it was demonstrated that this modification leads to the destabilization of 
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1. Chapter One - Introduction 
 
1.1 The distribution of DNA methylation 
 
1.1.1 DNA molecules as an information repository 
 
The heritable information required for the development and function of cellular life is 
carried in the form of DNA molecules (Avery et al, 1944). The information content of 
DNA is embodied in the sequence of bases (adenine, thymine, cytosine and guanine) in 
each polynucleotide chain. The double helical structure of DNA with complementary 
base-pairing of adenine to thymine and cytosine to guanine between anti-parallel 
polynucleotide strands reveals how DNA molecules can be copied, and thus how 
information can be transmitted through cell divisions (Watson and Crick, 1953). In 
addition to the heritable nucleotide sequence, extra information can be held in DNA 
molecules due to the possibility of covalent modifications of the bases, in particular 
methylation of the carbon 5 or the amine at the 4 position of cytosine, and also the amine 





























Figure 1.1 – Methylated bases found in DNA 
 
Methylation can occur on the carbon 5 or the amine at the 4 position of cytosine as well 
as the amine at the 6 position of adenine. The added methyl groups are shown in red. 
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1.1.2 Bacterial DNA methylation and restriction-modification systems 
 
In prokaryotes DNA methylation is a component of the ‘restriction-modification’ 
systems that protect the host from infection by bacteriophages. The host cell expresses 
DNA methyltransferase enzymes that chemically modify its own DNA as well as 
restriction endonucleases which specifically cleave DNA whose modification status is 
different to that of the host. Thus bacteriophage DNA can be recognised as foreign and 
destroyed by the cell (Wilson and Murray, 1991). Other functions of bacterial DNA 
methylation have been proposed including roles in DNA replication, repair and 
transcriptional regulation (Palmer and Marinus, 1994). Eukaryotic cells seem to lack 
restriction-modification systems but nevertheless many species still contain cytosine 
methylated at the carbon 5 position in their DNA. This suggests that an alternative 
function for DNA methylation exists in these organisms. 
 
1.1.3 The distribution of 5-methylcytosine across the eukaryotes 
 
In contrast to the situation in prokaryotes, methylation of eukaryotic genomes has been 
found exclusively at the carbon 5 position of cytosine. However, perhaps surprisingly 
for a covalent modification of the very molecule that stores the hereditary information of 
life, the presence and levels of 5-methylcytosine in eukaryotic genomes appear not to 
have evolved parsimoniously, and they can vary greatly from one organism to another.  
 
At one extreme organisms including the nematode worm Caenorhabditis elegans and 
the budding yeast Saccharomyces cerevisiae both lack detectable cytosine methylation 
and their genomes encode no proteins closely related to known DNA methyltransferase 
enzymes (Simpson et al, 1986; Proffitt et al, 1984; Goll and Bestor, 2005). At the other, 
some plants such as the tobacco plant Nicotiana tabacum methylate up to a third of the 
cytosine in their DNA (Montero et al, 1992). Between these two is a spectrum where 
evolutionary relationships between various eukaryotes often do not reflect the levels of 
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methylation they are observed to bear. Adult DNA from the fruit fly Drosophila 
melanogaster contains only trace amounts of 5-methylcytosine whereas DNA from the 
embryos comprises approximately 0.4% methylated cytosine predominantly in the 
context of CpT dinucleotides (Lyko et al, 2000). This situation is slightly unusual as in 
many other organisms the DNA methylation level does not depend so strongly on the 
tissue or life cycle stage examined (Bird and Taggart, 1980). 5-methylcytosine is also 
readily detectable in adults of the honey bee Apis mellifera and other social 
Hymenoptera (Wang et al, 2006; Kronforst et al, 2008), and so together with the fruit fly 
this is an example of how even organisms within the same phylogenetic class can show 
very different levels of DNA methylation. Fungi also show diverse amounts of 
methylation. Although Saccharomyces cerevisiae and Schizosaccharomyces pombe are 
devoid of the modification, this is not the case in Ascobolus immersus (Goyon et al, 
1996) or Neurospora crassa, the latter of which methylates 2-3% of its cytosine (Foss et 
al, 1993; Selker et al, 2003). Plants too show great variance in the abundance of 
genomic 5-methylcytosine between species. In contrast to the high methylation levels 
seen in the tobacco plant, the mustard weed Arabidopsis thaliana methylates only 7% of 
the cytosines available in its genome (Lister et al, 2008). An early study found cytosine 
methylation in all vertebrates examined and its contribution there to genomic DNA from 
somatic tissues ranges from just under 1% to 2% depending on the species in question 
(Vanyushin et al, 1970). Later work confirmed the presence of methylation in 
vertebrates and also found the modification, but to a lesser degree, in all non-arthropod 
invertebrates tested (Bird and Taggart, 1980). 
 
As well as the notable differences in the presence and abundance of DNA methylation 
between different eukaryotes, the distribution of this modification throughout different 
compartments of the genome also varies greatly from one organism to another. These 
methylation patterns are likely to reflect the different functions of DNA methylation 




1.1.4 Symmetrical methylation of CpG dinucleotides 
 
Early work on cytosine methylation in eukaryotes focussed on describing how this 
modification is distributed in genomes. Analysis of dinucleotides isolated from a DNAse 
digest of calf thymus DNA found methylated cytosine only in the context of CpG 
dinucleotides (Sinsheimer, 1955). A similar situation was subsequently found in the sea 
urchin with over 90% of its genomic 5-methylcytosine being associated with the 
sequence CpG (Grippo et al, 1968). A more recent nearest neighbour analysis showed 
that the mean contribution across various mouse tissues (excluding embryonic stem 
cells) of CpG methylation to total cytosine methylation was 93% (Ramsahoye et al, 
2000). A somewhat different situation is found in plants with SOLEXA sequencing of 
bisulphite treated DNA (Frommer et al, 1992) revealing 45% of the methylated 
cytosines in Arabidopsis thaliana to occur in sequence contexts other than CpG (Lister 
et al, 2008). 
 
It was subsequently demonstrated that the vast majority of CpG dinucleotides are either 
symmetrically methylated on both strands or not methylated at all, with hemimethylated 
sites being rare. An initial line of evidence in support of this was the fact that somatic 
32P-labelled Xenopus rDNA retains its resistance to digestion by the methylation-
sensitive restriction enzymes HpaII and HhaI even after reassociation with an excess of 
cloned, and therefore unmethylated, rDNA (Bird, 1978). These findings were consistent 
with studies of MspI digested calf thymus DNA. When end-labelled restriction 
fragments were digested to the corresponding 5’-deoxyribonucleoside monophosphates, 
5-methylcytidylic acid was found in approximately 90% of the ends indicating heavy 
and symmetrical methylation of CpGs within the sequence CCGG in calf thymus DNA 
(Cedar et al, 1979). More recent studies have uncovered strand-specific cycling of DNA 
methylation at an active promoter (Métivier et al, 2008; Kangaspeska et al, 2008) 
although the function of these hemimethylated sites is at present unknown. 
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1.1.5 Methylated and unmethylated compartments of the genome 
 
The distribution of symmetrically methylated CpGs within genomes is itself non-
random. A breakthrough in the understanding of DNA methylation patterns came from 
studies on the sea urchin Echinus esculentus. Digestion with methylation-sensitive 
restriction enzymes separates genomic DNA into high (>15 kb) and low (0.1 – 4 kb) 
molecular weight fractions. Furthermore, the methylation-insensitive restriction enzyme 
MspI (an isoschizomer of HpaII) digested the high molecular weight fractions to 
fragments mainly smaller than 5 kb. These experiments, together with the fact that 
tritiated methionine administered to embryos specifically labelled this high molecular 
weight fraction, showed that the sea urchin genome contains tracts of DNA where most 
of the CpG dinucleotides are methylated and tracts where most of them are not (Bird et 
al, 1979). This compartmental pattern is referred to as ‘mosaic methylation’ and is found 
in a variety of other organisms such as the sea quirt Ciona intestinalis (Simmen et al, 
1999; Suzuki et al, 2007). 
 
The term ‘global DNA methylation’ is often used to describe the distribution of this 
modification in vertebrate genomes. In contrast to the situation in the sea urchin, 
digestion of chicken DNA with methylation-sensitive restriction enzymes yields no low 
molecular weight DNA fraction that can be visualised by ethidium bromide staining. 
However, end-labelling of the digested DNA followed by agarose gel autoradiography 
revealed that over half of the HpaII fragments were concentrated in a low molecular 
weight (<0.5 kb) DNA fraction (Cooper et al, 1983). A similar situation occurs in the 
mouse where the methylated compartment dominates and unmethylated CpGs are 
concentrated in short relatively CpG rich regions known as CpG islands, which account 
for only approximately 1% of the genome (Bird et al, 1985). A recent study used a 
chromatography technique to purify human DNA enriched in unmodified CpG 
dinucleotides. Large scale sequencing of the fractionated DNA allowed the authors to 
estimate the presence of between 25,000 and 30,000 CpG islands in the human genome 
with approximately half of the identified CpG islands overlapping a known transcription 
 13
start site (Illingworth et al, 2008). These experimentally determined CpG islands showed 
good overlap with those predicted bioinformatically by the criteria of having more than 
55% G+C base composition as well as a CpG observed over expected frequency greater 
than 0.65 and length over 500 bp (Takai and Jones, 2002). 
 
1.1.6 5-methylcytosine as a mutagen 
 
Early nearest neighbour analyses revealed that CpG dinucleotides are underrepresented 
in the genomes of various animals (Josse et al, 1961; Swartz et al, 1962). For example, 
given the approximately 40% GC content of the human genome a 0.2 x 0.2 = 4% CpG 
frequency would be predicted. However, the observed frequency of CpG dinucleotides is 
actually approximately 0.8% or 5-fold less than expected. A likely explanation for this 
discrepancy would be inefficient repair of the T:G mismatches that arise from the 
spontaneous deamination of methylated cytosine to thymine. Strong support for this 
contention came from a study of nearest neighbour frequencies that revealed vertebrate 
CpG deficiencies to be matched by excesses of the dinucleotides arising from failure to 
repair this lesion, namely TpG and CpA (Bird, 1980). The implication of DNA 
methylation in CpG dinucleotide suppression is also bolstered by the observation that 
most of the CpG rich CpG islands in mammalian genome are usually methylation free 
(Bird et al, 1985; Illingworth et al, 2008). In cases where CpG rich regions are 
methylated, there is usually a good reason to expect their presence to be under positive 
selection pressure. For example, this is likely to be the case at imprinting control regions 
where methylation appears to regulate gene expression as will be discussed in section 
1.3.5. Similar forces also seem to shape the genomes of other organisms. In the sea 
squirt Ciona intestinalis, predictions of methylation based on bioinformatic analysis of 
CpG composition were largely validated by bisulphite sequencing (Suzuki et al, 2007). 
 
Other evidence supporting the notion that cytosine methylation causes mutations in 
mammalian cells includes the observation that in human DNA, restriction enzyme sites 
containing CpG dinucleotides are relatively much more polymorphic than ones that do 
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not (Barker et al, 1984). Furthermore, disproportionately many of the point mutations 
found in human genetic disorders and in the tumour suppressor gene p53 in cancer arise 
from cytosine to thymine transitions (Cooper and Youssoufian, 1988; Rideout et al, 
1990). Given that cytosine methylation has been tolerated by natural selection in spite of 
this mutagenic load, it seems likely that DNA methylation must be required for 
important functions in the organisms where it is present. Section 1.3 will examine the 
evidence for various functions proposed for DNA methylation, but first the apparatus 
that lays down this modification will be considered. 
 
1.2 DNA methylation machinery 
 
1.2.1 Identification of DNA methyltransferases 
 
Methylation is incorporated into genomic DNA post-synthetically (Scarano et al, 1965; 
Burdon and Adams, 1969; Sneider and Potter, 1969; Kappler, 1970). Methyltransferase 
activities specific for CpG dinucleotide containing DNA were originally identified in a 
variety of mammalian extracts (Gruenbaum et al, 1982; Bestor and Ingram, 1983). 
Purification of such an activity from mouse cells allowed peptide sequences from the 
protein to be obtained. Using this information the gene was cloned by screening a phage 
library with degenerate probes, and it was eventually named Dnmt1. The gene sequence 
revealed a C-terminal domain with homology to bacterial methyltransferases and an N-
terminal domain of unknown function (Bestor et al, 1988). 
 
Mouse embryonic stem cells homozygous for a null allele of Dnmt1 retained residual 
DNA methyltransferase activity as well as low but stable levels of DNA methylation. 
Extracts from these cells were able to methylate DNA in vitro (albeit with much reduced 
efficiency) and when infected with a retrovirus, these cells still carried out de novo 
methylation of the viral LTR (long terminal repeat). Taken together these experiments 
indicated the presence of DNA methyltransferase activities other than Dnmt1 in mouse 
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cells (Lei et al, 1996). Searches of expressed sequence tag (EST) databases for 
sequences with homology to Dnmt1 led to the identification of another candidate DNA 
methyltransferase, Dnmt2 (Yoder and Bestor, 1998). However, convincing evidence 
supporting a role for Dnmt2 in DNA methylation was not forthcoming and more recent 
work suggests that its major role is to methylate a cytosine in an aspartic acid transfer 
RNA (Goll et al, 2006). As of yet the biological significance of this conserved function 
is unknown, but as the protein is required in the cytoplasm rather than the nucleus for 
normal differentiation of the liver and brain in zebrafish (Rai et al, 2007), a pivotal role 
as a DNA methyltransferase appears unlikely. EST database searches by different 
investigators also led to the identification of the Dnmt3a and Dnmt3b genes, which 
turned out to encode bona fide CpG methyltransferase activities (Okano et al, 1998). 
Finally, Dnmt3L, a protein related to the mammalian DNA methyltransferases was 
identified. This protein lacks conserved catalytic motifs and is involved in regulating 
some of the functions of DNA methyltransferases discussed in section 1.3.5. 
 
1.2.2 Catalytic mechanism 
 
The crystal structure of the bacterial DNA cytosine-5-methyltransferase HhaI 
(Klimasauskas et al, 1994) provided strong evidence for a previously proposed catalytic 
mechanism for DNA methylation (Santi et al, 1983). The reaction mechanism consists 
of a nucleophilic attack on the carbon 6 of cytosine by an electron pair from a sulphur 
atom of a conserved catalytic cysteine (Figure 1.2A). This step is facilitated by the 
protonation of the nitrogen 3 position of cytosine by a conserved glutamic acid and leads 
to the formation of an intermediate where the enzyme is covalently bound to its substrate 
and electrons are pushed across the carbon 5 position. This enamine then attacks the 
methyl group of the co-factor s-adenosyl-L-methionine (SAM) thus transferring the 
group to the carbon 5 position of cytosine (Figure 1.2B). The removal of a proton from 
carbon 5 leads to reformation of the double bond between carbons 5 and 6 and the 




Figure 1.2 – Catalytic mechanism of cytosine methylation reaction (adapted from 
Jeltsch, 2006) 
 
(A) A lone pair of electrons from a sulphur atom of a conserved catalytic cysteine in 
DNA methyltransferases carries out a nucleophilic attack on the carbon 6 position of 
cytosine. The protonation of nitrogen 3 of cytosine by an enzymatic glutamic acid 
promotes this reaction. 
(B) The reactive 4-5 enamine formed attacks the methyl group of SAM leading to its 
transfer to carbon 5. This is coincident with the removal of a proton from nitrogen 3. 
The enzyme and substrate remain covalently bound via the sulphur atom attached to 
carbon 6. 
(C) Abstraction of a proton from the carbon 5 position leads to reformation of the double 
bond between carbons 5 and 6 and release of the enzyme by a β-elimination reaction. 





Thiolate attack at C6 Enamine attack on methyl donor
Abstraction of proton and release of
enzyme by β-elimination 
5-methylcytosine (reaction product)
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crystal structure of HhaI in complex with DNA was solved, it was difficult to see how 
this reaction could proceed as neighbouring nucleotides lie in the way of groups which 
would have to react with the C5 and C6 positions of cytosine. In the structure the target 
base is flipped out of the double helix so that it can be positioned in the active site of the 
enzyme. Due to the homology between the bacterial HhaI and the mammalian 
methyltransferase enzymes, it is likely that the catalytic mechanism is conserved. 
 
1.2.3 Maintenance methylation and epigenetics 
 
The evidence discussed in section 1.1 for symmetrical CpG methylation as well as the 
stable presence of heavily methylated and largely unmethylated sequences in the same 
organism, is consistent with the idea that methylation patterns are replicated during cell 
division. This view was supported by experiments where unmodified or artificially 
methylated foreign DNA sequences were inserted into cultured mouse cells (Wigler et 
al, 1981; Stein et al, 1982a). Although methylation patterns were not maintained with 
complete fidelity, the presence or absence of CpG methylation in tracts of DNA (and not 
the presence of cytosine methylation in other contexts) was faithfully sustained over 
many cell divisions. Consistent with this imperfect copying of methylation patterns, 
heterogeneous methylation was found at several genomic sites in solid tumours in spite 
of their clonality (Silva et al, 1993). Furthermore, bisulphite sequencing analysis of the 
endogenous FMR1 promoter revealed stability in individuals in the ratio of cells 
containing heavily methylated versus largely unmethylated tracts. Also it was revealed 
that heavily methylated clones are heterogeneous with respect to which individual CpGs 
lack the modification (Stöger et al, 1997). Therefore, like foreign DNA inserted into 
mouse cells, endogenous sequences also seem to retain their overall methylation status 
through cell divisions, but with little accuracy at the level of single CpG sites. 
 
Experiments in vitro revealed a strong preference of endogenous mammalian DNA 
methyltransferase activities as well as recombinant human DNMT1 for hemimethylated 
substrates (Gruenbaum et al, 1982; Bestor and Ingram, 1983; Pradhan, et al, 1999). Such 
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an activity would be expected to act preferentially on the hemimethylated sites generated 
during replication of fully methylated CpGs, and thus a mechanistic explanation for the 
copying of methylation patterns is provided. A number of proteins reported to interact 
with Dnmt1 are also likely to be involved in the copying of methylation patterns. For 
example, it has been proposed that the SRA (SET and RING associated) domain 
containing protein Np95/UHRF1 recruits the maintenance DNA methyltransferase to the 
hemimethylated CpG sites produced during S phase. Lines of evidence supporting this 
model include the interaction of recombinant Np95/UHRF1 with hemimethylated DNA 
in vitro, the observation of a physical interaction between DNMT1 and UHRF1, and the 
mislocalisation of Dnmt1 together with the loss of methylation seen in mouse embryonic 
stem cells where the Uhrf1 gene has been ablated (Bostick et al, 2007; Sharif et al, 
2007). 
 
The fact that DNA methylation represents information aside from the genome sequence 
that can be inherited through cell divisions supported the earlier suggestion that this 
modification of the genome might be involved in events requiring cellular memory such 
as changes in gene expression during differentiation and X-inactivation (Holliday and 
Pugh, 1975; Riggs, 1975). For this reason the study of DNA methylation and related 
phenomena is often considered to be part of a field known as ‘epigenetics’ (Bird, 2002). 
 
1.2.4 De novo methylation 
 
As discussed above, DNA methylation patterns can, at least to some extent, be stably 
propagated through cell divisions, but these patterns must somehow be established in the 
first place. In mammals, global demethylation of the genome by as yet unidentified 
demethylase activities occurs in preimplantation embryos and primordial germ cells 
(Reik et al, 2001). Subsequent to this, de novo DNA methylation must occur in order to 
re-establish methylation patterns. Although relatively inefficient enzymes in vitro, 
recombinant Dnmt3A and Dnmt3B showed no preference for hemimethylated over 
unmethylated substrate DNA indicating that these might be good candidates for a role in 
 19
de novo methylation in vivo. Consistent with this view these enzymes are relatively 
highly expressed in embryonic stem cells and the early mouse embryo (Okano et al, 
1998) where de novo DNA methyltransferase activity is at its highest (Jähner et al, 1982; 
Palmiter et al, 1982; Stewart et al, 1982). 
 
Genetic studies have also strongly implicated Dnmt3a and Dnmt3b in de novo 
methylation in vivo. Mouse embryonic stem cells where both Dnmt3a and Dnmt3b have 
been ablated fail to carry out de novo methylation of proviral DNA following infection 
with a retrovirus. This is in sharp contrast to wild-type cells and even Dnmt1-null cells, 
which can still methylate proviral DNA albeit with slower kinetics. Furthermore, mouse 
embryos lacking Dnmt3a and Dnmt3b showed essentially identical methylation levels at 
C-type retroviral DNA and intra-cisternal A particle (IAP) repeats to those seen in the 
blastocyst. The situation is different in Dnmt1-deficient embryos where methylation of 
these sequences is significantly lower than in the blastocyst. These comparisons were 
taken to mean that unlike Dnmt1, the methyltransferases Dnmt3A and Dnmt3B are not 
required for the maintenance of existing methylation. Rather they are needed to establish 
embryonic methylation patterns de novo subsequent to the relatively hypomethylated 
blastocyst stage (Okano et al, 1999). 
 
The model that emerged from the above lines of research proved to be too simplistic and 
required some modifications. Extended culture of mouse embryonic stem cells lacking 
both Dnmt3a and Dnmt3b gave rise to a progressive loss of CpG methylation, ultimately 
to levels comparable to Dnmt1-null cells (Chen et al, 2003). Taken together with the 
subtle defect in de novo methylation of proviral DNA seen in Dnmt1 knock-out cells, it 
is apparent that a cut and dried distinction between Dnmt1 as a maintenance enzyme 
versus Dnmt3a and Dnmt3b as de novo methyltransferases is not appropriate. A more 
realistic view of maintenance methylation likely involves passive demethylation due to 
imperfect completion of every hemimethylated site by Dnmt1 being offset by a degree 
of de novo methylation by Dnmt3A and Dnmt3B within methylated domains. 
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1.2.5 Factors required for targeting DNA methylation 
 
For a long time it was unclear how DNA methylation was targeted to certain regions of 
genomes whilst being excluded from others. However, recent studies have begun to 
throw some light upon this question. The situation is complex and the exact contribution 
of various factors depends on the organism being studied. Nevertheless, roles in this 
process are now starting to be delineated for RNA interference (RNAi), chromatin 
structure, DNA sequence, transcription, and a variety of proteins other than the DNA 
methyltransferase enzymes. 
 
A number of factors appear to be required for the efficient function of DNA 
methyltransferase enzymes. For example, the lysine demethylase mLSD1 is required for 
proper DNA methylation in mouse embryonic stem cells, and this is reported to be 
because Dnmt1 is hypermethylated on a lysine residue leading to its destabilization in 
Lsd1-deficient cells (Wang et al, 2009). A separate interaction of DNMT1 with PCNA 
(proliferating cell nuclear antigen) was proposed to be important for recruiting DNA 
methyltransferase activity to replication forks in S phase, and thus for the efficient 
methylation of newly synthesised DNA (Leonhardt et al, 1992; Chuang et al, 1997). 
However, this interaction may only be of moderate significance as a truncated form of 
DNMT1 which cannot interact with PCNA is recruited to DNA with only two-fold 
reduced efficiency (Spada et al, 2007). Although roles for LSD1 and PCNA in efficient 
DNA methylation remain plausible, it is not clear whether these factors play any part in 
targeting methylation to specific genomic regions. 
 
There is strong evidence that RNAi can direct transcriptional silencing and DNA 
methylation in plants. RNA-directed DNA methylation (RdDM) was first observed in 
tobacco plants carrying transgenic viral sequences where replication of the viral RNA 
induced methylation of the transgenic DNA but not the rest of the genome (Wassenegger 
et al, 1994). A similar effect was seen with a transcribed transgenic inverted repeat 
(Mette et al, 1999) thus correlating the presence of double stranded RNA with DNA 
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methylation at homologous sequences. The plant DNA methyltransferases responsible 
for the establishment of RdDM were subsequently found to be DRM and CMT3 rather 
than MET1, which is only involved in its maintenance (Cao et al, 2003; Jones et al, 
2001). It was demonstrated that mutations in the Arabidopsis RNAi pathway result in 
failure to establish methylation at certain genomic regions (Chan et al, 2004) and 
furthermore, a putative DNA-dependent RNA polymerase involved in this process has 
been identified (Herr et al, 2005; Onodera et al, 2005). The small RNAs produced by 
DICER-LIKE3 are then incorporated into ARGONAUTE4, which is thought to recruit 
methyltransferase enzymes to homologous DNA sequences (Zilberman et al, 2004; Li et 
al, 2006; Qi et al, 2006). Despite the clear evidence available in plants, whether or not 
RNAi can direct DNA methylation in mammalian cells remains a controversial issue 
(Morris et al, 2004; Ting et al, 2005). 
 
Several lines of evidence indicate that transcription might play a direct role in dictating 
DNA methylation patterns. Using transgenic mice it was shown that mutation of sites for 
the transcriptional activator Sp1 in the Aprt CpG island promoter leads to methylation of 
this region (Brandeis et al, 1994; Macleod et al, 1994). This is consistent with a model 
where transcription from a promoter normally keeps the region free from methylation. 
There is also circumstantial evidence that sequences that are transcribed through are 
preferentially targeted for DNA methylation. For instance, human coding regions are 
more likely to be methylated when they reside on the active rather than the inactive X 
chromosome (Hellman and Chess, 2007). Consistent with this, recent data from mouse 
studies suggested that transcription from nearby protein coding genes through imprinted 
differentially methylated regions is required for them to become methylated (Chotalia et 
al, 2009). The link between transcription and DNA methylation may prove to be 
extremely general. In the sea squirt methylation is often associated with gene bodies 
particularly at evolutionarily ancient housekeeping genes which are presumably 
transcribed in many tissues (Suzuki et al, 2007). Furthermore, coding regions also 
appear to be methylation targets in Arabidopsis (Zilberman et al, 2007). 
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Several avenues of research have implicated ATP-dependent chromatin remodelling 
enzymes in the targeting of DNA methylation. Genetic studies in Arabidopsis uncovered 
a requirement for DDM1 (deficient in DNA methylation 1), a SWI2/SNF2-like protein, 
for proper DNA methylation, especially of repetitive sequences (Vongs et al, 1993; 
Jeddeloh et al, 1999). Consistent with this finding, Lsh (lymphoid specific helicase), the 
mammalian homologue of DDM1, is also required for proper methylation in the mouse 
(Dennis et al, 2001). As well as promoting methylation of repetitive sequences, Lsh also 
seems to be required for the modification and silencing of certain genes. Chromatin 
immunoprecipitation revealed the presence of Lsh at the imprinted Cdkn1c locus. This 
gene loses methylation and is inappropriately expressed from the paternal allele in 
mouse embryos when Lsh is deleted, even though regulation of other imprinted genes is 
unaffected (Fan et al, 2005). Furthermore, Lsh is present at the Hox cluster and when the 
protein is removed there is reduced methylation and aberrant expression of some of 
these genes (Xi et al, 2007). Human cells carrying mutations in ATRX, another member 
of the SWI2/SNF2 family of proteins, show changes in DNA methylation patterns at 
rDNA arrays and several other repetitive sequences. This further suggests a role for 
chromatin remodelling in the targeting of DNA methylation (Gibbons et al, 2000). 
 
Covalent modifications of histones can also now be regarded as important in the 
targeting of DNA methylation patterns. Genetic studies have shown that cytosine 
methylation in Neurospora crassa is dependent on the trimethylation of histone H3 at 
lysine K9 by DIM-5 (Tamaru and Selker, 2001; Tamaru et al, 2003). Furthermore, the 
Neurospora homolog of HP1, a protein that binds to the N-terminal tail of histone H3 
only when it is methylated at lysine K9, is also required for DNA methylation (Freitag et 
al, 2004). The direct physical interaction observed between this protein and the 
Neurospora crassa DNA methyltransferase enzyme suggested a model where HP1 
recruits this enzyme to chromatin containing histone H3 methylated at lysine K9 (Honda 
and Selker, 2008). Mutations in KRYPTONITE from Arabidopsis, which encodes an H3 
lysine K9 methyltransferase, also cause a reduction in cytosine methylation levels 
arguing for a more general role for this histone mark in promoting DNA methylation 
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(Jackson et al, 2002). Furthermore, in mouse cells deficient for Suv39h1 and Suv39h2, 
two mammalian histone H3 lysine K9 methyltransferase enzymes, DNA methylation is 
reduced at pericentric heterochromatin. An interaction between Dnmt3b and HP1α 
together with the mis-localisation of Dnmt3b in these mutant cells suggests a similar 
mechanism is at work to the one described in Neurospora (Lehnertz et al, 2003). 
 
A case can now also be made for a role of histone H3 lysine K4 methylation in 
controlling which genomic regions are subject to DNA methylation. The N-terminal 
cysteine-rich domain of Dnmt3L was recently shown to associate with the N-terminal 
tail of histone H3 but only when it is not methylated at lysine K4 (Ooi et al, 2007). As 
Dnmt3L is a non-catalytic regulator of de novo DNA methyltransferases that is required 
for methylation of maternally imprinted loci and of retrotransposons in male germ cells 
(Bourc’his, et al, 2001; Bourc’his and Bestor, 2004), this suggests that the absence of 
methylation at lysine K4 of histone H3 might permit the recruitment of DNA 
methyltransferase activity to specific parts of the genome. 
 
Finally, the idea that specific DNA sequences (beyond the simple requirement for CpG 
dinucleotides) might govern methylation patterns by being better or worse substrates for 
methyltransferase enzymes was recently brought into focus (Jia et al, 2007). The crystal 
structural of a tetrameric complex of Dnmt3a and Dnmt3L revealed that the two active 
sites are separated by 40 Å approximately corresponding to one helical turn of DNA. 
This suggested that DNA methylation might be regulated by a preference of Dnmt3a for 
sequences with CpGs separated by approximately 10 base pairs or one helical turn. 
Supporting this idea, a periodicity of 8-10 base pairs was found in the methylation of 
stretches of DNA incubated with recombinant Dnmt3a in vitro and a similar periodicity 
was found in the CpG dinucleotides present in differentially methylated regions of 
maternally imprinted genes, but not randomly selected CpG islands. Given that Dnmt3a 
and Dnmt3L are required in germ cells for the establishment of imprints (Kaneda et al, 
2004; Bourc’his et al, 2001), an argument can be made that sequence preferences of 
methyltransferases contribute to the targeting of DNA methylation. 
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1.2.6 Aberrant DNA methylation 
 
As will be discussed in section 1.3, heavy methylation of promoter DNA is incompatible 
with transcription of the associated gene. Although DNA from tumour samples tends to 
be globally hypomethylated (Feinberg and Vogelstein, 1983; Gama-Sosa et al, 1983), 
promoters of tumour suppressor genes are frequently observed to be silenced and 
methylated in cancer giving rise to the suggestion that DNA methylation plays a role in 
carcinogenesis (Jones and Baylin, 2002). What remains unclear, however, is whether 
DNA methylation is a cause or consequence of such transcriptional silencing. Even if it 
is assumed to be causal, it is unknown whether methylation of tumour suppressor genes 
represents random aberrant events driving cancer development, or if it is dictated by 
genetically induced changes in oncogenes lying upstream in tumorigenesis.  
 
Evidence exists supporting each of the viewpoints described above. When different 
mouse cell lines are grown in culture many of the CpG islands of a similar set of 
dispensable genes acquire methylation (Antequera et al, 1990). This argues that 
methylation is either targeted to promoters that are already repressed or else it occurs 
randomly and is only selected against when it coincides with and represses the promoter 
of a gene required for proliferation. Consistent with the first interpretation most of the 
genes found to be methylated in colon cancer are also found to be transcriptionally 
inactive in the normal colon (Keshet et al, 2006). However, the second interpretation fits 
in with the fact that demethylating agents such as 5-azadeoxycytidine can often partially 
reactivate silenced genes in cancer (Jones and Baylin, 2002). Experiments favouring a 
model where activated oncogenes direct DNA methylation and silencing to promoters of 
specific tumour suppressors have been carried out by researchers studying Ras. In this 
case an elaborate pathway to specifically methylate and suppress certain growth 
inhibitory genes seems to be hijacked by Ras in the transformation process (Gazin et al, 
2007). In the light of these data, it seems most plausible that DNA methylation can be 
part of the oncogenic process both by being co-opted by activated oncogenes to silence 
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specific promoters, and by providing a source of random yet heritable changes in gene 
expression profiles. 
 
1.3 Functions of DNA methylation 
 
1.3.1 DNA methylation is essential for proper development in mammals 
 
Mice deficient for the maintenance methyltransferase enzyme Dnmt1 are not viable (Li 
et al, 1992) and when they are homozygous for a null allele of Dnmt1 development is 
arrested prior to the 8-somite stage (Lei et al, 1996). In addition to its enzymatic activity 
Dnmt1/DNMT1 associates with a variety of other proteins such as histone deacetylases 
and can function as a transcriptional repressor in some assays (Fuks et al, 2000; 
Robertson et al, 2000). However, it appears that the primary cause of the phenotype 
observed in the absence of Dnmt1 is the reduction in DNA methylation as embryonic 
stem cells expressing Dnmt1 with a conservative point mutation that abolishes its 
enzymatic activity show similar defects to those not expressing the protein at all 
(Damelin and Bestor, 2007). The de novo DNA methyltransferase enzymes are also 
critical for normal mammalian development. Dnmt3a-deficient mice appear normal at 
birth but soon become runted and usually die within four weeks. Dnmt3b mutants die in 
gestation showing developmental abnormalities including growth retardation and rostral 
neural tube defects (Okano et al, 1999). DNMT3B is also important for normal human 
development with mutations in this gene giving rise to ICF (immunodeficiency, 
centromere instability and facial anomalies) syndrome (Hansen et al, 1999). As many 
ICF mutations affect the catalytic domain of DNMT3B (Xu et al, 1999) and the satellite 
DNA of ICF patients is highly demethylated (Jeanpierre et al, 1993), it appears that the 
developmental defects here are likely to be down to loss of methyltransferase activity 
rather than some other function of the protein. 
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Although it is clear that DNA methylation is required for normal development, to date 
many of the molecular details of how a lack of DNA methylation leads to the defects 
described above remain to be elucidated. Many lines of evidence point to a potential role 
for DNA methylation in transcriptional repression and these will be considered later. 
First, however, a potential role for DNA methylation in the maintenance of genomic 
stability will be discussed. 
 
1.3.2 Genome stability 
 
Early observations of human cells administered with the demethylating agent 5-
azadexoycytidine revealed increased chromosome associations between satellites, 
secondary constrictions and telomeric regions (Viegas-Péquignot and Dutrillaux, 1976). 
Similar abnormal associations were seen between methylation deficient centromeric 
regions in mitogen stimulated cells from ICF patients (Jeanpierre et al, 1993; Xu et al, 
1999). Together these results suggested that DNA methylation might function in the 
maintenance of chromosome integrity. However, this conclusion should be treated with 
caution as any effects observed in experiments using 5-azadeoxycytidine could be due to 
its ability to crosslink proteins to DNA (Jüttermann et al, 1994) and the chromosome 
rearrangements observed in ICF are not seen in cells taken directly from patients (Xu et 
al, 1999). 
 
Genetic studies in mice have also asked whether DNA methylation might be involved in 
maintaining genomic stability. Embryonic stem cells null for Dnmt1 were reported to 
exhibit increased mutation rates and the types of mutations observed suggest a role for 
methylation in the suppression of mitotic recombination as well as faithful chromosome 
segregation during mitosis (Chen et al, 1998). Also supporting a role for methylation in 
the maintenance of genome stability, mice hypomorphic for Dnmt1 develop aggressive 
T cell lymphomas aged 4-8 months. These tumours often displayed trisomy of 
chromosome 15 indicating that demethylation could lead to carcinogenesis by promoting 
chromosome instability (Gaudet et al, 2003). However, once again these conclusions 
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must be treated with a degree of scepticism. An independent study found no evidence of 
an elevated mutation rate in Dnmt1-null embryonic stem cells (Chan et al, 2001) and 
ApcMin/+ mice develop fewer polyps, perhaps due to a decreased rate of loss of 
heterozygousity, when they are hypomorphic for Dnmt1 (Laird et al, 1995). 
 
Less disputed evidence that DNA methylation is important for genomic stability comes 
from studies of the fungus Neurospora crassa. In this organism complete loss of 
methylation due to mutation of the DNA methyltransferase gene dim-2 or partial loss of 
methylation induced by S-adenosylmethionine starvation leads to aneuploidy (Foss et al, 
1993). However, it is difficult to be confident that this is a direct consequence of DNA 
methylation defects rather than being a secondary effect of changes in gene expression 
due to loss of methylation. The same caution would have to be applied to mammalian 
systems even if the data supporting a role for DNA methylation in the maintenance of 
genome stability discussed here is taken at face value. 
 
1.3.3 Transcriptional repression 
 
A lot of early work suggested that DNA methylation might play a role in transcriptional 
repression. An inverse correlation was noted between methylation and expression levels 
of integrated viral genes in adenovirus-transformed cell lines (Sutter and Doerfler, 1980; 
Vardimon et al, 1980) and in support of a causal relationship cloned adenovirus E2a 
region microinjected into Xenopus oocytes was repressed specifically when methylated 
(Vardimon et al, 1982). Consistent with this result, artificially methylated transgenes 
inserted into mouse cells failed to be expressed compared to unmethylated controls 
(Stein et al, 1982b) and promoter CpG methylation also inhibited transcription of cloned 
genes in transfected cells and in transcription assays in vitro (Ben-Hattar and Jiricny, 
1988; Watt and Molloy, 1988; Iguchi-Ariga and Schaffner, 1989). Treatment of certain 
cell types with 5-azadexoycytidine led to the reactivation of some genes (Jones, 1985) 
implicating methylation in the repression of endogenous promoters, however, there are 
caveats associated with experiments using this drug that are mentioned above. Also it 
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must be kept in mind that cell lines often methylate promoters that are normally 
methylation free in tissues (Antequera et al, 1989) and so such experiments using 
cultured cells may reveal a role for methylation in gene silencing that is not present 
under physiological conditions. 
 
Later work firmly implicated methylation-mediated gene silencing in X-inactivation and 
imprinting as will be discussed in sections 1.3.4 and 1.3.5. However, compelling 
evidence for a general role for DNA methylation in gene repression under physiological 
conditions is still lacking. A recently described example which may prove to be an 
exception to this is the repression of the transcription factor gene Elf5 in embryonic stem 
cells (Ng et al, 2008). Elf5 is needed for the proliferative capacity of trophoblast cells 
and is aberrantly expressed in methylation deficient embryonic stem cells, where its 
promoter becomes demethylated. This results in aberrant differentiation of embryonic 
stem cells into trophoblast giant cells implying that DNA methylation controls 
development by regulating gene expression. Work on the endogenous Oct4 gene that is 
silenced and methylated during development, however, showed that DNA methylation 
occurs only after silencing and serves merely to stabilize the repressed state (Feldman et 
al, 2006). Whether this paucity of examples of genes being developmentally regulated 
by DNA methylation reflects the true biological role of methylation or the technical 
limitations of current methodologies is unclear. 
 
DNA methylation-mediated transcriptional repression has been shown to regulate 
parasitic repetitive DNA elements. Some relatively benign parasitic sequences transpose 
at high frequencies when cloned copies are transfected into human cells (Moran et al, 
1996) and IAP retroviral transcripts are upregulated over 50-fold in Dnmt1-deficient 
mouse embryonic stem cells (Walsh et al, 1998). Furthermore, tumours from mice 
hypomorphic for Dnmt1 are frequently found to express oncogenic Notch1 due to 
insertional mutagenesis by an IAP retrovirus (Howard et al, 2008). Studies in 
Arabidopsis also support the notion that DNA methylation functions to protect genomes 
from parasitic elements as mutations in this organism that cause decreased methylation 
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also lead to mobilization of transposons (Miura et al, 2001). Nevertheless the conclusion 
that a primary function of DNA methylation is to protect genomes from mutagenic 
transposition by parasitic elements is controversial. Some organisms such as the sea 
squirt Ciona intestinalis appear to target methylation to gene bodies rather than to 
transposable elements (Simmen et al, 1999; Suzuki et al, 2007). Also it has been argued 
that the hypomethylation of transposable elements observed in oocytes, testis and early 
mouse embryos, precisely at the time when transposition could be most damaging, 
makes it unlikely that the main purpose of DNA methylation is to suppress mobilization 
of these elements. An alternative but not mutually exclusive possibility is that 
transcription of parasitic elements represents ‘transcriptional noise’ which could 
interfere with the precise gene expression patterns required in various differentiated cell 





Mammalian females carry two copies of the X chromosome whereas males only have 
one. In order to equalize the expression levels of X-linked genes between the two 
genders females silence one copy of the X chromosome in each cell. Early in the 
development of placental mammals each cell of a female embryo randomly chooses one 
copy of the X chromosome for inactivation and then this decision is stably propagated in 
all of the daughters of that cell. This model was proposed partly on the basis of the 
mosaic phenotypes of female mice heterozygous for a variety of sex-linked mutations 
(Lyon, 1961) and has proved to be largely correct, only breaking down in the very early 
embryo, where the paternal X chromosome is subject to imprinted X inactivation (Mak 
et al, 2004; Okamoto et al, 2004). This state persists throughout development in the 
extraembryonic lineages, but in the embryo proper the silenced paternal X chromosome 
is reactivated before the onset of random X inactivation. Given that X inactivation 
involves a heritable epigenetic distinction between identical sequences present in the 
same cell, the involvement of DNA methylation in this process now seems like an 
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obvious hypothesis. Remarkably, however, this was predicted before CpG methylation 
was known to occur predominantly symmetrically and before any eukaryotic 
maintenance methyltransferase activities had been identified (Riggs, 1975). 
 
Support for this idea came from experiments using 5-azadexoycytidine. By using this 
drug to induce genomic demethylation in interspecies somatic cell hybrids it was 
possible to reactivate genes residing on the inactive X chromosome (Mohandas et al, 
1981) and this occurred concomitantly with the demethylation of the promoter of a 
reactivated gene (Hansen and Gartler, 1990). Evidence also emerged of differential 
methylation between the active and inactive X chromosomes. Digestion of human 
metaphase chromosomes with the methylation sensitive restriction enzyme HhaI 
followed by end-labelling with biotinylated dUTP and immunofluorescence revealed 
higher methylation levels on the active than the inactive X chromosome (Viegas-
Péquignot et al, 1988) and this observation was subsequently verified by microarray 
analysis of fragmented genomic DNA fractionated with an antibody against methylated 
cytosine (Weber et al, 2005). These results are somewhat surprising given the 
association between methylation and transcriptional repression. However, CpG islands 
on the inactive X chromosome do specifically acquire methylation consistent with a 
model where DNA methylation represses transcription from promoters on the inactive X 
(Wolf et al, 1984; Lock et al, 1986). Further supporting the link between methylation 
and repression is the fact that the CpG islands of genes which escape X-inactivation are 
infrequently methylated compared to those which are silenced (Carrel and Willard, 
2005; Illingworth et al, 2008). Genetic studies also support a role for DNA methylation 
in regulating mammalian dosage compensation. The expression pattern of X-linked lacZ 
transgenes in Dnmt1-deficient embryos revealed defective random X chromosome 
inactivation where DNA methylation is lacking (Sado et al, 2000). 
 
One feature of the role of DNA methylation in the regulation of X inactivation is that it 
appears to be required for the maintenance rather than the establishment of gene 
silencing. This is demonstrated by the fact that the X-linked mouse Hprt gene promoter 
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only becomes methylated after inactivation has taken place (Lock et al, 1987). This facet 
is also evident in the methylation mediated silencing of the non-coding Xist RNA 
promoter, which is mis-regulated in methylation-deficient differentiating Dnmt1-null 
cells but not in the corresponding embryonic stem cells (Beard et al, 1995). The Xist 
RNA is expressed exclusively from the inactive X chromosome, which it coats and is 
required for the establishment of silencing of in cis (Penny et al, 1996). Aberrant 
expression of the Xist RNA from the male active X chromosome in methylation-
deficient cells results in down regulation of many X-linked genes and may contribute to 
the apoptotic phenotype of differentiating Dnmt1-null embryonic stem cells (Panning 




Imprinted genes are expressed preferentially from either the maternal or paternal allele 
with conservative estimates predicting around one hundred mammalian genes likely to 
be regulated in this way (Reik and Walter, 2001). The first, and best studied, genes 
demonstrated to show imprinted expression profiles were the mouse Igf-2 and H19 loci, 
which are transcribed exclusively from the paternal and maternal alleles respectively 
(DeChiara et al, 1991; Bartolomei et al, 1991). Maternal inheritance of a deletion in the 
H19 gene leads to biallelic expression of Igf-2 (Leighton et al, 1995) implying that 
imprinting of these two loci, which lie only ninety kilobases apart (Zemel et al, 1992), is 
somehow connected. Igf-2 imprinting is independent of the presence of the H19 RNA 
(Jones et al, 1998) suggesting that a common regulatory mechanism exists for these two 
genes rather than the repression of one simply being downstream of the expression of 
the other. 
 
As was the case in X-inactivation, DNA methylation represented a strong candidate for a 
role in the regulation of imprinting, due to a need for heritable discrimination of two 
copies of the same sequence in one cell. Early evidence supporting this notion was the 
observation that foreign DNA inserted into particular mouse genomic regions would 
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show parent of origin-specific differences in DNA methylation levels (Sapienza et al, 
1987; Reik et al, 1987). This was backed up by analysis of the endogenous H19 locus, 
which is specifically methylated on the paternal allele (Ferguson-Smith et al, 1993; 
Bartolomei et al, 1993). Ultimately a causal role for DNA methylation in imprinting was 
established by genetic studies in mice. 
 
Mouse embryos null for Dnmt1 show aberrant biallelic expression of the H19 gene and 
silencing of the normally expressed paternal Igf-2 allele (Li et al, 1993). The finding that 
a deficiency in methylation can lead to erroneous gene repression may seem somewhat 
paradoxical given the implication of DNA methylation in transcriptional silencing. 
However, this was resolved by the discovery of a distant enhancer that normally only 
stimulates expression of the paternal Igf-2 allele. Such specificity arises because the 
maternal allele is shielded from this enhancer by the binding of the insulator protein 
CTCF to the unmethylated allele of the closely linked H19 differentially methylated 
region (Bell and Felsenfeld, 2000; Hark et al, 2000). Ablation of Dnmt3L in the mouse 
reinforced the evidence for a role for DNA methylation in imprinting. Heterozygous 
progeny of female mice null for Dnmt3L die mid-gestation and bisulphite sequencing 
revealed specific demethylation of differentially methylated imprinting control regions 
in maternal oocytes and embryos. This correlated with deregulated expression of 
imprinted genes and is the likely cause of the maternal effect lethality (Bourc’his, et al, 
2001). Conditional knock-out of Dnmt3a in mouse germ cells revealed a similar role for 
this gene in the establishment of imprints. Progeny of females lacking Dnmt3a in their 
germ cells die in utero with a lack methylation and biallelic expression of all maternally 
imprinted genes tested (Kaneda et al, 2004). Finally, except for the modification of 
imprinted regions, rescue of Dnmt1-null embryonic stem cells with a Dnmt1 cDNA 
largely restored genomic cytosine methylation. These cells fail to properly regulate 
imprinted genes thus firmly implicating a need for DNA methylation rather than some 
other function of the methyltransferase enzymes in this process (Tucker et al, 1996). 
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An initial reason for supposing that some genes might show parent of origin-dependent 
expression profiles was the early death of mouse embryos derived from zygotes 
reconstituted with two maternal genomes. Defective imprinting did indeed prove to be 
the only major barrier to the development of parthenogenetic mice. This is demonstrated 
by the fertile adult mice that can be generated in this fashion if one of the mothers bears 
deletions in certain imprinted regions such that the expression profile generated by her 
contribution to the progeny’s genome more closely resembles a paternal one (Kono et al, 
2004; Kawahara et al, 2007). Given that imprinting is disrupted in DNA methylation-
deficient mice, and given that the severe phenotype seen in parthenogenetic embryos is 
caused by defective imprinting alone, it seems likely that mis-regulation of imprinted 
genes may contribute strongly to the lethal phenotype of Dnmt1-deficient mice. 
 
1.4 Mediators of the methylation signal 
 
1.4.1 Identification of methyl-CpG binding proteins 
 
A major avenue of research in the DNA methylation field has focussed upon the 
identification and characterization of proteins that bind specifically to methylated DNA. 
A priori it is possible to imagine that DNA methylation mediates its effects by directly 
blocking the binding of proteins to DNA as is the case with CGBP, CTCF and c-Myc 
(Voo et al, 2000; Hark et al, 2000; Prendergast and Ziff, 1991). However, another 
theoretically possible mechanism is that proteins exist which can bind specifically to 
methylated DNA and mediate the effects of this modification by directly occluding other 
factors or by recruiting activities to somehow modify the local chromatin structure. The 
slow kinetics of repression of a transfected methylated gene suggested the effect was not 
simply due to blocking the binding of a transcriptional activator (Buschhausen et al, 
1985). Furthermore, methylated CpGs in mammalian nuclei were found to be 
specifically protected from restriction digest implying tight association with proteins 
specific for these sites (Antequera et al, 1989). 
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The first activity observed to be able to bind specifically to DNA containing methylated 
CpG sites was found in nuclear extracts of a variety of mammalian tissues and cell lines 
by electrophoretic mobility shift assay (EMSA). This activity was designated MeCP1 
(Meehan et al, 1989) and was indistinguishable from the mediator of methylation-
dependent transcriptional repression in transfected cells and in nuclear extracts in vitro 
(Boyes and Bird, 1991). However, the molecular identities of the proteins comprising 
MeCP1 initially remained unknown. A second methyl-CpG specific binding activity 
distinct from MeCP1 was uncovered in rat brain nuclear extracts using a Southwestern 
assay. Purification of this activity allowed a partial amino acid sequence to be obtained 
and this led to the cloning of the gene encoding MeCP2 (Lewis et al, 1992). A 
subsequent deletion analysis of recombinant MeCP2 identified a minimal region 
required for specific recognition of methylated DNA and this was termed the methyl-
CpG binding domain or the MBD (Nan et al, 1993). 
 
Having defined the methyl-CpG binding domain, searches of EST databases led to the 
identification of a family of MBD containing proteins. The human MBD1 gene was the 
first to be cloned (Cross et al, 1997) and this was quickly followed by the Mbd1, Mbd2, 
Mbd3 and Mbd4 genes from mouse (Hendrich and Bird, 1998). These reports also 
revealed that like MeCP2, the newly identified Mbd1, Mbd2, and Mbd4 proteins could 
all bind specifically to methylated DNA in vitro, with only Mbd3 not showing this 
property. It was later shown that the Xenopus laevis homolog of Mbd3 is able to bind 
specifically to methyl-CpG containing probes (Wade et al, 1999) although the biological 
significance of this evolutionary difference remains unclear. 
 
1.4.2 Structure of the MBD 
 
Nuclear magnetic resonance (NMR) studies of the isolated MBD domains of MeCP2 
and MBD1 revealed a wedge shaped α/β-sandwich structure comprising a four strand 
anti-parallel β-sheet attached to a short α-helix (Wakefield et al, 1999; Ohki et al, 1999). 
The structure of the MBD from MBD1 was later solved in complex with methylated 
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DNA by NMR (Ohki et al, 2001). Upon DNA binding a nine amino acid loop between 
the inner strands of the β-sheet becomes structured and together with the inner β-strands 
and the loop connecting to the α-helix this forms the majority of the interface with the 
major groove of the DNA. It was further suggested on the basis of this structure that the 
methyl groups on cytosine are recognised by contacts with specific hydrophobic amino 
acids. However, a more recent X-ray crystal structure of the MBD from MeCP2 in 
complex with methylated DNA cast doubt upon some of these conclusions (Ho et al, 
2008). While the overall fold of the domain is not challenged, hydrophobic contacts 
between the MBD and the methyl groups on cytosine were not observed. Rather it was 
suggested that water molecules, which it is known can be positioned in the major groove 
by 5-methylcytosine (Mayer-Jung et al, 1998), make specific contacts with conserved 








As described above, MeCP2 was originally identified based on its ability to bind to 
methyl-CpG containing DNA in vitro. Evidence also emerged that MeCP2 functions in 
this fashion in vivo. In mouse cells the protein localizes to pericentric heterochromatin 
where over 40% of the genomic 5-methylcytosine resides, and this localization is lost 
either when the MBD is abrogated or cells deficient in DNA methylation are used (Nan 
et al, 1996). Furthermore, MeCP2 was found by chromatin immunoprecipitation to be 
present in vivo exclusively at the maternal methylated allele of the imprinted U2af1-rs1 
gene (Gregory et al, 2001). 
 
Early studies on MeCP2 suggested that it might function as a methylation-dependent 
transcriptional repressor by recruiting histone deacetylase activities. MeCP2 was able to 
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repress methylated promoters in vitro and in transfection based reporter assays in vivo. A 
transcriptional repression domain was mapped to a central region of the protein using 
this second kind of assay (Nan et al, 1997) and consistent with the fact that repression 
was sensitive to the deacetylase inhibitor trichostatin A (TSA) this region was found to 
interact with mSin3A (Nan et al, 1998), which is a component of a histone deacetylase-
containing co-repressor complex (Zhang et al, 1997). 
 
A further clue to the function of MeCP2 came from the finding that this gene is mutated 
in Rett syndrome, a severe autism-spectrum neurological disorder (Amir et al, 1999). 
Targeted mutations of Mecp2 in mice gave rise to Rett syndrome-like phenotypes (Chen 
et al, 2001; Guy et al, 2001) and provided a tool with which to study Mecp2 function in 
a biologically relevant setting. Given that MeCP2 can function as a repressor, it might 
have been anticipated that the phenotypes seen in its absence were due to the aberrant 
expression of genes normally silenced in the brain. One candidate gene, Bdnf, was found 
to be slightly upregulated in resting Mecp2-deficient neurons in culture (Chen et al, 
2003; Martinowich et al, 2003). However, the significance of this finding is unclear as 
Bdnf is actually down regulated in the brains of Mecp2 mutant mice and transgenic over-
expression of Bdnf can ameliorate some of the Rett-like symptoms seen in these animals 
(Chang et al, 2006). Evidence has been presented to suggest that Mecp2 might repress 
various other promoters, but it is seldom clear what contribution, if any, mis-expression 
of these genes makes to the Rett-like phenotype (Horike et al, 2005; Nuber et al, 2005; 
Kriaucionis et al, 2006). Moreover, extensive microarray analysis of Mecp2-deficient 
mouse brains revealed only subtle changes in the expression levels of a handful of genes 
(Tudor et al, 2002). A more recent analysis of hypothalami from wild-type, Mecp2-null 
and Mecp2 over-expressing mice revealed that the protein seems to up regulate more 
genes than it down regulates leading to the notion that Mecp2 may function as a 
transcriptional activator (Chahrour et al, 2008). 
 
As MeCP2 functions as a repressor in various assays it is perhaps surprising that over-
expression of genes normally silenced in the brain does not readily account for the 
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defects observed in Rett syndrome and Mecp2-null mice. It remains possible that the 
brain is particularly sensitive to subtle changes in gene expression and that the small 
alterations documented do in fact underlie the Rett-like phenotype. Alternatively, gene 
expression changes that account for the defects may have been missed if they only occur 
in a subset of cells present in the whole brains or hypothalami analysed. Nevertheless, 
the idea that MeCP2 functions as something other than a transcriptional regulator in the 
maintenance of normal neurological function must now be entertained. For example, an 
RNA-mediated interaction between MeCP2 and the splicing factor YB1 was uncovered 
and this led to the observation of splicing defects in Mecp2 deficient mice. However, 
these effects are very subtle and it is not clear what contribution, if any, they make to the 
phenotype of these animals (Young et al, 2005). Other studies of MeCP2 have also 
largely failed to reveal why this protein is required for normal neuronal function. A 
variety of MeCP2 binding partners aside from mSin3A and YB1 have been reported 
including the histone deacetylase containing N-CoR complex as well as the chromatin 
remodelling enzymes Brahma and ATRX (Kokura et al, 2001; Harikrishnan et al, 2005; 
Nan et al, 2007). It is not clear in what fashion any of these interactions contribute to the 
normal function of MeCP2 and some of them are hotly contested (Hu et al, 2006; 
Harikrishnan et al, 2006). As MeCP2 is largely monomeric and has no stoichiometric 
binding partners in rat brain nuclear extracts (Klose and Bird, 2004) using biochemistry 




Subsequent to the cloning of the mouse Mbd2 gene, the protein encoded by the human 
homolog was shown to be a stable component of the histone deacetylase-containing 
nucleosome remodelling (NuRD) complex, which corresponded to the previously 
identified MeCP1 activity (Zhang et al, 1999). Transfection based reporter assays 
showed that MBD2 could function as a histone deacetylase and chromatin remodelling-
dependent transcriptional repressor (Ng et al, 1999; Feng and Zhang, 2001). Consistent 
with this, in vitro analysis showed that MBD2 promoted the binding of the NuRD 
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complex to nucleosomes containing methylated DNA, which were subsequently 
preferentially remodelled and deacetylated. These initial works had also suggested that 
MBD2 and MBD3 co-existed in the same NuRD complex, but more recent findings 
demonstrated the presence of distinct MBD2- and MBD3-containing NuRD complexes 
(Le Guezennec et al, 2006). 
 
The fact that MBD2 is a critical component of the MeCP1 activity has further been 
confirmed by analysis of Mbd2-deficient mice where this activity is absent. The 
generation of these mice, which are both viable and fertile, has facilitated the study of 
the normal function of Mbd2. The first phenotype to be reported in these animals was 
defective maternal behaviour (Hendrich et al, 2001) but how the absence of Mbd2 leads 
to this deficit remains unclear. It has also been observed that Mbd2-mutant mice show 
abnormal differentiation of helper T cells and this has been attributed to defective 
silencing of the Il-4 gene (Hutchins et al, 2002). Mbd2 also appears to be required in the 
colon to repress genes that are normally only expressed in the exocrine pancreas and 
duodenum (Berger et al, 2007) and another promoter identified as being directly 
repressed by Mbd2 is that of the Xist gene (Barr et al, 2007). In all of these cases there is 
evidence that Mbd2 represses transcription by recruiting histone deacetylase activity to 
promoters where DNA methylation is present. Therefore, in conjunction with the weight 
of evidence associating MBD2 with the NuRD complex, there is a strong case that Mbd2 
functions primarily to repress transcription from promoters which contain methylated 
sequences. It will be of interest to determine the complete set of promoters bound and 




Mbd4 was initially shown to interact with methylated rather than unmethylated DNA in 
vitro and over-expressed Mbd4 was localized to pericentric heterochromatin as would be 
expected for a methyl-CpG binding protein (Hendrich and Bird, 1998). A later study 
found that the MBD of this protein bound most efficiently to m5CpG:TpG mismatches, 
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which are the result of 5-methylcytosine deamination. Furthermore, the C-terminal 
glycosylase domain of MBD4 could efficiently remove the thymine base from such 
mismatches (Hendrich et al, 1999). This suggested that MBD4 may function as a DNA 
repair protein to protect the genome from the damage induced by the presence of DNA 
methylation. This hypothesis was confirmed by the three-fold increase in cytosine to 
thymine transitions in Mbd4-null mice and the consequent acceleration in tumour 
formation on an ApcMin/+ background (Millar et al, 2002). MBD4 has also been reported 
to be able to repress transcription and to bind to Sin3A and HDAC1 as well as being 
present at the methylated promoters of the p16 and hMLH1 genes (Kondo et al, 2005). 
However, evidence of gene regulation defects when MBD4 is removed is lacking. 
 
1.4.7 Kaiso and Kaiso-like proteins 
 
Aside from the MBD family there is a second group of proteins that specifically bind to 
methylated CpGs. Kaiso, the founder member of this group which has an N-terminal 
POZ domain and C-terminal zinc fingers, was originally purified from K652 cells as an 
activity that could bind specifically to methylated DNA (Prokhortchouk et al, 2001). As 
well as having affinity for methylated DNA, the zinc fingers of Kaiso can bind to a 
consensus sequence that lacks CpG dinucleotides (Daniel et al, 2002). However, in 
reporter assays, transfected Kaiso can still repress transcription in a methylation-
dependent manner (Prokhortchouk et al, 2001). There is also evidence that Kaiso can 
function to silence endogenous genes by recruiting histone deacetylase activity to 
methylated promoters (Yoon et al, 2003). Purification of the N-CoR complex from 
HeLa cells identified Kaiso as an associated protein and siRNA-mediated depletion of 
Kaiso resulted in loss of N-CoR from certain methylated promoters concomitant with 
aberrant gene expression. In Xenopus, Kaiso deficiency allows zygotic transcription to 
commence before the mid blastula transition with subsequent phenotypes including 
developmental arrest and apoptosis (Ruzov et al, 2004). However, Kaiso-null mice show 
no developmental abnormalities or changes in gene expression profiles (Prokhortchouk 
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et al, 2006). Therefore, as with MeCP2, the status of Kaiso as a transcriptional repressor 
in mammals is not as certain as it once seemed. 
 
Two more proteins, ZBTB4 and ZBTB38, were identified on the basis of homology with 
Kaiso (Filion et al, 2006). These proteins were also shown to be able to bind to 
methylated CpGs via their zinc finger domains and to repress transcription in reporter 
assays. The localization of these proteins to pericentric heterochromatin is also 
consistent with their binding to methyl-CpG and, furthermore, ZBTB4 and ZBTB38 as 
well as Kaiso were shown by chromatin immunoprecipitation to be present exclusively 
at the methylated paternal allele of the H19/Igf2 differentially methylated region. 
However, no causal role in imprinting was demonstrated. A full understanding of the 
functions of these Kaiso-like proteins will require the generation and analysis of mice 
lacking these factors. A schematic of all known MBD-containing and Kaiso-like 

















Figure 1.3 – Domain structure of methyl-CpG binding proteins 
 
MeCP2, MBD1 and MBD2 all contain a TRD. MBD1 additionally has zinc finger 
domains and MBD2 has an N-terminal glycine-arginine repeat region. The MBD of 
MBD3 contains a substitution such that it does not bind methylated DNA. MBD4 
contains a C-terminal glycosylase domain. Kaiso and the Kaiso-like proteins, ZBTB38 
and ZBTB4, have a conserved POZ/BTB domain as well as three central zinc fingers 
that mediate interaction with methylated DNA. 
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1.5 The methyl-CpG binding domain protein MBD1 
 
1.5.1 Identification of MBD1 
 
MBD1 was first identified in searches of EST databases for proteins bearing similarity to 
the MBD of MeCP2. The first human isoform to be uncovered was designated PCM1, 
and in addition to its N-terminal MBD this protein contains two central zinc finger 
domains with homology to those found in the DNA methyltransferase DNMT1 and 
HRX proteins. An antibody raised against MBD1 was reported to ‘supershift’ the 
MeCP1 activity in an EMSA and so it was initially concluded that MBD1 was a 
component of the MeCP1 complex (Cross et al, 1997). However, later studies using 
more specific antibodies demonstrated that this conclusion was erroneous and may have 
arisen due to cross-reactivity of the original antibody with some other component of the 
MeCP1 complex (Ng et al, 1999; Ng et al, 2000). MBD1 was also independently 
identified in a yeast one-hybrid screen as a factor that could bind to a motif from the 
FGF-2 promoter (Ueba et al, 1999). 
 
Since the earliest reports on MBD1 various isoforms of this protein have been identified 
both in human (Fujita et al, 1999) and in mouse (Hendrich and Bird, 1998; Jørgensen et 
al, 2004). These isoforms share a common N-terminal MBD as well as a C-terminal 
TRD (discussed in section 1.5.2), but differ in terms of which zinc finger domains are 
present and in other sequences at the C-terminus. 
 
1.5.2 DNA binding and transcriptional repression by MBD1 
 
Recombinant full-length human MBD1 (isoform PCM1) was shown to bind specifically 
to methylated DNA and to repress transcription in a methylation-dependent fashion in 
vitro (Cross et al, 1997). Recombinant mouse MBD1 was similarly shown to bind to 
DNA in a methylation-dependent manner in vitro (Hendrich and Bird, 1998). 
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Transiently expressed human MBD1 was shown to repress transcription from 
transfected reporter genes (Fujita et al, 1999). In the case of the isoforms MBD1v3 and 
MBD1v4 this was a methylation-dependent phenomenon. However, in the case of 
MBD1v1 and MBD1v2 repression of expression occurred irrespective of whether it was 
from a methylated promoter and the ability to repress unmethylated reporters depended 
on the presence of the zinc finger domain CxxC3 (Fujita et al, 2000). Consistent with 
this, the isolated CxxC3 domain from mouse Mbd1 binds specifically to unmethylated 
CpG containing DNA in vitro (Jørgensen et al, 2004). Furthermore, the localization of 
over-expressed MBD1 to mouse pericentric heterochromatin requires an intact MBD in 
wild-type cells, whereas an intact CxxC3 is needed for this to occur in DNA 
methylation-deficient cells. The ability of MBD1 to interact with either methylated or 
unmethylated CpGs via distinct domains should not be unexpected given that it was 
independently discovered in a yeast one hybrid screen (where DNA methylation is 
absent) and by sequence similarity to MeCP2. It remains to be determined whether in 
vivo MBD1 can interact simultaneously with modified and unmodified DNA or if these 
two modes of binding are mutually exclusive.  
 
PCM1 was shown to repress transcription from transfected reporter genes when tethered 
via a heterologous DNA binding domain and this assay allowed the mapping of a 
transcriptional repression domain (TRD) to the C-terminus of MBD1 (Ng et al, 2000). 
This initial study reported MBD1-mediated repression to be sensitive to TSA, 
suggesting that histone deacetylases might be involved in this silencing. However, a 
different group contradicted this finding and instead proposed that an interaction 
between MBD1 and MCAF (MBD1-containing chromatin-associated factor) is involved 
in repression (Fujita et al, 2003a). This interaction was uncovered in a yeast two-hybrid 
screen using the TRD of MBD1 as bait and it was verified to occur both in vitro and in 
vivo by co-immunoprecipitation of endogenous proteins and co-localization of over-
expressed proteins. Furthermore, mutations in the TRD that disrupt this interaction were 
found to interfere with repression and over-expression of MCAF stimulated MBD1-
mediated repression in reporter assays. 
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There is also evidence that MBD1 can repress endogenous genes. In HeLa cells the 
methylated CpG island promoter of p53BP2 was identified as an MBD1 binding site by 
cloning DNA fragments isolated by chromatin immunoprecipitation (Sarraf and 
Stancheva, 2004). This promoter, which is ordinarily silenced in HeLa cells can be 
reactivated either by treatment with 5-azadeoxycytidine or by siRNA-mediated depletion 
of MBD1. This study also found a direct interaction between MBD1 and the histone H3 
lysine K9 methyltransferase SETDB1, and showed that repression was SETDB1 
dependent. Additionally the presence at the p53BP2 promoter of SETDB1 together with 
the trimethylation of H3-K9, a modification frequently associated with silent 
heterochromatin (Peters et al, 2002), was found to depend upon MBD1. It is possible 
that this report together with the work on MCAF revealed different aspects of the same 
repressive mechanism as MCAF has been reported to stably associate with SETDB1 and 
stimulate its catalytic activity (Wang et al, 2003). Moreover, transient expression of 
SETDB1 in addition to MCAF further enhanced MBD1 mediated repression of a 
reporter gene (Ichimura et al, 2005). 
 
MBD1 has also been shown to interact with the p150 subunit of the chromatin assembly 
factor CAF-1 (Reese et al, 2003; Sarraf and Stancheva, 2004). Methylated DNA blocks 
this interaction in vitro, and in vivo it is only observed during S-phase where it depends 
upon the presence of active replication forks. Also reported was an S-phase specific 
MBD1-dependent interaction between CAF-1 and SETDB1. Taken together these data 
led to the proposal of a model where a complex of MBD1 and SETDB1 is displaced 
from methylated DNA during S-phase and is thus recruited to CAF-1 in order that 
nucleosomes are modified at on H3-K9 as they are deposited at a promoter silenced by 
DNA methylation and MBD1. This was born out by the observation that following 
transient depletion of MBD1 the recovery of H3-K9 trimethylation at the p53BP2 
promoter was dependent on cell division (Sarraf and Stancheva, 2004). Consistent with a 
link between CAF-1 and MBD1 an earlier study characterized the interaction between 
these two proteins and showed that over-expression of the C-terminus of CAF-1 p150 
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led to the mislocalization of MBD1 away from the otherwise still intact pericentric 
heterochromatin (Reese et al, 2003). 
 
The generation and analysis of Mbd1-null mice supported the view of Mbd1 as a 
transcriptional repressor only to a limited degree. These mice showed mild neurological 
phenotypes including lessened neurogenesis and decreased long term potentiation 
together with autism-like behavioural defects (Zhao et al, 2003; Allan et al, 2008). 
Consistent with this, mutations in human MBD1 have been reported in human patients 
with autism but the number of people examined in this study was low (Li et al, 2005). 
To date, however, the molecular basis for the defects seen in the absence of Mbd1 
remains unclear. Initial microarray based expression analysis of the hippocampi from 
Mbd1-null mice revealed few changes except for up-regulation of the intra-cisternal A 
particle (IAP) transcript (Zhao et al, 2003). A later study found a two-fold increase in 
the expression level of a serotonin receptor Htr2c in these animals (Allan et al, 2008). 
However, in both cases it is unclear if the effects are a direct consequence of the removal 
of MBD1, and if so, to what extent these transcriptional changes contribute to the 
phenotype. It remains possible that a more striking role for MBD1 as a transcriptional 
repressor will emerge in tissues other than the brain, perhaps under conditions not yet 
investigated. 
 
1.5.3 Regulation of MBD1 by SUMO modification 
 
The yeast two-hybrid screen that identified SETDB1 and the p150 subunit of CAF-1 as 
interaction partners of MBD1 also identified the SUMO (small ubiquitin-like modifier) 
E3 ligases PIAS1 and PIAS3 as putative MBD1 binding partners (Lyst et al, 2006). In 
mammals the SUMO family of proteins comprises SUMO-1, SUMO-2 and SUMO-3 
(Hay, 2005). The C-terminal diglycine motifs of these small proteins can be coupled to 
lysine residues within target proteins via an isopeptide bond in a fashion reminiscent of 
ubiquitin modification (Hay, 2005). SUMO modification will be discussed in more 
depth in chapter five. 
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A pool of MBD1 in HeLa cells was shown to be modified with SUMO-1 on lysine 450 
and lysine 489. Over-expression or depletion of the PIAS proteins identified as MBD1 
binding partners led respectively to an increase or a decrease in the level of SUMO 
modification of MBD1 (Lyst et al, 2006). SUMO modification of MBD1 by PIAS 
protein over-expression was further shown to disrupt its interaction with SETDB1 in 
vivo leading to loss of trimethylation of H3-K9 from the p53BP2 promoter and 
expression of this MBD1 target gene (Lyst et al, 2006). The disruption of the interaction 
between MBD1 with SETDB1 is unlikely to be direct as SUMO modification of 
recombinant MBD1 does not disrupt its interaction with recombinant SETDB1 (Lyst et 
al, 2006). To date no circumstances have been identified when a physiological change in 
gene expression is mediated via SUMO modification of MBD1. 
 
An independent study also documented SUMO modification of MBD1 (Uchimura et al, 
2006). In addition to SUMO-1 modified MBD1 this report uncovered conjugation to 
SUMO-2 or SUMO-3 or both SUMO-2 and SUMO-3 (the antibodies employed could 
not distinguish these highly similar proteins). Furthermore, evidence was presented that 
SUMO modification promotes the association of MBD1 with MCAF in vitro and also 
that SUMO is required for the recruitment of heterochromatic factors such as HP1β to 
MBD1 containing foci in vivo. In contrast to the work on MBD1 and PIAS proteins 
these experiments suggest that SUMO modification might be expected to facilitate, 
rather than antagonize, transcriptional repression. The exact reasons for these apparent 
discrepancies are at present unclear, although they may be in part due to the different 
cell lines used in these studies. 
 
1.5.4 Aims of this thesis 
 
The MBD1 binding proteins described in previous sections are only some of the ones 
reported in the literature. Some other interactions are supported by quite substantial 
evidence, but the physiological meaning of these associations is always unclear. 
Conversely, others may suggest how MBD1 could function as a transcriptional 
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repressor, but often the evidence for these interactions is flimsy. An example of an 
interaction in the first category is that of MBD1 with the DNA repair protein 
methylpurine DNA glycosylase (MPG) (Watanabe et al, 2003). The association of these 
proteins is supported by multiple lines of evidence including yeast two-hybrid, co-
localization of fluorescent protein fusions and co-immunoprecipitation of endogenous 
proteins (Watanabe et al, 2003). However, the functionality of this interaction remains 
completely unknown. Interactions in the second category include MBD1 binding to 
polycomb components (Sakamoto et al, 2007), HDAC3 (Villa et al, 2006) and 
heterochromatic proteins such as HP1 and Suv39h1 (Fujita et al, 2003b). These reports 
all suggest plausible mechanisms by which MBD1 could repress transcription. However, 
the evidence presented for the interactions concerned is always limited to some 
combination of in vitro experiments and analysis of over-expressed proteins in vivo. 
 
Despite numerous reported interaction partners for MBD1, and in contrast with the 
situations for MBD2 and MeCP2, which are stably associated with the NuRD complex 
and monomeric in nuclear extracts, respectively (Zhang et al, 1999, Feng and Zhang 
2001, Le Guezennec et al, 2006; Klose and Bird, 2004), it remained untested whether or 
not MBD1 formed part of a stable multi-subunit complex. If such a complex existed then 
its purification would allow the identification of its components. These would represent 
novel and likely informative MBD1 binding partners, or else they would help to 
determine which of the many reported MBD1 binding partners are most physiologically 
relevant by determining which ones associate with MBD1 in the greatest abundance and 
in the most stable fashion. Therefore a starting point of this work was to determine 
whether or not MBD1 is part of a stable multi-subunit complex, and if so, to purify it 
and identify its components. 
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2. Chapter Two - Materials and Methods 
 
2.1 Bacterial methods 
 
2.1.1 Bacterial culture conditions 
 
Escherichia coli (DH5α and BL21(DE3) strains) were grown routinely at 37˚C in Luria-
Bertani (LB) broth or on LB agar. Cells with plasmids were selected using antibiotics in 
the media (100 µg/ml ampicillin, 50 µg/ml kanamycin, 34 µg/ml chloramphenicol). 
 
2.1.2 Preparation of competent cells and transformation 
 
E.coli were streaked out onto LB agar and incubated overnight at 37˚C. A single colony 
was grown overnight at 37˚C in 2 ml SOB media (2% (w/v) tryptone (Bacto), 0.5% 
(w/v) yeast extract (Bacto), 10 mM NaCl, 2.5 mM KCl, 5 mM MgSO4, 5 mM MgCl2). 
The culture was transferred to 200 ml SOB media and grown at 20˚C until the optical 
density at 600 nm reached 0.5 before being cooled on ice for 10 min and centrifuged at 
3000 g for 15 min at 4˚C. The cells were resuspended in 67 ml TB (10 mM PIPES-KOH 
pH 6.75, 15 mM CaCl2, 0.25 M KCl, 55 mM MnCl2), incubated on ice for 10 min and 
then centrifuged again. Finally the cells were resuspended in 16 ml TB, DMSO was 
added drop-wise to a concentration of 7% (v/v) and after a further 10 min on ice the cells 
were made into aliquots before being snap frozen in liquid nitrogen and stored long-term 
at -80˚C. For transformation either 1 ng plasmid DNA or 10 µl ligation reaction product 
were mixed with 75 µl of thawed competent cell suspension and incubated on ice for 10 
min. The cells were then heat shocked at 42˚C for 2 min and then returned to ice for 10 
min. 0.5 ml of LB media was added to the cells, which were then incubated with shaking 
at 37˚C for 1 h. Cells were then transferred to LB agar or LB broth containing selective 
antibiotics and incubated overnight at 37˚C. 
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2.1.3 Plasmid preparation 
 
Plasmid DNA was purified from E.coli using a Quiagen miniprep kit except where the 
DNA was to be used for transfection of mammalian cells, in which case either a Quiagen 
midiprep or maxiprep kit was employed. 
 
2.1.4 Protein expression and cell lysis 
 
Plasmids were introduced into BL21(DE3) E.coli as described above. A 5 ml overnight 
culture was diluted into a larger volume (typically 1 litre) of antibiotic-containing LB 
broth and grown at 37˚C until the optical density at 600 nm reached 0.5. Expression was 
induced by addition of 1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) and the 
cells were then grown for 4 h at 30˚C. Cells were then collected by centrifugation for 10 
min at 5000 g at 4˚C, washed in PBS, collected again, and then cell pellets were frozen 
and stored at -80˚C. Pellets from 1 litre cultures were resuspended in 25 ml ice cold 
bacterial lysis buffer (NE1 supplemented with 300 mM NaCl and 1 mM DTT replaced 
by 13 mM β-mercaptoethanol) and disrupted by 3 min sonication on ice (output 4 at duty 
cycle 30% on a Branson Sonifier 250). Lysates were cleared by 20 min centrifugation at 
12,500 g at 4˚C followed by passing through a 0.2 µm pore syringe filter device. 
 
2.2 Molecular cloning 
 
2.2.1 Preparation of cDNA 
 
Cell pellets were resuspended in 1 ml per 2 million cells of Trizol® reagent (Invitrogen) 
and left to stand for 2 min at room temperature before the addition of 1/5 volume of 
chloroform. The mixture was vortexed and allowed to stand for a further 2 min. After 20 
min centrifugation at 14,000 g at 4˚C the top layer was taken and an equal volume of 
isopropanol was added. The RNA was precipitated for 1 h at -20˚C before being spun 
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down at 14,000 g for 30 min at 4˚C. The pellet was washed with ice cold 70% ethanol 
before being dried and dissolved in RNAse-free water (containing 2 mM DTT and 0.8 
u/µl Ribolock (Invitrogen)). 4 µg RNA and 1.5 µg oligo(dT) were then combined in 16 
µl RNAse free water (with 2 mM DTT and 0.8 u/µl Ribolock). After 10 min incubation 
at 65˚C the sample was set on ice and then added to a mixture of 2 µl 10 mM dNTPs 
(Fermentas), 6 µl first strand buffer (Invitrogen), 4 µl 75 mM DTT and 0.8 u/µl 
Ribolock. The mixture was incubated at 42˚C for 1 min then 2 µl of reverse transcriptase 
(Superscript II, Invitrogen) was added and the sample was left overnight at 42˚C. 
 
2.2.2 Polymerase chain reaction 
 
Polymerase chain reaction (PCR) was carried out in NEB buffer 4 supplemented with 3 
mM MgCl2, 10 mM dNTPs, 0.25 µM forward primer and 0.25 µM reverse primer. For a 
100 µl reaction 5 units of Taq polymerase (prepared by Dr Jose de las Heras) and 0.5 
units of Pfu DNA polymerase (Fermentas) were used. Template DNA was 1 ng plasmid 
DNA or serial dilutions of cDNA. The annealing temperature, elongation time, and 
number of cycles of PCR were varied according to the template DNA, product length 
and primers. In some instances, coding sequences for fusion proteins were constructed 
by PCR-mediated recombination. Initial PCR reactions were carried out where the 
reverse primer of one reaction and the forward primer of the other reaction carry 
overhangs such that the primers are complementary to each other. A second PCR used 
the products of the initial reactions as templates such that the sequences are joined in the 
final product. Restriction sites were included in primer sequences where appropriate. 
 
2.2.3 Restriction digests 
 
Restriction digests were carried out using enzymes from fermentas or NEB (New 
England Biolabs) either singly or in combination using the buffer, incubation time and 
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temperature recommended by the manufacturer. For cloning purposes 5 µg of plasmid 
DNA would be digested as well as 1 µg purified PCR product. 
 
2.2.4 Purification of restriction fragments and PCR products 
 
PCR products were purified using a Quiagen PCR purification kit. Restriction fragments 
were subjected to agarose gel electrophoresis (1% agarose in TAE), visualised under UV 
by ethidium bromide staining, excised and purified with a gel extraction kit (Eppendorf). 
 
2.2.5 Determination of DNA concentration and quality 
 
Nucleic acids were quantified based on their absorbance at 260 nm using a NanoDrop 
1000 (Thermo Scientific). The same instrument was used to verify that DNA used for 
transfections had an A260/280 ratio greater than 1.8. 
 
2.2.6 Dephosphorylation and ligation of DNA 
 
Whenever compatible ends were generated by restriction digestion of vector DNA the 
sample would subsequently have its 5’ phosphates removed prior to insert ligation. To 
this end digested and purified vector DNA would be incubated for 30 min at 37˚C with 5 
units of Antarctic Phosphatase (NEB) in the buffer provided by the manufacturer. The 
enzyme would then be heat inactivated at 65˚C for 10 min.  Ligations were carried out 
overnight at 16˚C using a 3:1 molar ratio of insert to vector DNA and 5 units of T4 DNA 
ligase (Fermentas) in 10 µl reactions using the buffer supplied by the manufacturer. 
 
2.2.7 DNA sequencing 
 
DNA sequencing was carried out using the BigDye® Terminator v3.1 Cycle Sequencing 
Kit (Roche) according to the manufacturer’s instructions. Reactions were then analysed 
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on an ABI sequencer by the ICAPB sequencing service at the University of Edinburgh. 
A complete list of plasmids generated in this study can be found in appendix I. 
 
2.3 Mammalian cell culture 
 
2.3.1 Culture conditions  
 
HeLa cells, Phoenix cells and mouse embryonic fibroblasts were grown routinely at 
37˚C under 5% CO2 in Dulbecco’s Modified Eagle’s Medium (Sigma) supplemented 
with 10% foetal bovine serum (Perbio) and penicillin-streptomycin-glutamine 
(Invitrogen). Cells were passaged by washing with Dulbecco’s PBS (Invitrogen) 
followed by treatment with 0.05% Trypsin and 0.53 mM EDTA (Invitrogen) in D-PBS 
to detach them from the flask. The reaction was stopped by adding one volume of serum 
containing growth medium. Cells were then diluted into fresh medium in a new flask or 
harvested by centrifugation for 5 min at 250 g followed by washing with D-PBS. Cell 
pellets were stored at -80˚C for future analysis. 
 
2.3.2 Cryogenic storage 
 
Cells were harvested using trypsin, centrifuged and then resuspended in 1 ml of growth 
medium supplemented with 20% DMSO per 5 million cells. Cells were frozen at -80˚C 
before transfer to liquid nitrogen for long term storage. Stored cells were defrosted by 
warming to 37˚C, washed in growth medium and seeded into a new culture vessel. 
 
2.3.3 Transfection and transduction 
 
Cells were transfected using the JetPei reagent (Autogen Bioclear) according to the 
manufacturer’s instructions. Retroviruses for transduction were produced by transfection 
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of Phoenix cells with pBABE vectors. The media was changed 24 h post transfection 
and the supernatant after 48 h was taken as viral stock. Serial dilutions of this were then 
applied to HeLa cells for 24 h to achieve infection. During infection the growth medium 
was supplemented with 5 µg/ml polybrene (Sigma). 
 
2.3.4 Preparation of nuclear extracts  
 
All steps were carried out at 4˚C unless otherwise stated. Cell pellets were resuspended 
in 2ml of nuclear extraction buffer NE1 (20 mM HEPES-KOH pH 7.5, 10 mM KCl, 1 
mM MgCl2, 0.1% Triton-X-100, 1 mM DTT and protease inhibitors (Sigma P8340)) per 
50 million cells and allowed to swell on ice for 5 min. The cells were disrupted with 10 
strokes of a Dounce homogenizer and nuclei were collected by centrifugation at 500 g 
for 5 min. In some cases the nuclei were then treated with 10 units (per million nuclei) 
benzonase (Merck) for 5 min at room temperature. This involved resuspending the 
nuclei in as small a volume of NE1 as possible before adding the enzyme. The nuclei 
were then resuspended in an appropriate volume of nuclear extraction buffer NE2 (NE1 
supplemented with 420 mM NaCl) such that the final concentration of NaCl was 300 
mM. In some cases the nuclei were resuspended in NE1 buffer supplemented with less 
than 420 mM NaCl such that the final salt concentration would be 150 mM. Finally the 
suspension was incubated with mixing for 40 min before being centrifuged for 20 min at 
14,000 g. The supernatant was taken as nuclear extract. 
 
2.3.5 Cell fixation and microscopy 
 
Cells expressing GFP fusion proteins were grown on coverslips, washed in D-PBS 
(Invitrogen) and then fixed by incubating in 4% paraformaldehyde in PBS for 10 min at 
room temperature. The cells were then permeabilized by incubation in 0.25% Triton-X-
100 in PBS for 3 min at room temperature. The coverslips were then mounted on slides 
using Vectashield® mounting medium containing 4',6-Diamidine-2'-phenylindole 
dihydrochloride (DAPI) and stored in the dark before analysis. Finally the cells were 
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observed using an Olympus BX61 microscope and a ColorViewII camera. The analySIS 
software package was used for image capture. 
 
2.4 Protein purification 
 
2.4.1 Purification of proteins containing a 3xFLAG-tag 
 
FLAG M2 agarose (Sigma) was equilibrated with the buffer used for nuclear extraction. 
Extracts were then mixed with the resin for 1 hour at 4˚C before being washed four 
times with nuclear extraction buffer. Bound proteins were then eluted by mixing for 4 h 
at 4˚C with this buffer containing 750 µg/ml 3X FLAG peptide (Sigma). Alternatively 
proteins were eluted by boiling the resin in Laemmli buffer. 
 
2.4.2 Immobilized metal affinity chromatography (IMAC) 
 
Chelating sepharose (Amersham) was charged with nickel ions according to the 
manufacturer’s instructions and then equilibrated with bacterial lysis buffer 
supplemented with 10 mM imidazole. Bacterial lysates or nuclear extracts were adjusted 
to 10 mM imidazole and incubated with the resin for 1 h at 4˚C with mixing. The resin 
was then poured into a disposable chromatography column (Biorad) and washed four 
times with twenty column volumes of wash buffer (bacterial lysis buffer supplemented 
20 mM imidazole). Proteins were then eluted by washing the resin five times with one 
column volume of the same buffer supplemented with 250 mM imidazole.  
 
2.4.3 Purification of proteins containing a GST-tag 
 
Mixtures containing a protein with a GST-tag were incubated for 1 h with mixing at 4˚C 
with glutathione sepharose (Amersham) pre-equilibrated with nuclear extraction buffer 
supplemented with 300 mM NaCl. After binding the resin was poured into a disposable 
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chromatography column (Biorad) and washed four times with twenty column volumes 
of nuclear extraction buffer. Proteins were then eluted by washing the column ten times 
with one column volume of elution buffer (50 mM Tris-HCl pH 8, 20 mM glutathione, 
300 mM NaCl, 0.1% Triton-X-100, 1 mM DTT). Eluted proteins were dialysed back 
into nuclear extraction buffer, made into aliquots and then stored at -80˚C. 
 
2.4.4 Cation exchange chromatography 
 
For an extract from a 1 litre bacterial culture expressing MBD1, 1 ml of SP sepharose 
(Amersham) was equilibrated with bacterial lysis buffer. The resin was then incubated 
with the clarified bacterial lysate with tumbling for 1 h at 4˚C before being applied to a 
disposable chromatography column. The resin was washed three times with ten column 
volumes of bacterial lysis buffer supplemented with 500 mM NaCl. Proteins were eluted 
with five 1 ml washes with this buffer supplemented with 1 M NaCl. 
 
2.5 Protein analysis 
 
2.5.1 Determination of protein concentration 
 
Concentrations of partially purified proteins were estimated by SDS-PAGE followed by 
Coomassie staining using serial dilutions of the test protein and known amounts of a 
BSA (bovine serum albumin) standard. Protein concentrations in extracts were estimated 
by measuring absorbance at 280 nm using a NanoDrop 1000 (Thermo Scientific) and 




Gels were cast and subjected to electrophoresis in the Mini-PROTEAN apparatus (Bio-
Rad). The upper stacking gel was composed of 125 mM Tris-HCl pH 6.8, 4% (w/v) 
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acrylamide/bis-acrylamide (37.5:1), 0.1% SDS, 0.05% ammonium persulfate (APS), 
0.2% TEMED. The lower separating gel was made of 375 mM Tris HCl pH 8.8, 7-20% 
(w/v) acrylamide/bis-acrylamide (37.5:1), 0.1% SDS, 0.05% APS, 0.2% TEMED. The 
running buffer was 25 mM Tris, 192 mM glycine, 0.1% SDS. Gels were run at 270 V. 
Prior to loading samples were boiled in Laemmli buffer (50 mM Tris-HCl pH 6.8, 100 
mM DTT, 2% SDS, 10% glycerol, 0.1% bromophenol blue). 
 
2.5.3 Coomassie staining 
 
After electrophoresis gels were rinsed briefly in water before being incubated in 
Coomassie staining solution (0.2% Coomassie (Sigma) (w/v), 50% methanol (v/v), 10% 
acetic acid (v/v)) for 1 h. Gels were then destained to reveal protein bands by repeated 
incubations and agitation in 50% (v/v) methanol with 10% (v/v) acetic acid. Finally gels 
were washed in water, wrapped in cellophane and dried. 
 
2.5.4 Western blotting 
 
After separation by SDS-PAGE proteins were transferred to 0.4 µm pore nitrocellulose 
membranes (Bio-Rad) using the Mini Trans-Blot® module (Bio-Rad). The transfer 
buffer used was 25 mM Tris, 192 mM glycine. Transfers were carried out for 1 h at 400 
mA. Membranes were stained with Ponceau S solution (2% Ponceau S (w/v), 30% 
trichloroacetic acid, 30% sulfosalicyclic acid) to ensure equal loading of lanes before 
being washed with PBS supplemented with 0.1% Tween-20. Membranes were incubated 
in blocking solution (4% fat free milk powder in TBS) for 30 min at room temperature. 
Primary antibodies were applied to membranes in blocking solution overnight at 4˚C 
typically at a concentration of 0.5 µg/ml. Primary antibodies used in Western blots were 
as follows: anti-MBD1 (IMG-306 from Imgenex for human and M254 from Santa Cruz 
for mouse), anti-SETDB1 (Upstate), anti-HDAC1 (sc-7872), HDAC3 (Active Motif), 
anti-G9a (Sigma), anti-GLP (MBL international), anti-EZH2 (a gift from Klaus Hansen), 
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anti-ACF1 (a gift from Patrick Varga-Weisz), anti-LSD1 (Bethyl), anti-GFP (CRUK), 
M2 anti-FLAG (Sigma) and HRP-conjugated anti-GST (Amersham). The membrane 
would then be washed with PBS supplemented with 0.1% Tween-20 before application 
of the HRP-conjugated secondary antibody (Sigma). After washing again with PBS 
supplemented with 0.1% Tween-20, bands were visualized by applying developing 
solution (100 mM pH 8.8, 0.01% H2O2, 1.5 mM luminol, 0.25 mM p-coumaric acid) to 




All steps were carried out at 4˚C unless otherwise stated. Nuclear extracts (typically 100 
µl at 10 mg/ml protein concentration) containing GFP fusion proteins were added to 2 
µg of monoclonal antibody against GFP (CRUK) and incubated with mixing for 4 h. The 
mixture was added to 5 µl of protein G sepharose (Amersham) pre-equilibrated with 
nuclear extraction buffer and capture of immunocomplexes was allowed to proceed for 1 
h with mixing. The protein G sepharose was then washed four times with 0.5 ml nuclear 
extraction buffer then bound proteins were used in enzymatic assays or eluted by boiling 
in Laemmli buffer for analysis by Western blotting.  
 
2.5.6 SUMO protease assay 
 
Substrates were mixed with sources of protease activity and incubated for 1 h at 37˚C in 
nuclear extraction buffer supplemented with 300 mM NaCl. The catalytic domain of the 
yeast SUMO protease Ulp1p was obtained from Invitrogen and used in accordance with 
the manufacturer’s instructions except the buffer conditions were the same as for the 
other SUMO protease assays. When nuclear extracts or fractions were the source of 
protease activity between 1 µg and 30 µg total protein were employed. Typically around 
50 ng of substrate were used. The reaction was then assayed by SDS-PAGE followed by 
Western blotting with antibodies against GST or against MBD1. 
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2.5.7 Gel filtration 
 
A 10 mm by 30 cm Superose 6 HR 10/30 column (Amersham) was calibrated with 
proteins of known Stoke’s radii (Amersham gel filtration calibration kit). The column 
was equilibrated with nuclear extraction buffer supplemented with 200 mM NaCl before 
loading the sample (typically just less than 0.5 ml) onto the column. The flow-rate was 
0.3 ml/min and 0.64 ml fractions were collected. The whole procedure was carried out at 
4˚C. Fractions were then analysed by SDS-PAGE followed by Western blotting. 
 
2.5.8 Sucrose gradient sedimentation 
 
Sucrose gradients were made in nuclear extraction buffer supplemented with 200 mM 
NaCl. Linear 2 ml gradients contained 5-20% (w/w) sucrose and were made by layering 
0.5 ml of sucrose solutions of decreasing concentrations on top of each other before 
being left to stand for 4 h at 4˚C. A sample of 150 µl would be layered on top of the 
gradient before centrifugation at 4˚C for 4 h at 368,000 g in an SW 55 Ti swinging 
bucket rotor. Fractions of 165 µl were collected from the top of the gradient and 
analysed by SDS-PAGE followed by Western blotting or Coomassie staining. For 
calibration purposes, identical gradients were run in parallel containing proteins of 
known sedimentation coefficients (Amersham gel filtration calibration kit). 
 
2.5.9 Mass spectrometry 
 
Proteins to be analysed were run approximately 1 cm by SDS-PAGE, stained with 
Coomassie and excised. Mass spectrometry was carried out by Flavia Alves in the 
laboratory of Juri Rappsilber as described elsewhere (Milligan et al, 2008) except that 
database used was IPI-Human. Analysis of post-translational modifications on histones 
H3 and H4 was carried out in the laboratory of Axel Imhof as described elsewhere 
(Loyola et al, 2006). 
 58
3. Chapter Three – Evidence for self association of MBD1 
 
3.1 Endogenous MBD1 does not behave as a monomer 
 
It was previously shown that MBD1 in HeLa nuclear extracts has a Stoke’s radius of 
approximately 5.4 nm as assessed by size exclusion chromatography (Ng et al, 2000). 
However, in Western blots the MBD1 antibody used in this study recognised a doublet 
in HeLa nuclear extracts with the faster migrating of the two bands corresponding 
closely to the migration of recombinant hexahistidine-tagged MBD1 expressed in E.coli 
(isoform PCM1). In contrast the monoclonal MBD1 antibody used in subsequent studies 
and validated by siRNA depletion experiments (Sarraf and Stancheva, 2004) recognises 
bands of lower molecular weight than recombinant PCM1 expressed in either E.coli or 
exogenously in HeLa cells (see section 5.7). This result cast doubt on the specificity of 
the antibody used in the earlier size exclusion analysis of MBD1. It was therefore 
decided to re-visit this observation as well as carrying out a more thorough biophysical 
analysis of the endogenous MBD1 in HeLa cells. 
 
In gel filtration the endogenous MBD1 protein in HeLa nuclear extracts eluted from a 
Superose 6 column in the same fashion as the apoferritin 443 kDa size standard (Figure 
3.1A) indicating a Stoke’s radius of approximately 6.1 nm. By analysing the same 
extracts on 5-20% sucrose gradients a sedimentation coefficient of S = 5.4 was 
determined (Figure 3.1B). Given the Stoke’s radius and sedimentation coefficient it is 
possible to calculate the molecular mass of a protein or protein complex even when 
present in a crude extract (Siegel and Monty, 1966). This is achieved by substituting 
these values into the following equation derived by Siegel and Monty: 
 
 
Mr = 6π η20,w •s20,w •RS •N / (1 - ρ20,w v) 
 
 59
In this equation RS = Stoke’s radius (cm), s20,w = sedimentation velocity (S x 10-13), η20,w 
= viscosity of water at 20 ˚C (0.01002 g/cm/s), N = Avogadro’s number (6.022 x 1023 
mol-1), ρ20,w = density of water at 20 ˚C (0.9981 g/cm3), and v = partial specific volume 
used (0.725 cm3/g). The application of this equation to the native MBD1 protein found 
in HeLa cells led to the calculation of a molecular mass of approximately 136 kDa. As 
the theoretical molecular mass of this protein is only 61 kDa it can be concluded that 








Figure 3.1 – Native MBD1 in HeLa nuclear extracts is not monomeric 
 
(A) Western blot using antibodies against MBD1 to analyse the elution of the native 
protein in HeLa nuclear extracts from a Superose 6 gel filtration column. A Stoke’s 
radius of 6.1 nm was measured. 
(B) Western blot analysis of migration of native MBD1 from HeLa extracts in 5-20% 
sucrose gradients. A sedimentation coefficient of S = 5.4 was measured. 
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3.2 Bacterially expressed MBD1 behaves as a monomer 
 
A similar biophysical analysis was carried out using untagged bacterially expressed 
MBD1, which had been partially purified using cation exchange chromatography. Gel 
filtration analysis revealed a Stoke’s radius of 5.4 nm (Figure 3.2A) and sucrose 
gradients revealed a sedimentation coefficient of 2.6 S (Figures 3.2B). From these values 
a mass of 58 kDa was calculated using the Siegel and Monty equation given above. This 
is in close agreement with the theoretical molecular mass of MBD1 of 61 kDa and so, it 
appears that recombinant MBD1 behaves as a monomer suggesting that the protein does 










Figure 3.2 – Recombinant MBD1 expressed in E.coli behaves as a monomer 
 
(A) Size exclusion analysis using a Superose 6 gel filtration column of recombinant 
MBD1 partially purified from E.coli. The fractions were analysed by Western blotting 
and a Stoke’s radius of 5.4 nm was measured. 
(B) Bacterially expressed MBD1 was fractionated on 5-20% sucrose gradients. Western 
analysis of the fractions revealed a sedimentation coefficient of S = 2.6 for this protein. 
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A plausible explanation for the differential behaviour of native MBD1 compared to the 
recombinant protein could be the stable interaction of the former with a binding partner. 
However, this remained only a tentative hypothesis as incorrect folding of the 
recombinant protein could not be ruled out, and so self association of the native protein 
was still a possibility. 
 
3.3 SETDB1 association does not explain the apparent size of MBD1 
 
MBD1 has previously been reported to form a stable complex with the histone H3 lysine 
K9 methyltransferase SETDB1 with the majority of MBD1 in HeLa nuclear extracts 
being involved in this interaction (Sarraf and Stancheva, 2004). MBD1 has also been 
reported to interact with MCAF (Fujita et al, 2003a) which is a co-factor of SETDB1 
(Wang et al, 2003). Therefore association with one or both of these proteins might be 
expected to lead to an increased apparent size of MBD1 in HeLa nuclear extracts as 
assessed by gel filtration chromatography and sucrose gradient sedimentation. However, 
given the molecular masses of SETDB1 and MCAF being 143 kDa and 135 kDa 
respectively, it seems that these proteins are too large, even individually, to account for 
the size of MBD1 measured here. Furthermore, SETDB1 and MCAF are known to form 
hetero-multimers together making this problem even more pronounced (Wang et al, 
2003).  
 
Gel filtration analysis of SETDB1 in HeLa extracts was carried out here (Figure 3.3) and 
this confirmed the large apparent size of the protein that was previously noticed and 
explained by association with MCAF (Wang et al, 2003). Furthermore, it is evident that 
there is very limited, if any, overlap between the elution profiles of SETDB1 and MBD1 
(Figure 3.3 compared with Figures 3.1A or 3.4). This makes the existence of a stable 








Figure 3.3 – Separation of MBD1 and SETDB1 by gel filtration  
 
HeLa nuclear extracts were fractionated on a Superose 6 gel filtration column. Western 
blot using SETDB1 antibodies reveals the elution profile of this protein. SETDB1 has a 





3.4 Nucleic acid does not contribute to the apparent size of MBD1 
 
Transcription of rDNA is regulated in part by the nucleolar chromatin remodelling 
complex NoRC. TIP5 (TTF-interacting protein 5), the largest subunit of NoRC, contains 
a TAM (TIP5/ARBP/MBD) domain which has similarity to the methyl binding domain. 
TIP5 is known to strongly associate with 150-300 nucleotide RNAs, which show 
complementarity to regulated sequences in the rDNA promoter (Mayer et al, 2006). This 
leads to the hypothesis that the MBD of MBD1 might be stably associated with an RNA 
molecule leading to the large apparent molecular mass of MBD1 in HeLa nuclear 
extracts. In order to test this possibility, isolated HeLa nuclei were treated with the 
promiscuous benzonase nuclease which contains both DNAse and RNAse activities. 
This reaction was carried out as described in chapter two except the incubation time was 
1 h and the temperature was 37 ˚C. Proteins were then extracted from the nuclei in the 
usual way and the nuclear extract was fractionated on a Superose 6 gel filtration column. 
The Stoke’s radius of native MBD1 in HeLa nuclear extracts was unchanged by this 
treatment indicating that stable association with RNA does not account for the large 





Figure 3.4 – Nucleic acid does not contribute to the large apparent size of MBD1 
 
HeLa nuclear extracts treated with benzonase nuclease were fractionated on a Superose 
6 gel filtration column and the fractions analysed by Western blot. MBD1 is found to 
elute in the same fractions as when the extract is not treated with benzonase. 
 
 
3.5 Affinity tagging of MBD1 
 
Given that at this stage neither self-association, binding of SETDB1 nor interaction with 
nucleic acid seemed likely to explain the apparent molecular mass of MBD1, the notion 
of a stable interaction with an as yet unidentified binding partner was entertained. 
Historically the biochemical fractionation of proteins has frequently led to the 
identification of stably associated polypeptides. For example, in the case of histone 
deacetylases, other components of the Sin3a and NuRD co-repressor complexes were 
found in this way (Zhang et al, 1997; Zhang et al, 1999). However, attempts to purify 
native MBD1 and identify associated proteins using conventional chromatography 
techniques were unsuccessful (data not shown). This was partly due to difficulties in 
eluting a large proportion of native MBD1 from many of the chromatography resins 
tested, making it impossible to achieve great enough enrichments. Nevertheless, this line 
of work found that even after a five column purification procedure, native MBD1 
maintained its large apparent size as assessed by gel filtration. Therefore any binding 
partners of MBD1, which contributes to its size, are stably associated and the putative 
complex should be biochemically purifiable.  
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A more modern approach towards the isolation of protein complexes involves 
expression of a protein of interest as a fusion with tags that facilitate its purification. For 
example, purification of a tagged form of the histone H3 lysine K4 demethylase 
JARID1d revealed an interaction with Ring6a/MBLR which is a protein with homology 
to components of the polycomb complex PRC1 (Lee et al, 2007). Therefore, in order to 
investigate the nature of the putative MBD1-containing complex, a retroviral system was 
used to express this protein in HeLa cells as a fusion with a C-terminal S-tag (Terpe, 
2003), streptavidin binding peptide (Wilson et al, 2001), histidine hexamer and GFP-tag 
(MBD1-SSH-GFP).  
 
Fluorescence microscopy of HeLa cells expressing MBD1 tagged in this way revealed a 
diffuse localization with approximately six more strongly fluorescent foci per cell 
(Figure 3.5A). In contrast GFP fused to the affinity tags alone was localized more evenly 
throughout the cell (Figure 3.5B). The localization observed here for exogenous MBD1 
is very similar to that observed for the endogenous protein by immunofluorescence 
(Sakamoto et al, 2007) (Figure 3.5C). It seemed therefore that the tagging and over-
expressing of MBD1 in this fashion did not perturb its normal behaviour in this assay, 
and so purifications of this protein were undertaken. 
 
Purification of MBD1-SSH-GFP, however, proved to be a fruitless endeavour. In spite 
of being readily detectable in the microscope, this protein was surprisingly absent from 
nuclear extracts as assessed by Western blotting with antibodies against MBD1. These 
apparently contradictory observations were resolved by the discovery that MBD1-SSH-
GFP is not extracted from the nucleus under the same conditions as the endogenous 
protein, with MBD1-SSH-GFP extraction requiring the solubilisation of a nuclear pellet 
fraction by sonication (Figure 3.5D). The differential solubility of endogenous MBD1 
and over-expressed MBD1-SSH-GFP is perhaps surprising in the light of the correct 
localization of the exogenous protein. However, given this crude biochemical distinction 
between the two entities, work with this construct was abandoned as it seemed unlikely 




Figure 3.5 – Generation of affinity tagged MBD1 
 
(A) Fluorescence microscopy of HeLa cells expressing MBD1-SSH-GFP and DAPI 
stained. MBD1 forms approximately six bright foci against a diffuse nuclear signal. 
(B) Fluorescence microscopy image of HeLa cells expressing SSH-GFP and stained 
with DAPI. The protein distributes throughout the cell. 
(C) Immunoflourescence (taken from Sakamoto et al, 2007) showing the localization of 
endogenous MBD1 in HeLa cells. The strong foci against the background of diffuse 
nuclear signal is similar to the pattern observed for MBD1-SSH-GFP. 
(D) Western analysis of subcellular fractions of HeLa cells expressing MBD1-SSH-GFP 
using antibodies against MBD1 (upper panel) and GFP (lower panel). MBD1-SSH-GFP 
is found in the nuclear pellet fraction whereas the native protein is in the nuclear extract. 
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In order to try to overcome this problem MBD1 was expressed in HeLa cells with 
various other combinations of tags. Initially GFP was removed from the version of 
MBD1 described above whilst a 3xFLAG tag was added to its N-terminus, and this 
fusion protein was expressed under the control of a CMV (Cytomegalovirus) promoter 
by transient transfection. In contrast to the previous case, this protein could be extracted 
from the nucleus using 0.3 M sodium chloride. However, when these extracts were 
fractionated on a Superose 6 gel filtration column, this form of MBD1 was found to 
elute at the void volume indicating the formation of an aggregate (data not shown). Once 
again, therefore, a construct had to be discarded due to major biochemical differences 
between endogenous and exogenous MBD1. Finally MBD1 was similarly expressed 
under the control of a CMV promoter except this time with only N-terminal 3xFLAG 
and S-tags (FS-MBD1). This protein was readily extracted from the nucleus and when 
these extracts were fractionated by either sucrose gradient sedimentation (Figure 3.6A) 
or size exclusion chromatography (Figure 3.6B and 3.6C) both the Stoke’s radius and S 
value of FS-MBD1 were found to closely match what was observed for the endogenous 
protein. Therefore the use of these tags appears not to alter these critical biochemical 
properties of MBD1 and so a potentially useful tool with which to study this protein had 
been generated.  
 
3.6 Absence of stable and stoichiometric MBD1 binding partners 
 
In order to try to identify any stable binding partners of FS-MBD1 the over-expressed 
fusion protein was immunoprecipitated from HeLa nuclear extracts using the M2 
monoclonal antibody against the FLAG epitope. Following elution from the matrix 
using the 3xFLAG peptide purified proteins were separated by SDS-PAGE and then 
stained with Coomassie. Although purified FS-MBD1 could be readily visualized with 
Coomassie, no other proteins appeared to co-purify in stoichiometric amounts that might 
be able to account for the observed molecular mass of MBD1 (Figure 3.7A). Even when 




Figure 3.6 – Affinity tagging of MBD1 does not alter its Stoke’s radius or S value 
 
(A) Nuclear extracts from HeLa cells expressing FS-MBD1 were applied to a 5-20% 
sucrose gradient and the fractions analysed by Western blotting with MBD1 antibodies. 
The S values for FS-MBD1 and the endogenous protein are indistinguishable. 
(B) Superose 6 size exclusion chromatography of nuclear extracts from HeLa cells 
expressing FS-MBD1. Fractions were analysed by Western blot with antibodies against 
MBD1. The Stoke’s radius of FS-MBD1 is indistinguishable to that of native MBD1. 
(C) As above except the gel filtration fractions were analysed by Western blot with 
antibodies against the FLAG epitope. This confirms that FS-MBD1 has a very similar 









solubilize chromatin, only the histones were found to strongly co-purify with FS-MBD1 
(Figure 3.7B). Control experiments performed in parallel using putative chromatin 
remodelling enzyme LSH tagged and expressed in a similar way confirmed that FS-
MBD1 was indeed responsible for the major band seen on the gels. Furthermore, 
Western blot analysis revealed that SETDB1, a factor which has been published to 
interact with MBD1, is absent amongst the co-purifying proteins (Figure 3.7C). 
 
The failure to observe MBD1 binding partners when they might have been predicted to 
exist has a number of plausible explanations. For instance it could be the case that any 
MBD1 interacting proteins were removed during the wash steps of the FS-MBD1 
purification. Alternatively, it could be the case that MBD1 self associates, but that this 
possibility had seemed unlikely due to aberrant behaviour of bacterially expressed 
MBD1. In order to try to distinguish these possibilities the biophysical properties of the 
purified FS-MBD1 shown below (Figure 3.7A) were analysed. Surprisingly, it was not 
possible to detect this protein in the fractions following size exclusion analysis on a 
Superose 6 column (data not shown). This could be due to a combination of the dilution 
of the protein inherent in this technique as well as binding of purified MBD1 to the gel 
filtration matrix. However, sucrose gradient sedimentation revealed that some of this 
protein has a similar S value to the endogenous MBD1 found in HeLa nuclear extracts 
with a fraction of FS-MBD1 also forming an aggregate at the bottom of the gradient 
(Figure 3.8A). A similar investigation of FS-MBD1 purified from nuclease solubilized 
chromatin revealed the protein to fractionate in three peaks (marked by asterisks). Firstly 
some of the protein migrated in the same fashion as that in the previous experiment, a 
second peak further down the gradient appeared to correspond to nucleosome-associated 
MBD1 and finally a third peak at the bottom of the gradient suggested some aggregation 
of this protein too (Figure 3.8B). These observations argue that self association may 
account for the observed molecular mass of MBD1. Given that the derived mass 
calculated from the Siegel and Monty equation (136 kDa) is close to double the 




Figure 3.7 – Absence of proteins strongly co-purifying with FS-MBD1 
 
(A) Coomassie stained gel of FS-MBD1 expressed in HeLa cells and purified from 
nuclear extracts using the M2 monoclonal FLAG antibody reveals no abundant co-
purifying proteins. 
(B) Coomassie stained gel of FS-MBD1 purified at physiological ionic strength from 
nuclease solubilized chromatin. Only the histones strongly co-purify. 
(C) Western blot analysis using SETDB1 antibodies reveals that this protein does not co-





Figure 3.8 – Purified FS-MBD1 maintains its S value 
 
(A) Western blot analysis of sucrose gradient fractions reveals that the purified MBD1 
analysed in this way elutes in the same manner as does the native protein in extracts. 
(B) Coomassie stained gel of fractions from a sucrose gradient analysing FS-MBD1 




3.7 Co-immunoprecipitation of MBD1 over-expressed in HeLa cells 
 
MBD1 self association was tested further by co-immunoprecipitation assays. To this end 
3xFLAG-tagged MBD1 (amino acids 1-395) and untagged full length MBD1 were 
simultaneously over-expressed in HeLa cells. A truncated form of MBD1 was used in 
addition to the full length protein in order that the two could be resolved by Western 
blotting. Amino acids 1-395 were selected as experiments discussed in chapter six 
(performed by Alex Tuck) using in vitro translated MBD1 suggested that this portion of 
the protein was sufficient for self association. As a control 3xFLAG-tagged MeCP2 was 
co-expressed with untagged MBD1. Nuclear extracts were prepared from these cells and 
immunoprecipitations were performed using the M2 monoclonal antibody against the 
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FLAG epitope. Co-immunoprecipitation of untagged MBD1 was assessed by Western 
blotting using antibodies against this protein and found to occur with FS-MBD1(1-395) 
but not FS-MeCP2 (Figure 3.9A). Western blotting with anti-FLAG antibodies 
confirmed that both 3xFLAG-tagged proteins had been successfully expressed and 
precipitated (Figure 3.9B). The experiment described above adds weight to the 
suggestion that MBD1 interacts with itself. Also the fact that the transcriptional 
repression domain (TRD) is absent from FS-MBD1(1-395) further suggests that the 




Figure 3.9 – Self association of MBD1 by co-immunoprecipitation 
 
(A) FS-MBD1 (1-395) or FS-MeCP2 were expressed in HeLa cells with full length 
untagged MBD1. Nuclear extracts were subject to immunoprecipitation with an antibody 
against the FLAG epitope and bound proteins were analysed by Western blotting with 
MBD1 antibodies. An interaction between MBD1 and itself but not MeCP2 is detected. 
(B) Western analysis with antibodies against the FLAG epitope reveals both FS-MBD1 
(1-395) and FS-MeCP2 were successfully expressed and immunoprecipitated. 
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4. Chapter Four - Proteomics of MBD protein partners 
 
4.1 Nuclease allows extraction of MBD1 at mild ionic strength 
 
As shown in chapter three, MBD1 appears to be devoid of stably and stoichiometrically 
associated binding partners in HeLa nuclear extracts. This is surprising given that an 
earlier report found MBD1 to be stoichiometrically associated with SETDB1 in these 
cells (Sarraf and Stancheva, 2004). The absence of stable binding partners has also been 
reported for MeCP2 as well as the putative chromatin remodelling enzyme LSH (Klose 
and Bird, 2004; Myant and Stancheva, 2008). One possible interpretation of these 
observations is that these proteins function autonomously and do not interact adaptively 
with other proteins inside the cell. However, this seems unlikely as an interaction with 
DNMT1 is required for LSH to function as a transcriptional repressor in reporter assays 
(Myant and Stancheva, 2008) and MeCP2 appears to silence transcription via a 
substoichiometric association with the co-repressor Sin3a (Nan et al, 1998). 
 
The ionic strength of the buffers used to extract nuclear proteins may have contributed to 
the failure to find stable binding partners of proteins such as MBD1, MeCP2 and LSH. 
In order to try to exclude or overcome this problem, attempts were made to extract 
MBD1 from the nucleus under milder conditions. This was achieved by using the 
promiscuous nuclease benzonase to solubilize chromatin and its associated proteins. 
Western analysis of the extracts made using various salt concentrations after benzonase 
or control treatment of HeLa nuclei revealed that nuclease treatment caused more MBD1 
to be extracted at mild ionic strength (Figure 4.1A). Examination of the same extracts by 
SDS-PAGE followed by Coomassie staining showed that benzonase treatment also 
increased the total amount of protein released from isolated nuclei at physiological ionic 
strength (Figure 4.1B). Also MBD1 from mouse embryonic fibroblasts appeared to be 
more tightly associated with chromatin than the protein in HeLa cells, and the increase 




Figure 4.1 – Extraction of MBD1 from nuclei treated with benzonase 
 
(A) Western blotting with antibodies against human MBD1 reveals more of this protein 
is extracted from HeLa nuclei across a range of sodium chloride concentrations after 
pre-treatment with benzonase. 
(B) Analysis of the same extracts by SDS-PAGE followed by Coomassie staining 
reveals that benzonase treatment leads to an increase in the total protein extracted from 
HeLa nuclei at a range of sodium chloride concentrations. 
(C) Western blotting with antibodies against mouse MBD1 reveals more MBD1 is 
extracted from MEF nuclei at different salt concentrations after benzonase treatment. 
Mouse MBD1 appears to be more resistant to salt extraction than the human protein. 
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An earlier report showed that MeCP2 can be solubilized by treatment of nuclei with 
micrococcal nuclease (Meehan et al, 1992) and so this protein seems to behave similarly 
to MBD1. The dual specificity of benzonase for DNA and RNA has the additional 
advantage that complexes purified from extracts made using this enzyme should not be 
contaminated by long-range indirect RNA-mediated interactions between basic proteins. 
This concern is particularly relevant for the MBD-containing proteins under examination 
here which have all been reported to interact strongly with RNA in vitro (Jeffery and 
Nakielny, 2004). 
 
 4.2 Purification of 3xFLAG-tagged chromatin-associated proteins 
 
With the extraction procedure described above in hand, attempts were made to uncover 
binding partners of MBD1, MeCP2 and LSH that may previously have been missed due 
to the use of extraction buffers of higher ionic strength. To this end these proteins were 
transiently expressed in HeLa cells as fusions with N-terminal 3xFLAG and S tags. This 
combination of tags was chosen because, as demonstrated in chapter three, the Stoke’s 
radius and sedimentation coefficient of exogenous MBD1 tagged in this fashion are 
indistinguishable from the values for the endogenous protein. Also the Stoke’s radius of 
MeCP2 expressed with these tags in HeLa cells appeared to be the same as that found 
for the native protein in rat brain by Klose and Bird (data not shown). Mbd2 bearing a 
3xFLAG tag was employed as a positive control because the NuRD complex would be 
predicted to readily co-purify with this protein. Furthermore, comparing four different 
proteins in parallel has the advantage of guarding against incorrectly designating factors 
that bind to the affinity resin or tag as interacting with the protein of interest. Such 
events should be recognised by the fact that they occur in all purifications carried out. It 
is especially important to control for this in the experiments described here due to the 
mild conditions used. Also the proteins under scrutiny are expected to bind to the 
nucleosomal DNA released by benzonase, and therefore co-purification is possible due 
to residence on the same piece of DNA rather than a genuine direct protein-protein 
interaction. Some of these artefactual identifications would be expected to occur for 
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multiple DNA binding proteins and so by comparing several factors it was reasoned that 
it should be possible, at least to some degree, to guard against being misled by this 
caveat.  
 
Purification of these over-expressed proteins was accomplished by immunoprecipitation 
using an antibody against the 3xFLAG tag. A single step purification was used so that 
the duration of the experiment would be limited and complexes, which occur in vivo but 
gradually dissociate in vitro, might still be detected. Extraction, immunoprecipitation 
and wash buffers were used containing only 150 mM sodium chloride in order to try to 
preserve protein-protein interactions. Bound proteins were removed from the affinity 
matrix by competitive elution using the 3xFLAG peptide. Elution of the isolated proteins 
in this way allows their analysis by SDS-PAGE and staining with Coomassie or silver 
without the risk of a binding partner being missed due to co-migration with the antibody 
chains in the gel. A mock purification from cells that had not been transfected yielded no 
proteins that could be visualized by Coomassie staining (Figure 4.2A – lane 1) and the 
same procedure using cells transiently expressing tagged LSH gave a largely 
homogenous preparation of this protein (Figure 4.2A – lane 2). Taken together these 
observations support the view that the conditions being used in this experiment were not 
so mild as to lead to a high signal to noise ratio. The MBD1 sample contained more 
substoichiometric co-purifying proteins as assessed by Coomassie staining and these 
potentially represent binding partners. This sample also contained a large amount of 
histones indicating that MBD1 associates with nucleosomes under these conditions 
(Figure 4.2A – lane 3). The purified MeCP2 sample was also found to contain a large 
amount of histones as well as two major degradation products (marked by asterisks) as 
revealed by Western blotting with antibodies against the 3xFLAG tag (Figure 4.2B) and 
a variety of faintly staining bands only just visible overleaf (Figure 4.2A – lane 4). In 
contrast the parallel experiment with MBD2 yielded many bands that stained strongly 
with Coomassie some of which were of greater molecular weight than MBD2 and 
therefore could not simply correspond to degradation products (Figure 4.2A – lane 5). 
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By and large, as would be expected, the proteins in this sample correspond to the well 







Figure 4.2 – Purification of 3xFLAG-tagged DNA binding proteins from nuclease 
solubilized chromatin using the M2 monoclonal antibody 
 
(A) 3xFLAG tagged LSH, MBD1, MeCP2 and MBD2 were transiently expressed in 
HeLa cells, precipitated using the M2 monoclonal antibody and eluted using the 
3xFLAG peptide. Proteins were then separated by SDS-PAGE and visualized by 
staining with Coomassie. 
(B) Western blotting with antibodies against the 3xFLAG tag reveals that the major 




4.3 Identification of co-purifying proteins by mass spectrometry 
 
In some respects the experiment outlined above could be considered as a failure because 
none of LSH, MBD1 or MeCP2 co-purified with striking amounts of non-histone 
proteins as assessed by SDS-PAGE and staining with Coomassie. However, by using 
mass spectrometry, it is possible to identify even low abundance proteins in relatively 
complex mixtures. Therefore, in an attempt to identify novel substoichiometric binding 
partners for the proteins under investigation, samples were prepared in the same way and 
then analysed by mass spectrometry in collaboration with the laboratory of Dr Juri 
Rappsilber. Eluting proteins from the affinity matrix using the 3xFLAG peptide rather 
than by denaturation facilitates the identification of low abundance peptides as the mass 
spectra are not complicated by the presence of a large excess of antibody. For a similar 
reason, prior to analysis by mass spectrometry, the samples were run a short distance in 
an 18% acrylamide gel in order to separate the abundant histones from the rest of the 
mixture. This also has the advantage of removing the 3xFLAG peptide from the 
preparations to be analysed. 
 
Complete lists of the proteins identified by mass spectrometry as co-purifying with each 
of LSH, MBD1, MeCP2 and MBD2 are given in appendix II. In summary 150 proteins 
were identified in the sample generated from the mock purification from untransfected 
cells, 159 proteins were found with LSH, 183 proteins with MBD1, 177 with MeCP2 
and 188 with MBD2. Inspection of the list of protein co-purifying with MBD2 shows 
that this technique allowed successful enrichment for the NuRD complex. Of the 
eighteen proteins reported to be associated with this complex (Le Guezennec et al 2006) 
twelve were identified in the experiment described here and in all cases on the basis of 
more peptides than found with any of the other bait proteins used. Also PRMT1 was 
identified in this sample consistent with another report on an interaction with this protein 
and arginine methylation of MBD2 (Tan and Nakielny, 2006). It can therefore be 
concluded that the method employed here is able to accurately isolate and identify 
genuine protein-protein interactions. 
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The lists of proteins identified were then filtered to remove entries that are likely to 
represent contaminants rather than biologically relevant binding partners. Proteins found 
to co-purify with two or more baits were discarded as were those identified on the basis 
of only one or two peptides. Finally proteins annotated as ‘mitochondrial’ were removed 
as were the bait proteins, when identified in the sample analysed subsequently in the 
mass spectrometer. The filtered lists of proteins co-purifying with LSH, MBD1 and 
MeCP2 are given below (Table 1). The unique proteins found with MBD2 were not 
considered further at this stage because the stringent filtering criteria employed led to the 
subtraction of many components of the NuRD complex due to their low level co-
purification with other proteins examined (see appendix II and section 4.4). 
 
Few of the proteins listed with LSH are likely to represent genuine interaction partners. 
Most of them are either not localized to the nucleus or are found in complexes 
represented by different subunits as co-purifying with one of the other baits tested here. 
In some regards this is similar to what is observed in the list of proteins identified in the 
mock purification from untransfected cells. Furthermore, the DNA methyltransferase 
enzymes, which associate with LSH (Zhu et al, 2006; Myant and Stancheva, 2008), were 
not found even in the unfiltered list of proteins co-purifying with this factor. However, 
the situation with the samples containing MBD1 and MeCP2 was more promising. 
Among the 33 polypeptides identified uniquely in the MeCP2 experiment lie ATRX, 
two components of the Sin3 co-repressor complex (Sin3a and SAP180), four 
components of the nuclear co-repressor complex (NCoR1, HDAC3, TBL1X and 
TBL1XR1) and BAF60a which is associated with the BRG1 chromatin remodelling 
complex. All of these complexes are documented as interacting with MeCP2 (Nan et al, 
2007; Nan et al, 1998; Kokura et al, 2001; Harikrishnan et al, 2005). Likewise in the 
case of MBD1 both RING2 and CBX8 were both among the 26 proteins identified as 
present in the sample. These two proteins are components of a polycomb repressive 
complex 1 (Bárdos et al, 2000) and such a complex has been reported to interact with 
MBD1 (Sakamoto et al, 2007). 
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As well as the rediscovery of several known interactions, novel candidate binding 
partners for both MBD1 and MeCP2 were also uncovered. Among the factors found 
uniquely with MBD1 were the histone H3 lysine K4 demethylase LSD1, the histone 
acetyltransferase MYST2, the centromere component CENP-B, and two homologues 
(SUHW3 and SUHW4) of the Drosophila insulator protein suppressor of hairy wing 
(Dorsett, 1993). LSD1 has been implicated in transcriptional repression (Shi et al, 2004; 
Lee et al, 2005) as have the yeast homologues of MYST2 (Reifsnyder et al, 1996). Also 
MBD1 is enriched at centromeres on metaphase chromosomes (Ng et al, 2000) and 
DNA methylation is known to regulate the function of another insulator protein, CTCF 
(Hark et al, 2000). Therefore all of these represent biologically plausible interactions 
which merit further investigation. In the case of MeCP2 the polymerase associated factor 
(PAF) complex was identified by the presence of four subunits (Parafibromin, PD2, Ctr9 
and WDR61) all of which are absent in all the other samples. This potential interaction 
with the PAF complex, a group of proteins involved in transcriptional elongation 
(Chaudhary et al, 2007), could imply a hitherto unsuspected role for MeCP2 in the 
regulation of this process. MeCP2 also pulls down the transcription elongation factor 
SPT6 and its interaction partner IWS1 (Brès et al, 2008) augmenting the temptation to 
speculate that this protein plays a role downstream of the initiation of transcription. 
 
Some of the other proteins identified should be treated with extra caution as some are 
components of well characterized complexes represented here by other subunits which 
co-purify with different baits. For example, the histone H3 lysine K9 methyltransferase 
G9a is identified as co-purifying with MBD1 alone but GLP, a similar enzyme which is 
reported to make stable heterodimers with G9a (Tachibana et al, 2005) is found in both 
the MBD1 and MeCP2 containing samples. Likewise EED, a component of the 
polycomb repressive complex 2, is found only with MBD1 whereas EZH2, the catalytic 
component of this complex, is again found with both MBD1 and MeCP2. Similarly, 
although the chromatin assembly factor ACF1 was found uniquely with MeCP2, its 





LSH (88) MBD1 (32) MeCP2 (43) 
Keratin, type I cytoskeletal 9 (25) TIF1-alpha (12) Parafibromin (16) 
AHNAK (8) RNAPII large subunit (10) Nipped-B-like protein (14) 
Junction plakoglobin (6) SUHW4 (8) SPT6 (13) 
26S proteasome non-ATPase 
regulatory subunit 1 (5) 
FLYWCH-type zinc finger 1 
(8) TBL1XR1 (13) 
Annexin A2 (5) CKII subunit alpha (7) NCoR1 (13) 
Elongation factor 1-delta (4) G9a (7) PD2 (11) 
hnRNP K (4) TFIIIC1 (7) Ctr9 (11) 
Long-chain-fatty-acid-CoA ligase 3 
(4) BPTF (6) 
ligase III, DNA, ATP-dependent 
(10) 
DDOST (3) EED (6) Spectrin beta chain, brain 1 (9) 
4F2 cell-surface antigen (3) LSD1 (6) Probable RNA helicase DDX46 (9) 
HSP90 beta (3) MCM4 (5) ACF1 (9) 
WDR76 (3) HLTF (5) 40S ribosomal protein SA (8) 
NS1A binding protein (3) SPT5 (5) Sin3a (8) 
U4/U6.U5 tri-snRNP-associated 
protein 1 (3) 
MAX dimerization protein 5 
(5) SAP180 (7) 
Spindlin-1 (3) CENPB (4) Keratin, type II cytoskeletal 6E (7) 
 TRIM26 (4) Importin alpha-3 subunit (6) 
No Transfection MYST2 (4) APC subunit 1 (6) 
Desmoplakin (9) CBX8 (3) IWS1 homolog (6) 





Keratin 5b (6) RING2 (3) P37 AUF1 (5) 
Splicing factor 3 subunit 1 (4) β-catenin-like protein 1 (3) ANP32B (5) 
Similar to E2F7 (4) PHD interacting protein (3) DNMT3B (5) 
Keratinocyte proline-rich protein (4) Prolyl 3-hydroxylase 2 (3) APC subunit 3 (5) 
Transglutaminase 3 E (3) SUHW3 (3) HDAC3 (4) 
Keratin, type II cytoskeletal 2 oral (3) Zinc finger protein 262 (3) WDR61 (4) 
KIAA1546 protein (Fragment) (3) Zinc finger protein 592 (3) H3.3 (4) 
Pre-mRNA-processing factor 19 (3)  MCM5 (4) 
Paraspeckle protein 1 (3)  TBL1X (4) 
NCBP1 (3)  ANP32A (3) 
  BAF60a (3) 
  ATRX (3) 
  
similar to Snf2-related CBP 
activator protein (3) 
  hnRNP Q (3) 
 
 
Table 1 – Lists of factors co-purifying with LSH and MBD-containing proteins 
 
Only proteins represented by three or more peptides and identified uniquely with one of 
the baits are listed. Number of peptides observed given in brackets. Components of 
complexes which represent known interactions are shown in red. 
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4.4 Validation of mass spectrometry data by Western blotting 
 
The next step in this line of research was to investigate which of the candidates 
identified represent genuine interaction partners of the proteins under investigation. To 
this end the experiment described above was repeated except co-purifying proteins were 
analysed by SDS-PAGE followed by Western blotting with various antibodies rather 
than mass spectrometry. This has the benefits of being somewhat more quantitative, 
establishing reproducibility and verifying the presence or absence of co-purifying 
proteins by an independent technique. 
 
Probing with antibodies against HDAC1 revealed a pattern that might have been 
predicted from the mass spectrometry data and what is reported in the literature. The 
protein is absent in the mock purification using untransfected cells, a weak signal is 
present in the LSH sample with a slightly stronger signal in the MBD1 and MeCP2 
samples and a stronger signal still in the lane containing MBD2 (Figure 4.3 – top panel). 
Using antibodies against EZH2 and GLP also suggested reproducibility as consistent 
with the mass spectrometry data both of these proteins were found most strongly with 
MBD1 and MeCP2 (Figure 4.3 – second and fourth panels). G9a is also apparently 
present predominantly in both of these samples (Figure 4.3 – fifth panel) in spite of 
being unique to MBD1 as assessed by mass spectrometry, although as discussed in the 
previous section, this is not a great surprise due to the presence of GLP with both MBD1 
and MeCP2. Western blot analysis of LSD1 revealed that it too co-purified with both 
MBD1 and MeCP2 (Figure 4.3 – third panel). This is slightly surprising given that 
LSD1 was only found with MBD1 by mass spectrometry. The reason for this 
discrepancy is unclear and so this emphasises the need to confirm the candidates found 
by mass spectrometry using an alternative technique to analyse biologically independent 
purifications. Finally, Western blotting with antibodies against HDAC3 and ACF1 bears 
out exactly what was found in the previous sections with both of these proteins co-
purifying uniquely with MeCP2 (Figure 4.3 – sixth and seventh panels). Given that 
ISWI, a stable binding partner of ACF1, was found by mass spectrometry to co-purify 
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with MBD1 and MBD2 as well as MeCP2, there was a possibility that ACF1 would not 
be found uniquely with MeCP2. Therefore, even the proteins listed in section 4.3 that are 





Figure 4.3 – Western blots for factors co-purifying with LSH and MBD proteins  
 
Purifications were carried out as for the mass spectrometry experiment. Samples were 
then analysed by Western blotting. Most proteins are present in the predicted samples 
based on the mass spectrometry data. LSD1 is unexpectedly found in the MeCP2 
sample. It is conformed that HDAC3 and ACF1 co-purify uniquely with MeCP2. 
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4.5 Histone modifications associated with MBD proteins 
 
Post translational modifications of the histones are believed to regulate many aspects of 
chromatin structure and function. Such modifications are known to recruit proteins to 
specific regions of the genome and thus regulate processes such as DNA repair (Sanders 
et al, 2004) and DNA methylation (Ooi et al, 2007). It is therefore possible that in 
addition to DNA sequence and CpG methylation, histone modifications might be 
involved in targeting different MBD proteins to different regions of the genome. This is 
a plausible scenario for MBD2 as the p66α and p66β components of the NuRD complex 
both interact preferentially with non-acetylated histone tails in vitro (Brackertz et al, 
2006). Also, recombinant nucleosome-bound MeCP2 can be chemically cross-linked to 
histone H3 in vitro (Nikitina et al, 2007) indicating a close contact between these two 
proteins with the potential to be regulated by a modification. 
 
As well as the possibility that histone modifications recruit MBD-containing proteins, it 
has also been reported that these proteins in fact recruit enzymes which covalently 
modify histones. MBD2 is a component of a histone deacetylase nucleosome 
remodelling (NuRD) complex and MeCP2 associates with the histone deacetylase 
containing Sin3a co-repressor complex as well as a previously unidentified histone H3 
lysine K9 methyltransferase activity (Fuks et al, 2003). Furthermore, MBD1 is reported 
to interact with histone deacetylases as well as H3-K9 methyltransferase activities (Villa 
et al, 2006; Fujita et al, 2003; Sarraf and Stancheva, 2004). Therefore it is of interest to 
investigate whether specific histone modifications might be found on the nucleosomes 
associated with different MBD-containing proteins. Given that nucleosomes strongly co-
purify with MBD1, MeCP2 and MBD2, it is possible to ask by mass spectrometry 
whether specific post-translational modifications are found on these histones. Therefore, 
in collaboration with the laboratory of Dr Axel Imhof, the bands corresponding to 
histones H3 and H4 co-purifying with each of MBD1, MeCP2 and MBD2 were cut out a 
Coomassie stained gel similar to the one shown above (Figure 4.2A) and analysed by 
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mass spectrometry. As a control, the H3 and H4 bands from the input lane from an 
extract used for a mock purification were cut out and similarly analysed. 
 
The mass spectra generated provide information on the relative abundance of only a 
subset of potential histone modifications. The peaks corresponding to unmodified and 
acetylated histone H4 amino acids 4-17 did not vary strikingly between samples (data 
not shown). Likewise the relative amounts of the peptides corresponding to histone H3 
residues 9-17 in the monomethylated, dimethylated, trimethylated/acetylated or 
unmodified state did not vary substantially between preparations (data not shown). A 
zoom of the region of the spectrum corresponding to various states of histone H3 amino 
acids 27-40 is displayed blow (Figure 4.4). It is difficult to discern alterations in the 
relative levels of unmodified, trimethylated/acetylated, dimethylated or K27Me2K36Me3 
peptides, however, the peptide corresponding to K27Me2K36Me2 is almost two-fold 
enriched in the MBD2 sample. 
 
The significance of this observation is somewhat doubtful as the data presented only 
represent a single experiment. To pursue this line of enquiry it would therefore be 
necessary to validate the result presented here by Western blot analysis of the histones 
co-purifying with MBD2 and other proteins. This would also enable the extension of this 
line of experiments to include observations of modification states not interrogated by the 
mass spectrometry detailed here. If the finding described above proves to be robust then 
it might prove fruitful to investigate whether the presence of MBD2 is a cause or a 
consequence of this combination of histone marks. In the latter case it would be of 
interest to ask which component of the NuRD complex is responsible for this targeting. 
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Figure 4.4 – Mass spectra showing peptides corresponding to different modification 
states of amino acids 27-40 of histone H3.  
 
The peak which corresponds to the K27Me2K36Me2 appears to be enriched in the 
MBD2 sample relative to the spectra obtained from the input, MBD1 and MeCP2 
samples. No substantial differences are observed in other modification states. 
 86
5. Chapter Five - Regulation of SUMO modification of MBD1 
 
5.1 Ubiquitin-like modifiers 
 
The C-termini of ubiquitin and ubiquitin like proteins can be conjugated to lysine 
residues in target proteins by the formation of isopeptide bonds. In addition to ubiquitin 
this group of proteins includes the poorly characterized NEDD8 and ISG15 as well as 
the SUMO (small ubiquitin-like modifier) family. These post-translational modifications 
increase the complexity of eukaryotic proteomes and provide a mechanism with the 
potential to regulate the function of almost any protein. The mammalian SUMO family 
comprises three different proteins; namely SUMO-1, SUMO-2 and SUMO-3. SUMO-1 
shows approximately 50% sequence identity to SUMO-2 and SUMO-3 with the latter 
two of these proteins, which differ in only three N-terminal amino acids, yet to be 
functionally distinguished (Hay, 2005). The mechanism of conjugation initiates with the 
adenylation of the C-terminus of SUMO by the E1 activating enzyme which consists of 
a SAE1 and SAE2 heterodimer. The linkage with AMP is then broken to allow the C-
terminal carboxyl group of SUMO to link to a sulphydryl group in SAE2. Subsequently, 
SUMO is transesterified to a sulphydryl in the E2 conjugating enzyme UBC9 from 
where it can be directly transferred to target proteins. This contrasts to the situation with 
ubiquitin where there is also an absolute requirement for an E3 ligase enzyme (Hay, 
2005). Finally SUMO can be cleaved from substrates by specific SUMO protease 
enzymes and this completes the ‘SUMO cycle’ which is shown below (Figure 5.1). 
 
SUMO modification was first described in mammalian cells as a covalent modification 
of the GTPase activating protein RanGAP1 (Matunis et al, 1996), which is required for 
proper localization of this protein to the nuclear pore complex (Mahajan et al, 1997). 
Since then many other substrates for SUMO modification have been found by proteomic 
analyses (Li et al, 2004; Vassileva and Matunis, 2004; Vertegaal et al, 2004; Zhao et al, 
2004) suggesting roles for SUMO in the regulation of diverse cellular processes. This is 
 87
consistent with other studies linking SUMO to proper cell cycle progression (Johnson 
and Blobel, 1997; Seufert et al, 1995), the DNA damage response (Hoege et al, 2002), 
subcellular transport (Lin et al, 2003), antagonization of ubiquitination (Desterro et al, 









Figure 5.1 – The SUMO cycle (adapted from Hay, 2005) 
 
SUMO is covalently joined to an E1 enzyme. It is then transferred to an E2 enzyme via a 
transesterification reaction before being ligated to a lysine of a substrate. The cycle is 




SUMO modification of transcription factors is frequently associated with transcriptional 
repression (Gill, 2005). For example, there is evidence that SUMO modification of the 
Ets family transcription factor Elk-1 enhances its association with HDAC2 leading to 
transcriptional repression (Yang and Sharrocks, 2004). Furthermore, when targeted to a 
promoter by fusion with the Gal4 DNA binding domain, both SUMO-1 and SUMO-2 
were able to silence transcription indicating that SUMO has an intrinsic repressive 
ability (Yang et al, 2003; Holmstrom et al, 2003). However, there are also cases where it 
can lead to gene activation. This appears to be so with SUMO modification of Ikaros, 
heat shock transcription factors, the nuclear factor of activated T cells (NFAT) and the 
tumour suppressor p53, under some circumstances (Gómez-del Arco et al, 2005; 
Goodson et al, 2001; Hong et al, 2001; Terui et al, 2004; Rodriguez et al, 1999). 
 
The level of SUMO modification of individual proteins can be controlled by E3 ligase 
enzymes as well as SUMO protease activities, which can cleave SUMO from conjugated 
proteins. Although not absolutely required for modification, various SUMO E3 ligases, 
which can increase the efficiency of conjugation to SUMO of different substrates, have 
been uncovered. To date these comprise the PIAS family, RanBP2 and the Polycomb 
protein Pc2. Evidence exists that each enzyme promotes the modification of a different 
set of substrates (Melchior et al, 2003). For instance, over-expression of the SUMO E3 
ligase PIAS1 (but not the other enzymes PIAS3, PIAS3L, PIASxα, PIASxβ, PIASγ or 
Pc2) led to increased SUMO modification and inhibited activity of the progesterone 
receptor PR-A (Jones et al, 2006). The first activity shown to be able to remove SUMO 
from substrates was Ulp1p from budding yeast (Li and Hochstrasser, 1999) and 
subsequently mammalian activities have been uncovered on the basis of sequence 
homology. Evidence that different proteases can target different SUMO modified 
proteins comes from budding yeast (Li and Hochstrasser, 2003). The accumulation of 
SUMO conjugates seen in Ulp2 deletion strains can be rescued by removal of the non-
catalytic N-terminus of Ulp1. The fact that this truncation of Ulp1 leads to increased 
conjugation in wild-type strains suggests that the two yeast SUMO proteases have 
distinct sets of substrates. 
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MBD1 is subject to modification with SUMO-1 at two lysine residues (450 and 489) in 
its C-terminus. This modification indirectly disrupts the interaction of MBD1 with the 
co-repressor SETDB1 thus antagonizing its ability to repress transcription. Furthermore, 
the levels of the E3 SUMO ligases PIAS1 and PIAS3 control the amount of SUMO 
modification of MBD1 (Lyst et al, 2006). An independent study found MBD1 to be 
modified with SUMO-1 and SUMO-2/3, and presented evidence that this enhanced the 
interaction of MBD1 with MCAF leading to the formation of heterochromatin at MBD1 
containing foci (Uchimura et al, 2006). The reasons for the apparent discrepancies 
between these two studies are unclear although they could involve differences in the cell 
lines employed. It is also unknown to date whether or not MBD1 function might be 
regulated by SUMO protease activities. Therefore the impact that such enzymes might 
have on SUMO modification of MBD1 was investigated. 
 
5.2 Recombinant MBD1-SUMO is efficiently cleaved in vitro 
 
Methods have recently been established for the production of recombinant SUMO 
modified proteins in E.coli (Mencía and de Lorenzo, 2004; Uchimura et al, 2004). 
Indeed, sufficient quantities of protein were produced to allow the determination of the 
X-ray crystal structure of thymine DNA glycosylase conjugated to SUMO-1 (Baba et al, 
2005). A similar method was previously applied to GST-tagged MBD1 in order to test 
the effect of SUMO modification on binding to SETDB1 in vitro (Lyst et al, 2006). 
Briefly, this involved expressing GST-tagged MBD1 in E.coli simultaneously with 
HIS6-tagged SUMO-1 as well as the E1 and E2 SUMO ligase enzymes. Conjugates were 
then purified from the bacterial lysates using nickel affinity followed by glutathione 
sepharose chromatography and this SUMO modified MBD1 was then used as a substrate 
to test various protease activities. When incubated with the commercially available 
catalytic domain of the budding yeast SUMO protease, Ulp1, GST-tagged SUMO 
modified MBD1 was efficiently cleaved to yield the unmodified fusion protein (Figure 
5.2A and Lyst et al, 2006). It is not surprising that a yeast enzyme should be effective 
against human proteins as the isolated catalytic domain of Ulp1 is known to be highly 
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promiscuous with its substrate specificity normally being conferred by a regulatory 
domain which localizes the protein to nuclear pores (Panse et al, 2003). 
 
To date six mammalian proteins (SENP1-3 and SENP5-7) have been shown to possess 
SUMO protease activity. Of these only SENP1 and SENP2 are preferentially active 
against SUMO-1 rather than SUMO-2/3 conjugates with the other four showing the 
opposite specificity (Mukhopadhyay and Dasso, 2007; Lima and Reverter, 2008). In the 
HeLa cells used in the experiments described here, MBD1 is reported to be modified 
only with SUMO-1 and not SUMO-2/3 (Lyst et al, 2006). Therefore SENP1 and SENP2 
appeared to be the best candidates for a role in the regulation of the activity of MBD1, 
and so the activity of these enzymes was tested against recombinant SUMO-1 modified 
MBD1. To this end, full-length GFP-tagged SENP1 and SENP2 as well as GFP alone 
were transiently expressed in HeLa cells and then purified from nuclear extracts by 
immunoprecipitation using an antibody against GFP. These proteins were then incubated 
with recombinant SUMO-1 modified GST-MBD1 and deconjugation was monitored by 
SDS-PAGE followed by Western blotting with antibodies against GST. This revealed 
that both GFP-SENP1 and GFP-SENP2 but not GFP alone were able to remove SUMO 
from GST-MBD1 (Figure 5.2B). Furthermore, this activity was also found using 
limiting amounts of nuclear extracts from HeLa cells expressing GFP-SENP1 or GFP-
SENP2 but not those expressing GFP alone (Figure 5.2C). This second result also argues 
that the activity observed in the immunoprecipitated SENP proteins is intrinsic to the 
enzymes rather than residing in some co-purifying factor. An activity capable of 
cleaving recombinant SUMO-modified MBD1 was also detected in non-limiting 
amounts of extracts from untransfected HeLa cells. This activity was sensitive to NEM 
but not EDTA, PMSF or a commercially available protease inhibitor cocktail (Figure 
5.2D). It could therefore potentially explain why the levels of SUMO-modified MBD1 
in HeLa nuclear extracts are dependent on the presence of NEM in the buffer (Lyst et al, 




Figure 5.2 – Cleavage of recombinant SUMO modified MBD1 in vitro 
 
(A) Coomassie staining of recombinant GST-tagged SUMO modified MBD1 either 
treated or mock treated with the SUMO protease Ulp1. 
(B) Recombinant GST-tagged SUMO modified MBD1 revealed by Western blotting 
after incubation with either GFP, GFP-SENP1 or GFP-SENP2 that had been 
immunoprecipitated from HeLa nuclear extracts. 
(C) Recombinant GST-tagged SUMO modified MBD1 revealed by Western blotting 
after incubation with limiting amounts of HeLa nuclear extracts from cells transiently 
expressing either GFP, GFP-SENP1 or GFP-SENP2. 
(D) Recombinant GST-tagged SUMO modified MBD1 revealed by Western blotting 
after incubation with HeLa nuclear extracts with or without various protease inhibitors. 
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5.3 Native MBD1-SUMO is refractory to SUMO proteases in vivo 
 
Given the results of the in vitro experiments described above, it was hypothesized that at 
least one of SENP1 or SENP2 might contribute to the regulation of SUMO modification 
of MBD1 in vivo. To test this notion GFP-SENP1, GFP-SENP2 and GFP alone were 
transiently expressed in HeLa cells, which were then directly lysed in hot Laemmli 
buffer. This buffer instantly denatures most proteins so that the levels of SUMO 
modification of MBD1 in vivo could be assayed without the confounding effects of 
SUMO ligation and removal occurring in vitro. Furthermore, in order to avoid the 
diluting effects of non-expressing cells, a small amount of plasmid DNA carrying a 
puromycin resistance gene was co-transfected into these cells. Having established that a 
concentration of 2.5 µg/ml puromycin was required to kill HeLa cells by overnight 
treatment, this allowed untransfected cells to be removed by overnight drug selection on 
the day after transfection. Fluorescence microscopy confirmed that over 95% of the 
surviving cells were expressing GFP or a fusion protein thereof (Figure 5.3A) and SDS-
PAGE followed by Western blot analysis of extracts from these cells using antibodies 
against GFP revealed they were ectopically expressing fusion proteins of the predicted 
size (Figure 5.3B). However, probing the same membrane with antibodies against 
MBD1 revealed no changes in the levels of unmodified MBD1 versus SUMO modified 
MBD1, even when SENP1 or SENP2 were over-expressed (Figure 5.3C). It therefore 
seems unlikely that SUMO modification of MBD1 is regulated by these enzymes in 
vivo. The apparent inconsistency with the in vitro data is not a great surprise as SENP1 
has previously been reported to be a much more promiscuous enzyme in vitro than in 











Figure 5.3 – Over-expression of SENP1 or SENP2 does not reduce levels of MBD1 
SUMO modification in vivo 
 
(A) Fluorescence microscopy confirms expression of GFP, GFP-SENP1 or GFP-SENP2 
in over 95% of the surviving transfected cells following puromycin treatment. 
(B) Western blot analysis of HeLa whole cell extracts using antibodies directed against 
GFP confirms expression of GFP, GFP-SENP1 or GFP-SENP2. 
(C) Western blot analysis using antibodies against MBD1. Levels SUMO conjugated 
MBD1 and unmodified MBD1 in HeLa whole cell extracts following expression of 
either GFP alone, GFP-SENP1 or GFP-SENP2 are indistinguishable. 
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5.4 Native MBD1-SUMO is refractory to SUMO proteases in vitro 
 
As alluded to at the end of the last section, one possible explanation for the differential 
susceptibility of SUMO modified MBD1 to cleavage in the experiments described above 
is the distinction between in vitro and in vivo analyses. Alternatively this discrepancy 
could arise due to the different sources of MBD1 being used as a bacterially expressed 
GST fusion is being compared with a native protein from HeLa cells. 
 
In order to distinguish these possibilities the abilities of GFP-SENP1 and GFP-SENP2 to 
cleave SUMO from native MBD1 were assayed in vitro. HeLa cells were transfected 
with GFP-SENP1, GFP-SENP2 or GFP alone, and these proteins were purified from 
nuclear extracts by immunoprecipitation using an antibody against GFP. Control 
reactions using recombinant SUMO-modified MBD1 as a substrate confirmed that once 
again catalytically active SENP1 and SENP2 had been purified (Figure 5.4A). Nuclear 
extracts from untransfected HeLa cells containing native SUMO-modified and 
unmodified MBD1 were also incubated with these immunopurified SENP proteins. 
Western blotting with antibodies against MBD1 revealed that native SUMO-modified 
MBD1 was unaffected by incubation with these proteases (Figure 5.4B). Therefore the 
apparently contradictory results previously obtained by analysis of native MBD1 in vivo 
versus recombinant MBD1 in vitro are explained by differences intrinsic to the 
substrates rather than the reaction conditions used. This is also the case for cleavage of 
recombinant compared to native SUMO-modified MBD1 both by endogenous SUMO 
protease activity in HeLa nuclear extracts and by the catalytic domain of the yeast 
enzyme Ulp1 (Figure 5.4C). In the case of the protease activity endogenous to HeLa 
nuclear extracts, cleavage of SUMO from recombinant MBD1 and the resistance to 
cleavage of the native protein can be observed in the same reaction. Therefore this 
experiment contains internal controls thus demonstrating an intrinsic difference between 





Figure 5.4 – Native SUMO modified MBD1 resists SUMO proteases in vitro 
 
(A) GFP, GFP-SENP1 and GFP-SENP2 were expressed in HeLa cells and purified using 
an antibody against GFP. The precipitated proteins were incubated with recombinant 
SUMO modified GST-MBD1 and the reaction products were analysed by Western blot. 
(B) The same purified proteins were incubated with HeLa nuclear extracts containing 
MBD1 and MBD1-SUMO. The protease activities were assayed by Western blot with 
antibodies against MBD1. 
(C) The SUMO protease activities in HeLa nuclear extracts and Ulp1 both readily cleave 
recombinant MBD1-SUMO but not native MBD1-SUMO in vitro. 
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These results suggest that GST-tagged MBD1 is not a very good substrate to use in the 
study of SUMO modification of MBD1. Incorrect folding of bacterially expressed 
MBD1 might provide an explanation for these results. Alternatively, in contrast to 
previous reports, it appears that an as yet unidentified isoform other than PCM1 is the 
most abundant isoform of MBD1 in HeLa cells (see section 5.7). This too could be an 
important part of the explanation for the results described above. 
 
5.5 SUMO modification destabilizes native MBD1 in vitro 
 
It has previously been shown that the amount of SUMO modified MBD1 detectable in 
HeLa nuclear extracts increases substantially when the cysteine protease inhibitor NEM 
is included in the extraction buffers (Lyst et al, 2006). However, despite being 
catalytically active when expressed in HeLa cells, neither GFP-SENP1 nor GFP-SENP2 
is able to cleave SUMO from native MBD1. This raises the possibility that SUMO 
conjugated MBD1 is a substrate for a known SUMO protease that has previously been 
reported either to be localized in the cytoplasm or to be specific for SUMO-2/3 
conjugates, and which was therefore not tested here. Equally plausible is that MBD1 
might be a substrate for an as yet uncharacterized protease. One method, which can be 
employed to discover such enzymes, is the chromatographic fractionation of extracts 
showing an in vitro activity followed by identification of the proteins involved by mass 
spectrometry. With this in mind, an assay was devised for the activity in HeLa nuclear 
extracts that degrades native SUMO modified MBD1. 
 
In order to establish a useful assay, native SUMO modified MBD1 needed to be rapidly 
purified away from the unmodified protein as well as the endogenous protease activity 
of interest. Removal of the unmodified protein would allow the progression of the 
reaction to be monitored by the production of unconjugated MBD1 as well as the 
disappearance of the SUMO modified version. This separation was enabled by the 
differential extractability of unmodified and SUMO conjugated MBD1 from HeLa 
nuclei at physiological ionic strength (Figure 4.1A). After pre-extraction with buffer 
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containing 200 mM NaCl HeLa nuclear proteins were extracted from the pellet by 
sonication in the same buffer thus generating a protein fraction that was enriched in 
SUMO modified MBD1, but largely devoid of the unmodified protein. Separating 
modified MBD1 away from endogenous SUMO protease activities would improve any 
assay using this protein as a substrate because a greater proportion of any cleavage 
observed would be attributable to the fractions under scrutiny. This purification was 
achieved based on the affinity of MBD1 and SUMO modified MBD1 for immobilized 
nickel ions that had been uncovered during early attempts to purify a native MBD1-
containing protein complex. Thus having partially purified native SUMO modified 
MBD1 by manipulation of the nuclear extraction protocol followed by immobilized 
metal affinity chromatography, a suitable substrate for the desired assay was in hand. 
Were a conventional Dignam HeLa nuclear extract to be used as a source of protease 
activity for this assay, then the analysis would be complicated by the presence of MBD1, 
both SUMO modified and unmodified, in this material. To circumvent this problem the 
flow-through after the application of a Dignam nuclear extract to a nickel column was 
selected as a starting material for a potential fractionation. This fraction was designated 
‘Ni2+-FT’ and contains most of the proteins found in the original extract, but is strongly 
depleted for both MBD1 and SUMO modified MBD1 (Figure 5.5). 
 
To test the usefulness of these protein fractions in an assay for SUMO protease activity 
the ‘Ni2+-FT’ fraction was incubated with the native SUMO modified MBD1 enriched 
extract and then the levels of the modified and unmodified protein were analysed by 
Western blotting with antibodies against MBD1 (Figure 5.5). The efficient separation of 
SUMO modified and unmodified MBD1 into nuclear pellet and extract fractions is 
shown (compare lanes 1 and 3) as is the ability of an Ni2+ ion containing column to 
deplete MBD1 from extracts (compare lanes 1 and 2). However, although treatment of 
native SUMO modified MBD1 with ‘Ni2+-FT’ leads to the destruction of this protein, 
this is not accompanied by the appearance of unmodified MBD1 (lane 4). This effect is 
attributable to an activity in ‘Ni2+-FT’ as the levels of SUMO modified MBD1 are not 
affected in this way when they are incubated with buffer alone in a control reaction in 
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parallel (lane 3). From these experiments it can be concluded that SUMO modification 
destabilizes MBD1 in vitro and that no activity exists in HeLa nuclear extracts capable 





Figure 5.5 – Destabilization of native SUMO modified MBD1 in vitro 
 
Western blot reveals that fractionation of HeLa nuclear proteins into nuclear extract and 
nuclear pellet efficiently separates SUMO modified and unmodified MBD1 (compare 
lanes 1 and 3). Nuclear extracts can be efficiently depleted of MBD1 taking the flow-
through from a nickel column (lane 2). Native SUMO modified MBD1 is destroyed by 
an activity in HeLa nuclear extracts without being converted to detectable unmodified 
MBD1 (compare lane 3 with buffer alone to lane 4 where the ‘Ni2+-FT’ fraction was 
added). Ponceau staining confirms approximately equal protein loading of the lanes. 
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5.6 MBD1-SUMO is not degraded by the proteasome in vivo 
 
Recent reports have shown that modification of PML (promyelocytic leukaemia) protein 
with SUMO-2/3 is a signal for ubiquitination by the E3 ligase RNF4 and subsequent 
proteasomal degradation (Tatham et al, 2008; Lallemand-Breitenbach et al, 2008). 
These works also presented evidence that SUMO-1 can be a substrate for modification 
with SUMO-2/3 and that this might reflect a mechanism for the proteasomal targeting of 
some proteins modified with SUMO-1. Given that native SUMO modified MBD1 seems 
to be preferentially degraded in extracts without conversion to the unmodified form of 
the protein, it was hypothesised that SUMO modification of MBD1 might target the 
protein for proteasomal degradation, perhaps via ubiquitination by RNF4. It was 
therefore asked whether SUMO modified MBD1 might be specifically degraded by the 
proteasome in vivo. 
 
The proteasome can be inhibited in cells using the drug MG132 (Lee and Goldberg, 
1998). If SUMO modified MBD1 is targeted for ubiquitin-mediated degradation by the 
proteasome then following treatment of HeLa cells with this drug an accumulation of 
SUMO modified or other high molecular weight forms of MBD1 would be predicted. 
Cells were treated with MG132 or vehicle (DMSO) over a time course and whole cell 
extracts prepared under denaturing conditions were then analysed by SDS-PAGE 
followed by Western blotting with antibodies against either SUMO-2/3 or MBD1. 
Consistent with previous reports MG132 treatment, but not control treatment with 
DMSO, led to an increase in high molecular weight SUMO-2/3 conjugates (Figure 
5.6A). This indicates successful inhibition of the proteasome in the experiment described 
here. However, no alteration was observed in the profile of MBD1 revealed by Western 
blotting (Figure 5.6B) suggesting that SUMO modification does not target MBD1 for 









Figure 5.6 – SUMO modified MBD1 is not targeted by the proteasome in vivo 
 
(A) HeLa cells were treated with either DMSO or MG132 for defined amounts of time. 
Western blot analysis whole cell extracts using antibodies against SUMO-2/3 showed 
increasing levels of high molecular weight SUMO-2/3 conjugates over time specifically 
when the cells were treated with MG132. 
(B) The same membrane probed with an antibody against MBD1. Treatment of HeLa 
cells with MG132 does not lead to accumulation of MBD1 or SUMO modified MBD1. 
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5.7 PCM1 is not the major isoform of MBD1 in HeLa cells 
 
There are various possible explanations for the different behaviour observed for 
recombinant SUMO modified MBD1 with respect to the native protein. It is possible 
that bacteria do not possess a chaperone that is required for proper folding of full length 
MBD1 or perhaps the purification scheme somehow disrupts the normal structure of the 
protein. An alternative explanation considered was that the isoform of MBD1 expressed 
in HeLa cells might not be the one, namely PCM1, which was expressed in and purified 
from E.coli. Part of the reason for entertaining this possibility was the fact that tagged 
forms of MBD1 used in this study consistently migrated slightly more slowly in SDS-
PAGE than would be expected by simply adding the size of the tag to that of the 
endogenous MBD1 protein observed in HeLa cells. Furthermore, SUMO modification 
of the FS-MBD1 protein (PCM1 isoform described in chapters 3 and 4) was never 
observed in extracts even when modification of the endogenous protein was easily 
detectable. 
 
Five isoforms of human MBD1 have been previously described in the literature (Cross et 
al, 1997; Fujita et al, 1999). These isoforms vary in sequence at the C-terminus as well 
as by which zinc finger domains are present in the central region of the protein (Figure 
5.7A). Previously the major isoform of MBD1 in HeLa cells was reported to be PCM1 
(Sarraf and Stancheva, 2004). This claim was based on RT-PCR analysis using primers 
flanking the first zinc finger of MBD1, in order that different sized PCR products would 
be observed depending on the presence or absence of this domain. In these experiments 
only a product corresponding to mRNA without this region was observed, and so it was 
concluded that PCM1, the only MBD1 isoform lacking this domain, must be the major 
variant of MBD1 present in HeLa cells. However, this interpretation assumed 
approximately equal amplification efficiencies of differently sized PCR products and 
therefore may not have been valid. This line of experimentation was therefore revisited 
and control PCR reactions using plasmid DNA as template were carried out in order to 
compare the amplification efficiencies of these PCR products. Both variant 3 and PCM1 
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isoforms of MBD1 amplified efficiently under the conditions previously used (Figure 
5.7B) so it is unlikely that the conclusion that most MBD1 transcripts in HeLa code for a 
protein lacking the first zinc finger is erroneous.  
 
Given the evidence that PCM1 is the most abundant isoform of MBD1 at the RNA level 
it might be expected that this is the most abundant version at the protein level too. 
However, recombinant untagged MBD1, and untagged MBD1 expressed in HeLa cells 
both migrate differently to the endogenous protein when assayed by SDS-PAGE 
followed by Western blotting (Figure 5.7C) with an antibody previously shown to be 
specific for MBD1 by siRNA mediated depletion of the protein (Sarraf and Stancheva, 
2004). An earlier study using a different antibody found endogenous MBD1 migrated 
similarly to recombinant MBD1 in SDS-PAGE (Ng et al, 2000) but this result must now 
be treated with caution given that the specificity of the antibody was not verified by 
genetic means. Therefore the most abundant form of MBD1 in HeLa cells is likely a 
novel isoform that lacks the first zinc finger but is not PCM1. This has important 





Figure 5.7 – An uncharacterized isoform accounts for most of the MBD1 protein in 
HeLa cells 
 
(A) Schematic of the domains present in different MBD1 isoforms (adapted from Fujita 
et al, 1999). The only known isoform lacking the first zinc finger domain is PCM1. 
(B) PCR using primers upstream and downstream of the first zinc finger of human 
MBD1 with the templates being PCM1-conaining and/or MBD1 variant 3 containing 
plasmid DNA. The longer product corresponds to variant 3 and the shorter product to 
PCM1. No bias is observed towards amplification of the shorter sequence. 
(C) Western blot showing untagged bacterially expressed MBD1 (isoform PCM1) next 
to HeLa nuclear extracts containing only endogenous MBD1 and HeLa nuclear extracts 





6. Chapter Six - Discussion 
 
6.1 MBD1 potentially forms dimers 
 
Up until now a detailed study of the biophysical properties of MBD1 has been lacking. 
Whereas MeCP2 behaves as an elongated monomer in nuclear extracts (Klose and Bird, 
2004) and MBD2 is a component of the NuRD complex (Zhang et al, 1999; Feng and 
Zhang, 2001; Le Guezennec et al, 2006) this aspect of MBD1 function remained to be 
addressed. The starting point of the work in this thesis, therefore, was to ask whether or 
not MBD1 is a component of a stable multi-subunit protein complex. A number of lines 
of evidence presented in chapter three suggest that MBD1 does not stably interact with 
other proteins, but might self associate to form dimers. Firstly, the molecular mass of 
endogenous MBD1 derived from its Stoke’s radius and sedimentation coefficient is 
close to double the theoretical molecular mass of this protein. Secondly, 3xFLAG-
tagged MBD1 expressed in HeLa cells recapitulates these properties and after 
purification to near homogeneity the S value of this protein is observed to be unchanged. 
Thirdly, untagged full-length over-expressed MBD1 co-immunoprecipitates with an 
over-expressed 3xFLAG-tagged version of the protein (amino acids 1-395). Finally, 
recent experiments by a rotation student indicate that 3xFLAG-tagged MBD1 produced 
in rabbit reticulocyte lysates interacts with similarly expressed MYC-tagged MBD1. 
Using these in vitro translated proteins the region of MBD1 responsible for its putative 
self association was mapped to the zinc finger domains (Alex Tuck, unpublished data). 
This may then represent a similar situation to the one reported for the transcription factor 
Ikaros, which forms dimers via its zinc fingers (McCarty et al, 2003). 
 
Despite these results doubt still remains over the conclusion that MBD1 self associates, 
and further work is required to test this hypothesis more rigorously. Although the FS-
MBD1 protein used here is indistinguishable to endogenous MBD1 in terms of its 
Stoke’s radius and sedimentation coefficient, a number of differences have still been 
 105
noted between these two forms of the protein, and so caution must be exercised when 
using FS-MBD1 as a model. For example, no interaction was found between FS-MBD1 
and SETDB1, and SUMO modification of FS-MBD1 was not detected in extracts where 
modification of the endogenous protein was readily observed. Also, although FS-MBD1 
migrates similarly to the endogenous protein in sucrose gradients at physiological ionic 
strength, the use of 420 mM sodium chloride leads to FS-MBD1 behaving like the 
bacterially expressed protein (like a monomer). This is not the case for endogenous 
MBD1, which maintains its S value even at the higher salt concentration (data not 
shown). Furthermore, given that a proportion of purified FS-MBD1 forms an aggregate 
as assessed by sucrose gradient sedimentation, it is not clear whether the co-
immunoprecipitation data can be confidently interpreted as supporting the existence of 
MBD1 dimers. Another cause for concern is the fact that only over-expressed MBD1 co-
immunoprecipitates with a 3xFLAG tagged version of the protein whilst the endogenous 
form remains unbound. A particularly useful experiment in resolving whether or not 
MBD1 forms dimers would be size exclusion analysis of a homogeneous preparation of 
FS-MBD1. 
 
If the conclusion that MBD1 forms dimers is substantiated then it will be of interest to 
ask what the physiological significance of this self association might be. As the TRD 
appears to be dispensable for the interaction it seems unlikely that the formation of 
dimers is required for transcriptional repression per se (although it cannot be completely 
ruled out that self association was not ‘rescued’ by the Gal4 DNA binding domain used 
in reporter assays to map the TRD). An alternative possibility is that self association 
confers DNA sequence binding specificity and is thus required for correct targeting of 
MBD1 to specific parts of the genome. The appropriate spacing of two methyl binding 
domains and two non-methyl CpG binding zinc fingers could lead to the protein having 
high affinity for sites with a certain spacing of methylated and non-methylated CpGs. 
Another suggestion is that MBD1 self association might bring together different regions 
of genomic DNA and so lead to the formation of higher order chromatin structures and 
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compaction of the genome. A potentially fruitful line of future research might involve 
examining what effect SUMO modification has on self association of MBD1. 
 
6.2 Binding partners of MBD proteins 
 
Chapter four described experiments designed to identify interaction partners for MBD1, 
MeCP2, MBD2 and LSH that might have been missed by the approaches taken in 
previous studies. The method employed here utilized benzonase nuclease to solubilize 
these chromatin associated proteins under less stringent conditions than had been used in 
earlier works (Klose and Bird, 2004; Myant and Stancheva, 2008; Le Guezennec et al, 
2006). Over-expressed 3xFLAG-tagged fusion proteins were purified using an antibody 
against this epitope, and co-purifying proteins were identified by mass spectrometry. 
 
On the one hand the screen seems to have been successful in that a number of known 
interaction partners were re-discovered for all three MBD-containing proteins examined, 
and at the same time several putative novel binding proteins were identified. Also the 
stringent filtering criteria, which excluded any factors co-purifying with more than one 
of the bait proteins make the occurrence of false positives due to non-specific 
interactions with the tag or purification matrix used unlikely. Furthermore, Western blot 
analysis of samples prepared similarly revealed the data to be relatively robust and 
reproducible by an independent technique. On the other hand, however, the histone H3 
lysine K9 methyltransferase SETDB1 as well as the chromatin assembly factor CAF1 
were notable by their absence in the list of proteins co-purifying with MBD1. Given the 
weight of evidence for binding between MBD1 and SETDB1 (yeast two-hybrid, binding 
of recombinant proteins in vitro and reciprocal stoichiometric co-immunoprecipitation of 
endogenous proteins), the results of any experiment which is apparently inconsistent 
with this interaction must be treated with caution. It should also be kept in mind that the 
experiment described here is potentially prone to false negatives. For instance, it is 
certainly possible that not all of the interaction partners of these proteins are expressed 
in HeLa cells. It also cannot be ruled out that some proteins genuinely do interact with 
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more than one of the baits investigated here, and that such proteins would have been 
ignored due to attempts to guard against false positives. Indeed, this has clearly occurred 
with the histone deacetylases HDAC1 and HDAC2, which are known to interact with 
both MeCP2 and MBD2. 
 
Co-immunoprecipitation between endogenous proteins is often viewed as a ‘gold 
standard’ for the verification of protein-protein interactions (Mackay et al, 2007). This 
type of experiment would be required to confirm that the putative interactions uncovered 
here do not represent over-expression artefacts. It will also be necessary to test the 
possibility that these candidate interactions are simply mediated by the fragments of 
DNA generated during generation of the extracts. Although the identification of proteins 
as co-purifying uniquely with one of the bait proteins goes some way to excluding this 
possibility, it is still plausible that the proteins examined here are bound to different 
genomic regions whose chromatin is composed of different complements of proteins. 
Testing for binding in vitro between recombinant proteins would go some way to ruling 
out the possibility of nucleosomal DNA mediated interactions and an additional 
approach currently being pursued is to repeat the screen using proteins harbouring point 
mutations such that they can no longer interact with DNA. 
 
6.3 Regulation of SUMO modification of MBD1 
 
Chapter five of this thesis focussed on SUMO modification of MBD1 and in particular 
whether this might be regulated by SUMO protease activities. Native SUMO modified 
MBD1 was found to be refractory to all such activities tested both in vitro and in vivo. 
The sensitivity of this protein to the absence of NEM in extraction buffers was 
confirmed, but surprisingly this appeared to be due to degradation of the protein rather 
than deconjugation of SUMO. The fact that the presence of SUMO conjugated proteins 
is often dependent on the presence of NEM or denaturing agents in extraction buffers is 
generally presumed to be due to the activity of SUMO proteases, but the data on MBD1 
suggest that for some SUMO substrates at least, this might not be the case. The results 
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presented here are perhaps slightly surprising given that SUMO was readily cleaved 
form recombinant MBD1 by a variety of protease activities. One viewpoint is that the 
recombinant protein is misfolded and that this explains its different behaviour to native 
MBD1. However, another potentially more interesting resolution of the data is that 
different isoforms of MBD1 could show differential susceptibility to SUMO protease 
activities. Consistent with this notion is the fact that SUMO modification of over-
expressed FS-MBD1 was not observed even in extracts where native SUMO modified 
MBD1 conjugates were present. This situation could be explained if SUMO is more 
readily cleaved from the PCM1 isoform than whichever version of MBD1 represents 
most of the protein in HeLa cells. 
 
An urgent priority in future research on MBD1 will be to determine which isoforms are 
most abundantly expressed at the protein level in the tissues and cell lines under 
examination. Evidence is presented here that PCM1 behaves differently to the most 
abundant isoform of MBD1 present in HeLa cells in a variety of assays. This is not 
limited to behaviour with respect to SUMO modification, but also includes interaction 
with SETDB1 and susceptibility of putative self association to increasing ionic strength. 
If over-expression of MBD1 accounted for these changes then an alteration in the 
behaviour of the endogenous protein in the same extracts would be predicted. This, 
however, is not observed, and so a strong case can be argued for different isoforms of 
MBD1 being biochemically distinct. If it proves impossible to identify the most 
abundantly expressed MBD1 isoform, then it would be prudent to abandon approaches 
to the study of this protein which involve its over-expression. 
 
6.4 Conclusions and future perspectives 
 
Twenty years on since the identification of the first methyl-CpG binding activity 
(Meehan et al, 1989) the field has moved some way towards understanding how the 
DNA methylation signal is interpreted by the cell. Genetic studies in mice have revealed 
phenotypic abnormalities that occur when the proteins which specifically recognise 
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methylated DNA are ablated. In the case of Mbd2, there has been a degree of success in 
uncovering the molecular details of how this protein’s absence leads to defects in the 
immune system and large intestine (Hutchins et al, 2002; Berger et al, 2007). Without 
Mbd2, specific genes seem to be mis-expressed concomitant with hyperacetylation of 
histones at their promoters. This is consistent with earlier work which identified MBD2 
as a component of the NuRD complex (Zhang et al, 1999) and showed it to function as a 
histone deacetylase-dependent transcriptional repressor in reporter assays (Ng et al, 
1999). With Mbd1 and Mecp2, however, it is still almost completely unknown how their 
absence leads to the neurological phenotypes observed in the null mice (Zhao et al, 
2003; Chen et al, 2001; Guy et al, 2001). Although early work using reporter assays 
suggested that these proteins function as transcriptional repressors (Fujita et al, 1999; 
Nan et al, 1997), this has not been substantiated by expression analysis of Mbd1- or 
Mecp2-null mice (Zhao et al, 2003; Tudor et al, 2002). Thus little is fully understood 
about the physiological roles of these proteins. 
 
The identification of binding partners can be useful in forming hypotheses as to what the 
functions of poorly characterized proteins might be. The tentative finding that MBD1 
forms dimers is of some interest in this respect. For example, it is possible to imagine 
that MBD1 self association leads to the appropriate positioning of DNA binding 
domains such that a consensus binding sequence which can direct the protein to specific 
regions of the genome exists. In the light of this, chromatin immunoprecipitation 
experiments to identify loci occupied by MBD1 are a particularly pertinent avenue of 
research. In the case of MeCP2, the identification of a putative interaction with the PAF 
complex (Chaudhary et al, 2007) is arguably the most interesting finding here. If this 
interaction is borne out then it suggests a potential role for MeCP2 in the regulation of 
transcriptional elongation and mRNA processing that would merit further investigation. 
Perhaps then, the key to understanding the molecular defects in Rett syndrome and 
Mecp2-null mice is to let go of the idea that MeCP2 functions primarily as a 
transcriptional repressor of specific genes. 
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Appendix I – Plasmids used in this study 
 
pET42a-MBD1 – Used to express MBD1 free of tags in E.coli. Full length MBD1 
(isoform PCM1) was cloned with a C-terminal stop codon between the NdeI and XhoI 
sites of pET42a. 
 
pBABE HYGRO MBD1-SSH-GFP – Used to make retroviruses for expression of 
MBD1 with C-terminal SBP-tag, S-tag, histidine hexamer and GFP-tag. The coding 
sequences were joined by PCR mediated recombination before being cloned into the 
EcoRI and BamHI sites of pBABE HYGRO. 
 
pBABE HYGRO SSH-GFP – Used to make retrovirus for expression of an SBP-tag, S-
tag and histidine hexamer with a C-terminal GFP. Generated using the same strategy as 
for pBABE HYGRO MBD1-SSH-GFP except the sequence of MBD1 was not included. 
 
pF-MBD1-SSH – Used to express MBD1 with an N-terminal 3xFLAG tag and C-
terminal SBP-tag, S-tag and histidine hexamer. The SSH tag was cloned into the XbaI 
site of p3xFLAG-CMV-10. MBD1 was then cloned between the NotI and BglII sites. 
 
pFS-MBD1 – Used to express MBD1 with N-terminal 3xFLAG- and S-tags in HeLa 
cells. The backbone vector was produced by cloning an S-tag between the HindIII and 
NotI sites of p3xFLAG-CMV-10. Full length MBD1 (isoform PCM1) was cloned 
between the NotI and BglII sites of the resulting plasmid. 
 
pFS-LSH – Same as pFS-MBD1 except LSH coding sequence was used instead. 
 
pFS-MeCP2 – Same as pFS-MBD1 except MeCP2 coding sequence was used instead. 
 
pF-Mbd2 – A gift from Aimee Deaton. The mouse mbd2 sequence is cloned into 
p3xFLAG-CMV-10 between the NotI and BglII sites. 
 
pFS-MBD1(1-395) – Same as pFS-MBD1 except only the region coding for amino acids 
1-395 was cloned. 
 
pGST-MBD1 -  Used to express MBD1 as a GST fusion in E.coli. Full length MBD1 
(isoform PCM1) was cloned between the EcoRI and SalI sites of pGEX4t1. 
 
pBADE12 – A gift from Mario Mencía (see Mencía and de Lorenzo, 2004). Used to 
express the SUMO conjugation enzymes in E.coli. 
 
pRSFDuet1-SUMO-1 – Used to express SUMO-1 in E.coli with an N-terminal histidine 
hexamer. Full-length SUMO-1 up to the C-terminal diglycine motif was cloned between 
the BamHI and HindIII sites of pRSFDuet1. 
 111
 
pEGFP-C3-SENP1 – Used to express SENP1 as a GFP fusion in HeLa cells. The full 
length coding region was cloned between the HindIII and EcoRI sites of pEGFP-C3. 
 
pEGFP-C3-SENP2 – Used to express SENP2 as a GFP fusion in HeLa cells. The full 
length coding region was cloned between the HindIII and EcoRI sites of pEGFP-C3. 
 
pEGFP-C3 – The unmodified vector was used for the expression of GFP in HeLa cells. 
 
pEGFP-N1-MBD1 – Used to express untagged MBD1 in HeLa cells. Full length MBD1 
(isoform PCM1) was cloned with a C-terminal stop codon between the SacI and EcoRI 
sites of pEGFP-N1. 
 
pFS-MBD1(Var3) – Same as pFS-MBD1 except a different isoform was cloned. Used as 
a PCR template to rule out differential amplification of PCM1 and variant 3 isoforms. 
The first zinc finger of MBD1 was amplified from HeLa cDNA and then used with 









The proteins purified using the M2 anti-FLAG antibody and identified by mass 
spectrometry are listed in the following table. The samples proteins were found in are 










number Peptides Description 
IPI00418234 43 Methyl-CpG-binding protein 2 
IPI00003519 8 116 kDa U5 small nuclear ribonucleoprotein component 
IPI00003519 4 116 kDa U5 small nuclear ribonucleoprotein component 
IPI00816451 9 129 kDa protein 
IPI00005625 11 136 kDa protein 
IPI00456681 13 199 kDa protein 
IPI00031627 8 217 kDa protein 
IPI00031627 8 217 kDa protein 
IPI00414482 7 241 kDa protein 
IPI00018398 2 26S protease regulatory subunit 6A 
IPI00021435 3 26S protease regulatory subunit 7 
IPI00023919 2 26S protease regulatory subunit 8 
IPI00021926 2 26S protease regulatory subunit S10B 
IPI00021926 3 26S protease regulatory subunit S10B 
IPI00012268 2 26S proteasome non-ATPase regulatory subunit 2 
IPI00012268 6 26S proteasome non-ATPase regulatory subunit 2 
IPI00011603 4 26S proteasome non-ATPase regulatory subunit 3 
IPI00011603 6 26S proteasome non-ATPase regulatory subunit 3 
IPI00793917 1 27 kDa protein 
IPI00293845 13 275 kDa protein 
IPI00293845 7 275 kDa protein 
IPI00293845 13 275 kDa protein 
IPI00294242 6 28S ribosomal protein S31, mitochondrial precursor 
IPI00294242 8 28S ribosomal protein S31, mitochondrial precursor 
IPI00073779 4 28S ribosomal protein S35, mitochondrial precursor 
IPI00073779 10 28S ribosomal protein S35, mitochondrial precursor 
IPI00791156 3 31 kDa protein 
IPI00791156 1 31 kDa protein 
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IPI00555610 8 313 kDa protein 
IPI00163866 5 330 kDa protein 
IPI00023086 9 39S ribosomal protein L15, mitochondrial precursor 
IPI00027096 9 39S ribosomal protein L19, mitochondrial precursor 
IPI00411816 3 39S ribosomal protein L2, mitochondrial precursor 
IPI00162330 2 39S ribosomal protein L37, mitochondrial precursor 
IPI00162330 11 39S ribosomal protein L37, mitochondrial precursor 
IPI00783656 9 39S ribosomal protein L38, mitochondrial precursor 
IPI00009680 10 39S ribosomal protein L44, mitochondrial precursor 
IPI00185859 5 39S ribosomal protein L45, mitochondrial precursor 
IPI00023161 6 39S ribosomal protein L46, mitochondrial precursor 
IPI00008438 5 40S ribosomal protein S10 
IPI00216153 1 40S ribosomal protein S15 
IPI00221093 3 40S ribosomal protein S17 
IPI00013485 7 40S ribosomal protein S2 
IPI00011253 5 40S ribosomal protein S3 
IPI00011253 8 40S ribosomal protein S3 
IPI00419880 6 40S ribosomal protein S3a 
IPI00217030 13 40S ribosomal protein S4, X isoform 
IPI00021840 8 40S ribosomal protein S6 
IPI00013415 5 40S ribosomal protein S7 
IPI00216587 2 40S ribosomal protein S8 
IPI00216587 7 40S ribosomal protein S8 
IPI00553164 8 40S ribosomal protein SA 
IPI00027493 3 4F2 cell-surface antigen heavy chain 
IPI00383111 19 57 kDa protein 
IPI00383111 21 57 kDa protein 
IPI00383111 14 57 kDa protein 
IPI00383111 17 57 kDa protein 
IPI00011253 15 40S ribosomal protein S3 
IPI00419880 17 40S ribosomal protein S3a 
IPI00383111 27 6 57 kDa protein 
IPI00021439 15 Actin, cytoplasmic 1 
IPI00059366 18 H2A histone family, member Y isoform 2 
IPI00395865 16 Histone-binding protein RBBP7 
IPI00215734 21 HRMT1L2 protein 
IPI00438701 32 Isoform 1 of Methyl-CpG-binding domain protein 1 
IPI00434623 22 Isoform 1 of Methyl-CpG-binding domain protein 2 
IPI00549248 12 Isoform 1 of Nucleophosmin 
IPI00216592 14 Isoform C1 of Heterogeneous nuclear ribonucleoproteins C1/C2 
IPI00009865 1 Keratin, type I cytoskeletal 10 
IPI00019359 25 Keratin, type I cytoskeletal 9 
IPI00220327 38 Keratin, type II cytoskeletal 1 
IPI00220327 36 Keratin, type II cytoskeletal 1 
IPI00021304 34 Keratin, type II cytoskeletal 2 epidermal 
IPI00641950 18 Lung cancer oncogene 7 
IPI00171798 34 Metastasis-associated protein MTA2 
IPI00449049 42 Poly [ADP-ribose] polymerase 1 
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IPI00010590 88 606 Isoform 1 of Lymphoid-specific helicase 
IPI00008530 5 60S acidic ribosomal protein P0 
IPI00008530 4 60S acidic ribosomal protein P0 
IPI00008530 6 60S acidic ribosomal protein P0 
IPI00008530 11 60S acidic ribosomal protein P0 
IPI00554723 3 60S ribosomal protein L10 
IPI00412579 4 60S ribosomal protein L10a 
IPI00215719 2 60S ribosomal protein L18 
IPI00215719 6 60S ribosomal protein L18 
IPI00025329 4 60S ribosomal protein L19 
IPI00306332 4 60S ribosomal protein L24 
IPI00550021 11 60S ribosomal protein L3 
IPI00003918 9 60S ribosomal protein L4 
IPI00003918 4 60S ribosomal protein L4 
IPI00003918 8 60S ribosomal protein L4 
IPI00003918 15 60S ribosomal protein L4 
IPI00000494 4 60S ribosomal protein L5 
IPI00000494 7 60S ribosomal protein L5 
IPI00329389 1 60S ribosomal protein L6 
IPI00329389 4 60S ribosomal protein L6 
IPI00329389 7 60S ribosomal protein L6 
IPI00030179 10 60S ribosomal protein L7 
IPI00299573 13 60S ribosomal protein L7a 
IPI00031691 3 60S ribosomal protein L9 
IPI00472102 6 61 kDa protein 
IPI00472102 16 61 kDa protein 
IPI00465430 9 70 kDa protein 
IPI00465430 4 70 kDa protein 
IPI00465430 12 70 kDa protein 
IPI00478128 16 70 kDa protein 
IPI00465430 5 70 kDa protein 
IPI00181231 10 79 kDa protein 
IPI00334775 3 85 kDa protein 
IPI00797796 5 92 kDa protein 
IPI00025849 3 Acidic leucine-rich nuclear phosphoprotein 32 family member A 
IPI00021439 10 Actin, cytoplasmic 1 
IPI00021439 13 Actin, cytoplasmic 1 
IPI00021439 7 Actin, cytoplasmic 1 
IPI00021439 12 Actin, cytoplasmic 1 
IPI00022215 11 Activity-dependent neuroprotector 
IPI00022215 15 Activity-dependent neuroprotector 
IPI00022215 7 Activity-dependent neuroprotector 
IPI00033907 6 Anaphase-promoting complex subunit 1 
IPI00008248 3 Anaphase-promoting complex subunit 7 
IPI00008248 4 Anaphase-promoting complex subunit 7 
IPI00159899 4 ankyrin repeat and FYVE domain containing 1 isoform 1 
IPI00418169 5 annexin A2 isoform 1 
IPI00470657 5 Anti-colorectal carcinoma heavy chain 
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IPI00470657 8 Anti-colorectal carcinoma heavy chain 
IPI00470657 7 Anti-colorectal carcinoma heavy chain 
IPI00470657 6 Anti-colorectal carcinoma heavy chain 
IPI00470657 5 Anti-colorectal carcinoma heavy chain 
IPI00556297 2 Arginine/serine-rich splicing factor 6 variant (Fragment) 
IPI00328828 7 AT rich interactive domain 4B isoform 1 
IPI00220834 8 ATP-dependent DNA helicase 2 subunit 2 
IPI00220834 15 ATP-dependent DNA helicase 2 subunit 2 
IPI00742905 9 ATP-dependent RNA helicase A 
IPI00742905 14 ATP-dependent RNA helicase A 
IPI00742905 11 ATP-dependent RNA helicase A 
IPI00742905 17 ATP-dependent RNA helicase A 
IPI00742905 25 ATP-dependent RNA helicase A 
IPI00006987 7 ATP-dependent RNA helicase DDX24 
IPI00031508 2 ATP-dependent RNA helicase DHX8 
IPI00290684 6 Bifunctional polynucleotide phosphatase/kinase 
IPI00254408 6 bromodomain PHD finger transcription factor isoform 1 
IPI00328987 9 Bystin 
IPI00333010 3 calcium homeostasis endoplasmic reticulum protein 
IPI00333010 5 calcium homeostasis endoplasmic reticulum protein 
IPI00220959 3 Cartilage-associated protein precursor 
IPI00020602 7 Casein kinase II subunit alpha' 
IPI00444262 5 CDNA FLJ45706 fis, clone FEBRA2028457, highly similar to Nucleolin 
IPI00444262 16 CDNA FLJ45706 fis, clone FEBRA2028457, highly similar to Nucleolin 
IPI00444262 8 CDNA FLJ45706 fis, clone FEBRA2028457, highly similar to Nucleolin 
IPI00444262 26 CDNA FLJ45706 fis, clone FEBRA2028457, highly similar to Nucleolin 
IPI00444262 17 CDNA FLJ45706 fis, clone FEBRA2028457, highly similar to Nucleolin 
IPI00444046 3 CDNA FLJ46149 fis, clone TESTI4000621, moderately similar to Snf2-related CBP activator protein 
IPI00465294 1 Cell division cycle 5-like protein 
IPI00217357 4 Cell division cycle and apoptosis regulator protein 1 
IPI00217357 7 Cell division cycle and apoptosis regulator protein 1 
IPI00014264 3 Centaurin-beta 2 
IPI00014264 4 Centaurin-beta 2 
IPI00297579 4 Chromobox protein homolog 3 
IPI00307659 3 Chromobox protein homolog 8 
IPI00152535 1 Chromodomain helicase-DNA-binding protein 5 
IPI00386043 4 Chromosome 1 open reading frame 27 
IPI00386043 7 Chromosome 1 open reading frame 27 
IPI00014230 7 Complement component 1 Q subcomponent-binding protein, mitochondrial precursor 
IPI00008453 3 Coronin-1C 
IPI00016613 9 CSNK2A1 protein 
IPI00016613 4 CSNK2A1 protein 
IPI00028275 1 Cytoskeleton-associated protein 5 
IPI00396435 12 DEAH (Asp-Glu-Ala-His) box polypeptide 15 
IPI00396435 7 DEAH (Asp-Glu-Ala-His) box polypeptide 15 
IPI00396435 12 DEAH (Asp-Glu-Ala-His) box polypeptide 15 
IPI00396435 5 DEAH (Asp-Glu-Ala-His) box polypeptide 15 
IPI00025753 9 Desmoglein-1 precursor 
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IPI00025753 3 Desmoglein-1 precursor 
IPI00465233 7 DJ1014D13.1 protein 
IPI00465233 14 DJ1014D13.1 protein 
IPI00465233 9 DJ1014D13.1 protein 
IPI00465233 11 DJ1014D13.1 protein 
IPI00465233 12 DJ1014D13.1 protein 
IPI00329216 2 DNA (cytosine-5)-methyltransferase 3A 
IPI00329216 6 DNA (cytosine-5)-methyltransferase 3A 
IPI00293464 21 DNA damage-binding protein 1 
IPI00293464 4 DNA damage-binding protein 1 
IPI00293464 13 DNA damage-binding protein 1 
IPI00293464 9 DNA damage-binding protein 1 
IPI00184330 8 DNA replication licensing factor MCM2 
IPI00184330 6 DNA replication licensing factor MCM2 
IPI00013214 6 DNA replication licensing factor MCM3 
IPI00013214 8 DNA replication licensing factor MCM3 
IPI00018349 5 DNA replication licensing factor MCM4 
IPI00018350 4 DNA replication licensing factor MCM5 
IPI00413611 5 DNA topoisomerase 1 
IPI00413611 11 DNA topoisomerase 1 
IPI00027808 10 DNA-directed RNA polymerase II 140 kDa polypeptide 
IPI00012535 1 DnaJ homolog subfamily A member 1 
IPI00012535 7 DnaJ homolog subfamily A member 1 
IPI00025874 3 Dolichyl-diphosphooligosaccharide--protein glycosyltransferase 67 kDa subunit precursor 
IPI00003406 1 Drebrin 
IPI00026993 3 E3 ubiquitin-protein ligase RING2 
IPI00797945 15 E3 ubiquitin-protein ligase UHRF1 
IPI00797945 16 E3 ubiquitin-protein ligase UHRF1 
IPI00797945 8 E3 ubiquitin-protein ligase UHRF1 
IPI00745955 7 EBNA1 binding protein 2 
IPI00384472 1 EHMT1 protein 
IPI00384472 1 EHMT1 protein 
IPI00396485 7 Elongation factor 1-alpha 1 
IPI00396485 8 Elongation factor 1-alpha 1 
IPI00396485 9 Elongation factor 1-alpha 1 
IPI00396485 5 Elongation factor 1-alpha 1 
IPI00014424 2 Elongation factor 1-alpha 2 
IPI00014424 1 Elongation factor 1-alpha 2 
IPI00014424 2 Elongation factor 1-alpha 2 
IPI00023048 4 Elongation factor 1-delta 
IPI00000875 3 Elongation factor 1-gamma 
IPI00000875 4 Elongation factor 1-gamma 
IPI00000875 7 Elongation factor 1-gamma 
IPI00186290 7 Elongation factor 2 
IPI00186290 5 Elongation factor 2 
IPI00186290 9 Elongation factor 2 
IPI00186290 18 Elongation factor 2 
IPI00171248 6 embryonic ectoderm development isoform b 
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IPI00376787 6 enhancer of zeste 2 isoform a 
IPI00376787 6 enhancer of zeste 2 isoform a 
IPI00025491 4 Eukaryotic initiation factor 4A-I 
IPI00025491 12 Eukaryotic initiation factor 4A-I 
IPI00297982 6 Eukaryotic translation initiation factor 2 subunit 3 
IPI00290461 8 Eukaryotic translation initiation factor 3 subunit 1 
IPI00029012 7 Eukaryotic translation initiation factor 3 subunit 10 
IPI00029012 14 Eukaryotic translation initiation factor 3 subunit 10 
IPI00029012 7 Eukaryotic translation initiation factor 3 subunit 10 
IPI00029012 13 Eukaryotic translation initiation factor 3 subunit 10 
IPI00029012 29 Eukaryotic translation initiation factor 3 subunit 10 
IPI00012795 7 Eukaryotic translation initiation factor 3 subunit 2 
IPI00012795 9 Eukaryotic translation initiation factor 3 subunit 2 
IPI00647650 6 Eukaryotic translation initiation factor 3 subunit 3 
IPI00647650 5 Eukaryotic translation initiation factor 3 subunit 3 
IPI00290460 6 Eukaryotic translation initiation factor 3 subunit 4 
IPI00654777 1 Eukaryotic translation initiation factor 3 subunit 5 
IPI00654777 4 Eukaryotic translation initiation factor 3 subunit 5 
IPI00654777 4 Eukaryotic translation initiation factor 3 subunit 5 
IPI00654777 4 Eukaryotic translation initiation factor 3 subunit 5 
IPI00654777 7 Eukaryotic translation initiation factor 3 subunit 5 
IPI00013068 3 Eukaryotic translation initiation factor 3 subunit 6 
IPI00013068 7 Eukaryotic translation initiation factor 3 subunit 6 
IPI00013068 6 Eukaryotic translation initiation factor 3 subunit 6 
IPI00013068 11 Eukaryotic translation initiation factor 3 subunit 6 
IPI00013068 13 Eukaryotic translation initiation factor 3 subunit 6 
IPI00006181 12 Eukaryotic translation initiation factor 3 subunit 7 
IPI00006181 6 Eukaryotic translation initiation factor 3 subunit 7 
IPI00006181 9 Eukaryotic translation initiation factor 3 subunit 7 
IPI00006181 20 Eukaryotic translation initiation factor 3 subunit 7 
IPI00016910 4 Eukaryotic translation initiation factor 3 subunit 8 
IPI00016910 12 Eukaryotic translation initiation factor 3 subunit 8 
IPI00016910 4 Eukaryotic translation initiation factor 3 subunit 8 
IPI00016910 9 Eukaryotic translation initiation factor 3 subunit 8 
IPI00016910 17 Eukaryotic translation initiation factor 3 subunit 8 
IPI00012079 4 Eukaryotic translation initiation factor 4B 
IPI00012079 3 Eukaryotic translation initiation factor 4B 
IPI00439415 6 eukaryotic translation initiation factor 4B 
IPI00012079 6 Eukaryotic translation initiation factor 4B 
IPI00010105 5 Eukaryotic translation initiation factor 6 
IPI00026970 16 FACT complex subunit SPT16 
IPI00026970 6 FACT complex subunit SPT16 
IPI00026970 18 FACT complex subunit SPT16 
IPI00026970 8 FACT complex subunit SPT16 
IPI00005154 8 FACT complex subunit SSRP1 
IPI00005154 4 FACT complex subunit SSRP1 
IPI00005154 12 FACT complex subunit SSRP1 
IPI00005154 11 FACT complex subunit SSRP1 
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IPI00218132 4 F-box-like/WD repeat protein TBL1X 
IPI00002922 13 F-box-like/WD repeat protein TBL1XR1 
IPI00302592 89 filamin A, alpha 
IPI00302592 80 filamin A, alpha 
IPI00302592 88 filamin A, alpha 
IPI00302592 58 filamin A, alpha 
IPI00302592 72 filamin A, alpha 
IPI00642018 8 FLYWCH-type zinc finger 1 isoform b 
IPI00069750 3 fuse-binding protein-interacting repressor isoform a 
IPI00102069 5 GA17 protein 
IPI00102069 3 GA17 protein 
IPI00016801 4 Glutamate dehydrogenase 1, mitochondrial precursor 
IPI00219018 3 Glyceraldehyde-3-phosphate dehydrogenase 
IPI00005132 6 guanine nucleotide binding protein-like 3 (nucleolar)-like 
IPI00059366 13 H2A histone family, member Y isoform 2 
IPI00059366 6 H2A histone family, member Y isoform 2 
IPI00059366 14 H2A histone family, member Y isoform 2 
IPI00304925 1 Heat shock 70 kDa protein 1 
IPI00304925 10 Heat shock 70 kDa protein 1 
IPI00304925 4 Heat shock 70 kDa protein 1 
IPI00304925 2 Heat shock 70 kDa protein 1 
IPI00304925 4 Heat shock 70 kDa protein 1 
IPI00301277 1 Heat shock 70 kDa protein 1L 
IPI00339269 1 Heat shock 70 kDa protein 6 
IPI00788958 4 Heat shock 70kDa protein 9B variant (Fragment) 
IPI00788958 6 Heat shock 70kDa protein 9B variant (Fragment) 
IPI00465365 9 heterogeneous nuclear ribonucleoprotein A1 isoform a 
IPI00215965 5 heterogeneous nuclear ribonucleoprotein A1 isoform b 
IPI00215965 10 heterogeneous nuclear ribonucleoprotein A1 isoform b 
IPI00011274 1 heterogeneous nuclear ribonucleoprotein D-like 
IPI00003881 1 heterogeneous nuclear ribonucleoprotein F 
IPI00003881 1 heterogeneous nuclear ribonucleoprotein F 
IPI00304692 3 Heterogeneous nuclear ribonucleoprotein G 
IPI00304692 3 Heterogeneous nuclear ribonucleoprotein G 
IPI00304692 5 Heterogeneous nuclear ribonucleoprotein G 
IPI00026230 1 Heterogeneous nuclear ribonucleoprotein H' 
IPI00013881 4 heterogeneous nuclear ribonucleoprotein H1 
IPI00013881 7 heterogeneous nuclear ribonucleoprotein H1 
IPI00013881 5 heterogeneous nuclear ribonucleoprotein H1 
IPI00013881 7 heterogeneous nuclear ribonucleoprotein H1 
IPI00027834 4 heterogeneous nuclear ribonucleoprotein L isoform a 
IPI00027834 8 heterogeneous nuclear ribonucleoprotein L isoform a 
IPI00027834 5 heterogeneous nuclear ribonucleoprotein L isoform a 
IPI00027834 8 heterogeneous nuclear ribonucleoprotein L isoform a 
IPI00027834 10 heterogeneous nuclear ribonucleoprotein L isoform a 
IPI00171903 4 heterogeneous nuclear ribonucleoprotein M isoform a 
IPI00171903 9 heterogeneous nuclear ribonucleoprotein M isoform a 
IPI00171903 7 heterogeneous nuclear ribonucleoprotein M isoform a 
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IPI00171903 7 heterogeneous nuclear ribonucleoprotein M isoform a 
IPI00171903 8 heterogeneous nuclear ribonucleoprotein M isoform a 
IPI00012074 5 Heterogeneous nuclear ribonucleoprotein R 
IPI00012074 4 Heterogeneous nuclear ribonucleoprotein R 
IPI00012074 9 Heterogeneous nuclear ribonucleoprotein R 
IPI00012074 11 Heterogeneous nuclear ribonucleoprotein R 
IPI00479217 6 heterogeneous nuclear ribonucleoprotein U isoform b 
IPI00479217 7 heterogeneous nuclear ribonucleoprotein U isoform b 
IPI00479217 10 heterogeneous nuclear ribonucleoprotein U isoform b 
IPI00479217 12 heterogeneous nuclear ribonucleoprotein U isoform b 
IPI00479217 10 heterogeneous nuclear ribonucleoprotein U isoform b 
IPI00180764 4 Histone acetyltransferase MYST2 
IPI00013774 4 Histone deacetylase 1 
IPI00013774 12 Histone deacetylase 1 
IPI00289601 3 histone deacetylase 2 
IPI00289601 5 histone deacetylase 2 
IPI00289601 9 histone deacetylase 2 
IPI00289601 19 histone deacetylase 2 
IPI00026272 1 Histone H2A type 1-B 
IPI00026272 1 Histone H2A type 1-B 
IPI00081836 1 Histone H2A type 1-H 
IPI00081836 3 Histone H2A type 1-H 
IPI00081836 3 Histone H2A type 1-H 
IPI00081836 5 Histone H2A type 1-H 
IPI00216457 5 Histone H2A type 2-A 
IPI00003935 2 Histone H2B type 2-E 
IPI00003935 1 Histone H2B type 2-E 
IPI00794461 3 Histone H2B.d 
IPI00465070 1 Histone H3.1 
IPI00219038 4 Histone H3.3 
IPI00453473 6 Histone H4 
IPI00453473 4 Histone H4 
IPI00453473 4 Histone H4 
IPI00328319 2 Histone-binding protein RBBP4 
IPI00328319 3 Histone-binding protein RBBP4 
IPI00328319 11 Histone-binding protein RBBP4 
IPI00395865 10 Histone-binding protein RBBP7 
IPI00395865 2 Histone-binding protein RBBP7 
IPI00395865 11 Histone-binding protein RBBP7 
IPI00013788 3 HIV Tat-specific factor 1 
IPI00013788 12 HIV Tat-specific factor 1 
IPI00003362 7 HSPA5 protein 
IPI00003362 14 HSPA5 protein 
IPI00003362 8 HSPA5 protein 
IPI00003362 15 HSPA5 protein 
IPI00003362 7 HSPA5 protein 
IPI00375731 18 Hypothetical protein DKFZp686E2459 
IPI00375731 15 Hypothetical protein DKFZp686E2459 
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IPI00375731 20 Hypothetical protein DKFZp686E2459 
IPI00375731 12 Hypothetical protein DKFZp686E2459 
IPI00375731 12 Hypothetical protein DKFZp686E2459 
IPI00026533 2 Hypothetical protein DKFZp686M21107 
IPI00106955 7 Hypothetical protein LOC144097 
IPI00106955 6 Hypothetical protein LOC144097 
IPI00795088 7 Hypothetical protein XRCC5 
IPI00397801 1 Ifapsoriasin 
IPI00303292 1 Importin alpha-1 subunit 
IPI00303292 3 Importin alpha-1 subunit 
IPI00002214 1 Importin alpha-2 subunit 
IPI00002214 6 Importin alpha-2 subunit 
IPI00002214 7 Importin alpha-2 subunit 
IPI00002214 12 Importin alpha-2 subunit 
IPI00002214 7 Importin alpha-2 subunit 
IPI00299033 6 Importin alpha-3 subunit 
IPI00012578 2 Importin alpha-4 subunit 
IPI00012578 10 Importin alpha-4 subunit 
IPI00747764 3 Importin alpha-7 subunit 
IPI00747764 2 Importin alpha-7 subunit 
IPI00014319 3 influenza virus NS1A binding protein isoform a 
IPI00291510 13 Inosine-5'-monophosphate dehydrogenase 2 
IPI00291510 12 Inosine-5'-monophosphate dehydrogenase 2 
IPI00005198 2 Interleukin enhancer-binding factor 2 
IPI00005198 4 Interleukin enhancer-binding factor 2 
IPI00005198 2 Interleukin enhancer-binding factor 2 
IPI00005198 9 Interleukin enhancer-binding factor 2 
IPI00299608 5 Isoform 1 of 26S proteasome non-ATPase regulatory subunit 1 
IPI00004511 3 Isoform 1 of 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 
IPI00004511 4 Isoform 1 of 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 
IPI00007423 5 Isoform 1 of Acidic leucine-rich nuclear phosphoprotein 32 family member B 
IPI00003627 2 Isoform 1 of Actin-like protein 6A 
IPI00003627 4 Isoform 1 of Actin-like protein 6A 
IPI00003627 2 Isoform 1 of Actin-like protein 6A 
IPI00003627 3 Isoform 1 of Actin-like protein 6A 
IPI00549736 6 Isoform 1 of Activating signal cointegrator 1 complex subunit 2 
IPI00430472 8 Isoform 1 of Activating signal cointegrator 1 complex subunit 3 
IPI00430472 12 Isoform 1 of Activating signal cointegrator 1 complex subunit 3 
IPI00301503 3 Isoform 1 of Arginine/serine-rich-splicing factor 10 
IPI00301503 2 Isoform 1 of Arginine/serine-rich-splicing factor 10 
IPI00301503 2 Isoform 1 of Arginine/serine-rich-splicing factor 10 
IPI00301503 4 Isoform 1 of Arginine/serine-rich-splicing factor 10 
IPI00513797 3 Isoform 1 of Beta-catenin-like protein 1 
IPI00296388 3 Isoform 1 of Bromodomain adjacent to zinc finger domain 2A 
IPI00296388 10 Isoform 1 of Bromodomain adjacent to zinc finger domain 2A 
IPI00412415 9 Isoform 1 of Bromodomain adjacent to zinc finger domain protein 1A 
IPI00069817 5 Isoform 1 of Bromodomain adjacent to zinc finger domain protein 1B 
IPI00069817 5 Isoform 1 of Bromodomain adjacent to zinc finger domain protein 1B 
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IPI00373870 1 Isoform 1 of Chromodomain helicase-DNA-binding protein 3 
IPI00373870 3 Isoform 1 of Chromodomain helicase-DNA-binding protein 3 
IPI00373870 9 Isoform 1 of Chromodomain helicase-DNA-binding protein 3 
IPI00000846 29 Isoform 1 of Chromodomain helicase-DNA-binding protein 4 
IPI00000846 3 Isoform 1 of Chromodomain helicase-DNA-binding protein 4 
IPI00000846 47 Isoform 1 of Chromodomain helicase-DNA-binding protein 4 
IPI00000846 64 Isoform 1 of Chromodomain helicase-DNA-binding protein 4 
IPI00012593 5 Isoform 1 of DNA (cytosine-5)-methyltransferase 3B 
IPI00021518 3 Isoform 1 of DNA damage-binding protein 2 
IPI00021518 5 Isoform 1 of DNA damage-binding protein 2 
IPI00031801 1 Isoform 1 of DNA-binding protein A 
IPI00296337 8 Isoform 1 of DNA-dependent protein kinase catalytic subunit 
IPI00296337 46 Isoform 1 of DNA-dependent protein kinase catalytic subunit 
IPI00296337 16 Isoform 1 of DNA-dependent protein kinase catalytic subunit 
IPI00296337 37 Isoform 1 of DNA-dependent protein kinase catalytic subunit 
IPI00296337 11 Isoform 1 of DNA-dependent protein kinase catalytic subunit 
IPI00394665 5 Isoform 1 of Double-stranded RNA-specific adenosine deaminase 
IPI00394665 8 Isoform 1 of Double-stranded RNA-specific adenosine deaminase 
IPI00396370 7 Isoform 1 of Eukaryotic translation initiation factor 3 subunit 9 
IPI00396370 7 Isoform 1 of Eukaryotic translation initiation factor 3 subunit 9 
IPI00396370 8 Isoform 1 of Eukaryotic translation initiation factor 3 subunit 9 
IPI00396370 23 Isoform 1 of Eukaryotic translation initiation factor 3 subunit 9 
IPI00289334 2 Isoform 1 of Filamin-B 
IPI00289334 6 Isoform 1 of Filamin-B 
IPI00003865 15 Isoform 1 of Heat shock cognate 71 kDa protein 
IPI00003865 17 Isoform 1 of Heat shock cognate 71 kDa protein 
IPI00003865 16 Isoform 1 of Heat shock cognate 71 kDa protein 
IPI00003865 17 Isoform 1 of Heat shock cognate 71 kDa protein 
IPI00003865 22 Isoform 1 of Heat shock cognate 71 kDa protein 
IPI00419373 2 Isoform 1 of Heterogeneous nuclear ribonucleoprotein A3 
IPI00419373 6 Isoform 1 of Heterogeneous nuclear ribonucleoprotein A3 
IPI00028888 6 Isoform 1 of Heterogeneous nuclear ribonucleoprotein D0 
IPI00028888 5 Isoform 1 of Heterogeneous nuclear ribonucleoprotein D0 
IPI00216049 4 Isoform 1 of Heterogeneous nuclear ribonucleoprotein K 
IPI00216049 5 Isoform 1 of Heterogeneous nuclear ribonucleoprotein K 
IPI00216049 7 Isoform 1 of Heterogeneous nuclear ribonucleoprotein K 
IPI00018140 1 Isoform 1 of Heterogeneous nuclear ribonucleoprotein Q 
IPI00006187 4 Isoform 1 of Histone deacetylase 3 
IPI00096972 7 Isoform 1 of Histone-lysine N-methyltransferase, H3 lysine-9 specific 3 
IPI00015526 6 Isoform 1 of Histone-lysine N-methyltransferase, H3 lysine-9 specific 5 
IPI00015526 5 Isoform 1 of Histone-lysine N-methyltransferase, H3 lysine-9 specific 5 
IPI00296432 6 Isoform 1 of IWS1 homolog 
IPI00185919 6 Isoform 1 of La-related protein 1 
IPI00185919 5 Isoform 1 of La-related protein 1 
IPI00185919 19 Isoform 1 of La-related protein 1 
IPI00641990 5 Isoform 1 of LAS1-like protein 
IPI00641990 7 Isoform 1 of LAS1-like protein 
IPI00010590 18 Isoform 1 of Lymphoid-specific helicase 
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IPI00165357 1 Isoform 1 of Metastasis-associated protein MTA3 
IPI00165357 8 Isoform 1 of Metastasis-associated protein MTA3 
IPI00438701 7 Isoform 1 of Methyl-CpG-binding domain protein 1 
IPI00169400 3 Isoform 1 of Mitochondrial 28S ribosomal protein S5 
IPI00169400 8 Isoform 1 of Mitochondrial 28S ribosomal protein S5 
IPI00023334 5 Isoform 1 of Mitochondrial 39S ribosomal protein L4 
IPI00289344 13 Isoform 1 of Nuclear receptor corepressor 1 
IPI00015953 8 Isoform 1 of Nucleolar RNA helicase 2 
IPI00015953 7 Isoform 1 of Nucleolar RNA helicase 2 
IPI00015953 11 Isoform 1 of Nucleolar RNA helicase 2 
IPI00015953 19 Isoform 1 of Nucleolar RNA helicase 2 
IPI00410693 5 Isoform 1 of Plasminogen activator inhibitor 1 RNA-binding protein 
IPI00008524 5 Isoform 1 of Polyadenylate-binding protein 1 
IPI00008524 4 Isoform 1 of Polyadenylate-binding protein 1 
IPI00008524 4 Isoform 1 of Polyadenylate-binding protein 1 
IPI00012726 1 Isoform 1 of Polyadenylate-binding protein 4 
IPI00216046 7 Isoform 1 of Probable global transcription activator SNF2L1 
IPI00216046 6 Isoform 1 of Probable global transcription activator SNF2L1 
IPI00216046 4 Isoform 1 of Probable global transcription activator SNF2L1 
IPI00022613 6 Isoform 1 of Probable nucleolar complex protein 14 
IPI00006702 5 Isoform 1 of Proline-, glutamic acid- and leucine-rich protein 1 
IPI00006702 5 Isoform 1 of Proline-, glutamic acid- and leucine-rich protein 1 
IPI00101186 5 Isoform 1 of Protein KIAA0690 
IPI00101186 15 Isoform 1 of Protein KIAA0690 
IPI00072377 8 Isoform 1 of Protein SET 
IPI00072377 10 Isoform 1 of Protein SET 
IPI00072377 8 Isoform 1 of Protein SET 
IPI00411733 7 Isoform 1 of Putative ATP-dependent RNA helicase DHX30 
IPI00006932 2 Isoform 1 of Putative RNA-binding protein Luc7-like 2 
IPI00375358 5 Isoform 1 of Replication factor C subunit 1 
IPI00375358 3 Isoform 1 of Replication factor C subunit 1 
IPI00375358 4 Isoform 1 of Replication factor C subunit 1 
IPI00163505 6 Isoform 1 of RNA-binding protein 39 
IPI00163505 3 Isoform 1 of RNA-binding protein 39 
IPI00163505 5 Isoform 1 of RNA-binding protein 39 
IPI00163505 6 Isoform 1 of RNA-binding protein 39 
IPI00163505 10 Isoform 1 of RNA-binding protein 39 
IPI00021187 5 Isoform 1 of RuvB-like 1 
IPI00021187 4 Isoform 1 of RuvB-like 1 
IPI00021187 7 Isoform 1 of RuvB-like 1 
IPI00021187 9 Isoform 1 of RuvB-like 1 
IPI00745872 7 Isoform 1 of Serum albumin precursor 
IPI00478292 38 Isoform 1 of Spectrin alpha chain, brain 
IPI00478292 23 Isoform 1 of Spectrin alpha chain, brain 
IPI00478292 44 Isoform 1 of Spectrin alpha chain, brain 
IPI00478292 7 Isoform 1 of Spectrin alpha chain, brain 
IPI00478292 10 Isoform 1 of Spectrin alpha chain, brain 
IPI00149044 8 Isoform 1 of Suppressor of hairy wing homolog 4 
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IPI00339381 5 Isoform 1 of SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 3 
IPI00216047 2 Isoform 1 of SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily C member 2 
IPI00062599 3 Isoform 1 of SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily D member 1 
IPI00298058 5 Isoform 1 of Transcription elongation factor SPT5 
IPI00159322 7 Isoform 1 of Transcription factor 20 
IPI00159322 7 Isoform 1 of Transcription factor 20 
IPI00220107 3 Isoform 1 of Transcriptional regulator ATRX 
IPI00410330 2 Isoform 1 of Transcriptional repressor p66 alpha 
IPI00410330 9 Isoform 1 of Transcriptional repressor p66 alpha 
IPI00107113 6 Isoform 1 of U3 small nucleolar RNA-associated protein 14 homolog A 
IPI00292000 10 Isoform 1 of U4/U6 small nuclear ribonucleoprotein Prp31 
IPI00292000 5 Isoform 1 of U4/U6 small nuclear ribonucleoprotein Prp31 
IPI00292000 11 Isoform 1 of U4/U6 small nuclear ribonucleoprotein Prp31 
IPI00292000 6 Isoform 1 of U4/U6 small nuclear ribonucleoprotein Prp31 
IPI00292000 6 Isoform 1 of U4/U6 small nuclear ribonucleoprotein Prp31 
IPI00000728 5 Isoform 1 of Ubiquitin carboxyl-terminal hydrolase 15 
IPI00410067 5 Isoform 1 of Zinc finger CCCH type antiviral protein 1 
IPI00029484 6 Isoform 1 of Zinc finger MYM-type protein 3 
IPI00029484 11 Isoform 1 of Zinc finger MYM-type protein 3 
IPI00003886 3 Isoform 2 of Guanine nucleotide-binding protein-like 3 
IPI00003886 6 Isoform 2 of Guanine nucleotide-binding protein-like 3 
IPI00155577 5 Isoform 2 of HEAT repeat-containing protein 3 
IPI00216746 4 Isoform 2 of Heterogeneous nuclear ribonucleoprotein K 
IPI00217540 6 Isoform 2 of Lysine-specific histone demethylase 1 
IPI00084571 10 Isoform 2 of Mitochondrial 39S ribosomal protein L39 
IPI00026466 14 Isoform 2 of Nipped-B-like protein 
IPI00220740 8 Isoform 2 of Nucleophosmin 
IPI00220740 3 Isoform 2 of Nucleophosmin 
IPI00220740 10 Isoform 2 of Nucleophosmin 
IPI00150057 5 Isoform 2 of SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily C member 2 
IPI00402183 3 Isoform 3 of Heterogeneous nuclear ribonucleoprotein Q 
IPI00005780 6 Isoform 3 of UDP-N-acetylglucosamine--peptide N-acetylglucosaminyltransferase 110 kDa subunit 
IPI00005780 6 Isoform 3 of UDP-N-acetylglucosamine--peptide N-acetylglucosaminyltransferase 110 kDa subunit 
IPI00106509 2 Isoform 4 of Heterogeneous nuclear ribonucleoprotein A/B 
IPI00106509 3 Isoform 4 of Heterogeneous nuclear ribonucleoprotein A/B 
IPI00106509 3 Isoform 4 of Heterogeneous nuclear ribonucleoprotein A/B 
IPI00106509 4 Isoform 4 of Heterogeneous nuclear ribonucleoprotein A/B 
IPI00219330 3 Isoform 5 of Interleukin enhancer-binding factor 3 
IPI00219330 4 Isoform 5 of Interleukin enhancer-binding factor 3 
IPI00219330 5 Isoform 5 of Interleukin enhancer-binding factor 3 
IPI00219330 5 Isoform 5 of Interleukin enhancer-binding factor 3 
IPI00023097 9 Isoform 5 of Protein polybromo-1 
IPI00023097 7 Isoform 5 of Protein polybromo-1 
IPI00023097 8 Isoform 5 of Protein polybromo-1 
IPI00396378 3 Isoform B1 of Heterogeneous nuclear ribonucleoproteins A2/B1 
IPI00396378 5 Isoform B1 of Heterogeneous nuclear ribonucleoproteins A2/B1 
IPI00396378 6 Isoform B1 of Heterogeneous nuclear ribonucleoproteins A2/B1 
IPI00396378 11 Isoform B1 of Heterogeneous nuclear ribonucleoproteins A2/B1 
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IPI00396378 14 Isoform B1 of Heterogeneous nuclear ribonucleoproteins A2/B1 
IPI00216592 6 Isoform C1 of Heterogeneous nuclear ribonucleoproteins C1/C2 
IPI00216592 12 Isoform C1 of Heterogeneous nuclear ribonucleoproteins C1/C2 
IPI00216592 11 Isoform C1 of Heterogeneous nuclear ribonucleoproteins C1/C2 
IPI00216592 10 Isoform C1 of Heterogeneous nuclear ribonucleoproteins C1/C2 
IPI00477313 1 Isoform C2 of Heterogeneous nuclear ribonucleoproteins C1/C2 
IPI00013933 9 Isoform DPI of Desmoplakin 
IPI00384456 10 Isoform GTBP-N of DNA mismatch repair protein MSH6 
IPI00384456 8 Isoform GTBP-N of DNA mismatch repair protein MSH6 
IPI00012773 6 Isoform Long of Metastasis-associated protein MTA1 
IPI00012773 7 Isoform Long of Metastasis-associated protein MTA1 
IPI00012773 18 Isoform Long of Metastasis-associated protein MTA1 
IPI00005614 31 Isoform Long of Spectrin beta chain, brain 1 
IPI00005614 29 Isoform Long of Spectrin beta chain, brain 1 
IPI00005614 38 Isoform Long of Spectrin beta chain, brain 1 
IPI00005614 11 Isoform Long of Spectrin beta chain, brain 1 
IPI00005184 12 Isoform Long of Transcription intermediary factor 1-alpha 
IPI00177817 2 Isoform SERCA2A of Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 
IPI00328230 9 Isoform Short of Spectrin beta chain, brain 1 
IPI00554711 6 Junction plakoglobin 
IPI00789324 8 JUP protein 
IPI00292715 2 keratin 34 
IPI00290078 2 keratin 4 
IPI00166205 6 Keratin 5b 
IPI00174775 1 Keratin 6 irs3 
IPI00816709 1 Keratin 6C 
IPI00376379 1 Keratin 77 
IPI00182654 1 Keratin, hair, basic, 1 
IPI00009865 1 Keratin, type I cytoskeletal 10 
IPI00384444 17 Keratin, type I cytoskeletal 14 
IPI00384444 3 Keratin, type I cytoskeletal 14 
IPI00384444 14 Keratin, type I cytoskeletal 14 
IPI00384444 3 Keratin, type I cytoskeletal 14 
IPI00217963 7 Keratin, type I cytoskeletal 16 
IPI00217963 2 Keratin, type I cytoskeletal 16 
IPI00217963 3 Keratin, type I cytoskeletal 16 
IPI00217963 7 Keratin, type I cytoskeletal 16 
IPI00450768 2 Keratin, type I cytoskeletal 17 
IPI00019359 27 Keratin, type I cytoskeletal 9 
IPI00019359 19 Keratin, type I cytoskeletal 9 
IPI00019359 10 Keratin, type I cytoskeletal 9 
IPI00019359 16 Keratin, type I cytoskeletal 9 
IPI00220327 29 Keratin, type II cytoskeletal 1 
IPI00220327 23 Keratin, type II cytoskeletal 1 
IPI00220327 22 Keratin, type II cytoskeletal 1 
IPI00021304 17 Keratin, type II cytoskeletal 2 epidermal 
IPI00021304 22 Keratin, type II cytoskeletal 2 epidermal 
IPI00021304 11 Keratin, type II cytoskeletal 2 epidermal 
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IPI00021304 7 Keratin, type II cytoskeletal 2 epidermal 
IPI00008359 3 Keratin, type II cytoskeletal 2 oral 
IPI00290857 1 Keratin, type II cytoskeletal 3 
IPI00009867 13 Keratin, type II cytoskeletal 5 
IPI00009867 4 Keratin, type II cytoskeletal 5 
IPI00009867 12 Keratin, type II cytoskeletal 5 
IPI00293665 7 Keratin, type II cytoskeletal 6B 
IPI00293665 5 Keratin, type II cytoskeletal 6B 
IPI00299145 7 Keratin, type II cytoskeletal 6E 
IPI00554648 2 Keratin, type II cytoskeletal 8 
IPI00554648 3 Keratin, type II cytoskeletal 8 
IPI00514908 4 Keratinocyte proline-rich protein 
IPI00175151 3 KIAA1546 protein (Fragment) 
IPI00305289 13 Kinesin-like protein KIF11 
IPI00305289 4 Kinesin-like protein KIF11 
IPI00305289 15 Kinesin-like protein KIF11 
IPI00029081 10 ligase III, DNA, ATP-dependent isoform alpha precursor 
IPI00031397 4 Long-chain-fatty-acid--CoA ligase 3 
IPI00153032 4 LTV1 homolog 
IPI00641950 5 Lung cancer oncogene 7 
IPI00641950 7 Lung cancer oncogene 7 
IPI00010388 4 Major centromere autoantigen B 
IPI00017297 4 Matrin-3 
IPI00017297 4 Matrin-3 
IPI00017297 5 Matrin-3 
IPI00017297 2 Matrin-3 
IPI00017297 3 Matrin-3 
IPI00171798 10 Metastasis-associated protein MTA2 
IPI00171798 12 Metastasis-associated protein MTA2 
IPI00418234 7 Methyl-CpG-binding protein 2 
IPI00012202 6 Methylosome protein 50 
IPI00012202 7 Methylosome protein 50 
IPI00004795 2 Methylosome subunit pICln 
IPI00013146 10 Mitochondrial 28S ribosomal protein S22 
IPI00013146 13 Mitochondrial 28S ribosomal protein S22 
IPI00022002 10 Mitochondrial 28S ribosomal protein S27 
IPI00022002 13 Mitochondrial 28S ribosomal protein S27 
IPI00018120 12 Mitochondrial 28S ribosomal protein S29 
IPI00018120 14 Mitochondrial 28S ribosomal protein S29 
IPI00010278 6 Mitochondrial 28S ribosomal protein S30 
IPI00169413 5 Mitochondrial 28S ribosomal protein S34 
IPI00549381 5 Mitochondrial ribosoMal protein L1 
IPI00032881 4 Mitochondrial ribosomal protein S23 
IPI00006440 7 mitochondrial ribosomal protein S7 
IPI00014835 10 mitochondrial ribosomal protein S9 
IPI00014835 11 mitochondrial ribosomal protein S9 
IPI00019733 6 mRNA-associated protein mrnp 41 
IPI00019502 47 Myosin-9 
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IPI00019502 7 Myosin-9 
IPI00019380 3 Nuclear cap-binding protein subunit 1 
IPI00290562 3 nuclear factor, interleukin 3 regulated 
IPI00290562 3 nuclear factor, interleukin 3 regulated 
IPI00031812 5 Nuclease sensitive element-binding protein 1 
IPI00031812 8 Nuclease sensitive element-binding protein 1 
IPI00015808 5 Nucleolar GTP-binding protein 2 
IPI00022970 3 Nucleoprotein TPR 
IPI00022970 8 Nucleoprotein TPR 
IPI00023860 7 Nucleosome assembly protein 1-like 1 
IPI00023860 8 Nucleosome assembly protein 1-like 1 
IPI00023860 12 Nucleosome assembly protein 1-like 1 
IPI00017763 3 Nucleosome assembly protein 1-like 4 
IPI00382617 5 P37 AUF1 
IPI00170596 8 Paired amphipathic helix protein Sin3a 
IPI00300659 16 Parafibromin 
IPI00103525 3 paraspeckle protein 1 
IPI00300333 11 PD2 protein 
IPI00783302 10 Pentatricopeptide repeat domain 3 
IPI00454969 9 PHD finger protein 14 
IPI00454969 6 PHD finger protein 14 
IPI00472782 9 PHD finger protein 14 isoform 1 
IPI00291916 3 pleckstrin homology domain interacting protein 
IPI00000495 4 PNAS-125 
IPI00410718 17 pogo transposable element with ZNF domain isoform 2 
IPI00410718 8 pogo transposable element with ZNF domain isoform 2 
IPI00449049 26 Poly [ADP-ribose] polymerase 1 
IPI00449049 12 Poly [ADP-ribose] polymerase 1 
IPI00449049 32 Poly [ADP-ribose] polymerase 1 
IPI00016610 2 Poly(rC)-binding protein 1 
IPI00016610 7 Poly(rC)-binding protein 1 
IPI00016610 5 Poly(rC)-binding protein 1 
IPI00016610 6 Poly(rC)-binding protein 1 
IPI00299526 8 Polycomb protein SUZ12 
IPI00299526 5 Polycomb protein SUZ12 
IPI00004968 3 Pre-mRNA-processing factor 19 
IPI00305068 7 Pre-mRNA-processing factor 6 
IPI00305068 5 Pre-mRNA-processing factor 6 
IPI00007928 7 Pre-mRNA-processing-splicing factor 8 
IPI00007928 4 Pre-mRNA-processing-splicing factor 8 
IPI00007928 6 Pre-mRNA-processing-splicing factor 8 
IPI00007928 6 Pre-mRNA-processing-splicing factor 8 
IPI00006725 1 Probable ATP-dependent RNA helicase DDX23 
IPI00329791 9 Probable ATP-dependent RNA helicase DDX46 
IPI00017617 1 Probable ATP-dependent RNA helicase DDX5 
IPI00017617 4 Probable ATP-dependent RNA helicase DDX5 
IPI00004459 4 Probable dimethyladenosine transferase 
IPI00217055 3 Prolyl 3-hydroxylase 2 precursor 
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IPI00105598 2 Proteasome 26S non-ATPase subunit 11 variant (Fragment) 
IPI00441473 15 Protein arginine N-methyltransferase 5 
IPI00441473 10 Protein arginine N-methyltransferase 5 
IPI00441473 11 Protein arginine N-methyltransferase 5 
IPI00441473 8 Protein arginine N-methyltransferase 5 
IPI00441473 11 Protein arginine N-methyltransferase 5 
IPI00300376 3 Protein-glutamine gamma-glutamyltransferase E precursor 
IPI00217413 6 Putative ATP-dependent RNA helicase DHX29 
IPI00217686 5 Putative rRNA methyltransferase 3 
IPI00479186 5 pyruvate kinase 3 isoform 1 
IPI00479186 15 pyruvate kinase 3 isoform 1 
IPI00418316 4 RACK7 isoform e 
IPI00418316 6 RACK7 isoform e 
IPI00001661 4 regulator of chromosome condensation 1 isoform a 
IPI00001661 6 regulator of chromosome condensation 1 isoform a 
IPI00290652 17 remodeling and spacing factor 1 
IPI00290652 4 remodeling and spacing factor 1 
IPI00290652 12 remodeling and spacing factor 1 
IPI00290652 14 remodeling and spacing factor 1 
IPI00006970 5 Ribosomal protein S2, bacterial and organelle form family protein 
IPI00413108 4 Ribosomal protein SA 
IPI00413108 9 Ribosomal protein SA 
IPI00413108 4 Ribosomal protein SA 
IPI00413108 13 Ribosomal protein SA 
IPI00005036 3 RNA-binding protein 5 
IPI00005036 4 RNA-binding protein 5 
IPI00009104 5 RuvB-like 2 
IPI00009104 4 RuvB-like 2 
IPI00009104 6 RuvB-like 2 
IPI00009104 7 RuvB-like 2 
IPI00009104 6 RuvB-like 2 
IPI00295940 12 Sad1/unc-84-like protein 2 
IPI00295940 9 Sad1/unc-84-like protein 2 
IPI00295940 7 Sad1/unc-84-like protein 2 
IPI00295940 6 Sad1/unc-84-like protein 2 
IPI00300786 2 Salivary alpha-amylase precursor 
IPI00456887 5 Scaffold attachment factor A2 
IPI00456887 5 Scaffold attachment factor A2 
IPI00456887 6 Scaffold attachment factor A2 
IPI00456887 6 Scaffold attachment factor A2 
IPI00456887 5 Scaffold attachment factor A2 
IPI00027251 11 Serine/threonine-protein kinase 38 
IPI00027251 9 Serine/threonine-protein kinase 38 
IPI00027251 17 Serine/threonine-protein kinase 38 
IPI00237011 6 Serine/threonine-protein kinase 38-like 
IPI00237011 9 Serine/threonine-protein kinase 38-like 
IPI00180615 4 Similar to E2F transcription factor 7 
IPI00737498 5 similar to MAX-interacting protein isoform 6 
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IPI00737498 6 similar to MAX-interacting protein isoform 6 
IPI00143753 7 similar to U2-associated SR140 protein 
IPI00143753 5 similar to U2-associated SR140 protein 
IPI00143753 8 similar to U2-associated SR140 protein 
IPI00029822 3 SMARCA4 isoform 2 
IPI00029822 4 SMARCA4 isoform 2 
IPI00029822 16 SMARCA4 isoform 2 
IPI00029822 11 SMARCA4 isoform 2 
IPI00333015 1 spectrin, beta, non-erythrocytic 1 isoform 2 
IPI00333015 1 spectrin, beta, non-erythrocytic 1 isoform 2 
IPI00550655 3 Spindlin-1 
IPI00017451 4 Splicing factor 3 subunit 1 
IPI00029764 6 Splicing factor 3A subunit 3 
IPI00029764 4 Splicing factor 3A subunit 3 
IPI00026089 19 Splicing factor 3B subunit 1 
IPI00026089 16 Splicing factor 3B subunit 1 
IPI00026089 26 Splicing factor 3B subunit 1 
IPI00026089 19 Splicing factor 3B subunit 1 
IPI00026089 12 Splicing factor 3B subunit 1 
IPI00221106 7 splicing factor 3B subunit 2 
IPI00221106 10 splicing factor 3B subunit 2 
IPI00221106 12 splicing factor 3B subunit 2 
IPI00300371 20 Splicing factor 3B subunit 3 
IPI00300371 14 Splicing factor 3B subunit 3 
IPI00300371 23 Splicing factor 3B subunit 3 
IPI00300371 26 Splicing factor 3B subunit 3 
IPI00300371 14 Splicing factor 3B subunit 3 
IPI00176706 5 Splicing factor 45 
IPI00176706 5 Splicing factor 45 
IPI00031556 7 Splicing factor U2AF 65 kDa subunit 
IPI00031556 4 Splicing factor U2AF 65 kDa subunit 
IPI00031556 4 Splicing factor U2AF 65 kDa subunit 
IPI00031556 7 Splicing factor U2AF 65 kDa subunit 
IPI00010204 2 Splicing factor, arginine/serine-rich 3 
IPI00007765 6 Stress-70 protein, mitochondrial precursor 
IPI00007765 3 Stress-70 protein, mitochondrial precursor 
IPI00007765 6 Stress-70 protein, mitochondrial precursor 
IPI00183642 3 Suppressor of hairy wing homolog 3 
IPI00297211 30 SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 5 
IPI00297211 9 SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 5 
IPI00297211 29 SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 5 
IPI00297211 18 SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 5 
IPI00234252 4 SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily C member 1 
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IPI00025815 2 TAR DNA-binding protein 43 
IPI00025815 2 TAR DNA-binding protein 43 
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IPI00549664 3 Testis-expressed sequence 10 protein 
IPI00549664 5 Testis-expressed sequence 10 protein 
IPI00104050 2 Thyroid hormone receptor-associated protein 3 
IPI00104050 3 Thyroid hormone receptor-associated protein 3 
IPI00413755 1 Transcription initiation factor TFIID subunit 4 
IPI00103554 4 Transcriptional repressor p66 beta 
IPI00103554 5 Transcriptional repressor p66 beta 
IPI00103554 17 Transcriptional repressor p66 beta 
IPI00022774 11 Transitional endoplasmic reticulum ATPase 
IPI00022774 5 Transitional endoplasmic reticulum ATPase 
IPI00022774 5 Transitional endoplasmic reticulum ATPase 
IPI00438229 5 tripartite motif-containing 28 protein 
IPI00438229 11 tripartite motif-containing 28 protein 
IPI00438229 7 tripartite motif-containing 28 protein 
IPI00438229 9 tripartite motif-containing 28 protein 
IPI00438229 13 tripartite motif-containing 28 protein 
IPI00010948 4 Tripartite motif-containing protein 26 
IPI00292894 12 TSR1, 20S rRNA accumulation, homolog 
IPI00166768 4 TUBA6 protein 
IPI00007750 2 Tubulin alpha-1 chain 
IPI00007750 1 Tubulin alpha-1 chain 
IPI00180675 6 Tubulin alpha-3 chain 
IPI00180675 1 Tubulin alpha-3 chain 
IPI00180675 1 Tubulin alpha-3 chain 
IPI00218343 12 Tubulin alpha-6 chain 
IPI00387144 6 Tubulin alpha-ubiquitous chain 
IPI00387144 6 Tubulin alpha-ubiquitous chain 
IPI00011654 2 Tubulin beta chain 
IPI00011654 7 Tubulin beta chain 
IPI00011654 2 Tubulin beta chain 
IPI00011654 2 Tubulin beta chain 
IPI00011654 5 Tubulin beta chain 
IPI00013475 1 Tubulin beta-2A chain 
IPI00007752 10 Tubulin beta-2C chain 
IPI00007752 1 Tubulin beta-2C chain 
IPI00007752 17 Tubulin beta-2C chain 
IPI00007752 9 Tubulin beta-2C chain 
IPI00375911 1 Type I inner root sheath specific keratin 25 irs1 
IPI00021417 3 U4/U6.U5 tri-snRNP-associated protein 1 
IPI00420014 10 U5 small nuclear ribonucleoprotein 200 kDa helicase 
IPI00420014 10 U5 small nuclear ribonucleoprotein 200 kDa helicase 
IPI00026320 2 Ubiquitin-protein ligase EDD1 
IPI00385928 2 Uncharacterized protein C4orf14 
IPI00385928 6 Uncharacterized protein C4orf14 
IPI00418471 8 Vimentin 
IPI00418471 5 Vimentin 
IPI00418471 4 Vimentin 
IPI00005492 3 WD repeat protein 5 
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IPI00005492 3 WD repeat protein 5 
IPI00005492 3 WD repeat protein 5 
IPI00019269 4 WD repeat protein 61 
IPI00016542 3 WD repeat protein 76 
IPI00477949 3 zinc finger protein 262 
IPI00022460 3 Zinc finger protein 592 
IPI00064212 5 Zinc finger protein KIAA1802 
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